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ABSTRACT 
Background 
There is a clear clinical need for interventions that limit the extent of injury 
associated with myocardial ischaemia-reperfusion injury (IRI). Two such 
interventions are classical (IPC) and remote (RIC) ischaemic preconditioning. 
The mechanism of action in both cases involves release of one or more 
humoral factors. However, the existence of a neural pathway remains 
equivocal. 
The aim of this thesis was to investigate the importance of a neural pathway 
in both classical and remote ischaemic conditioning, with particular focus on 
the vagus nerve and intrinsic cardiac ganglia. In addition, the efficacy of non-
invasive vagus nerve stimulation was investigated as a novel cardioprotective 
intervention. Finally, we performed a meta-analysis investigating the efficacy 
of RIC in animal in vivo models of myocardial infarction. 
Methods and Results 
This thesis first aimed to investigate the co-dependence between the neural 
and humoral pathways of RIC. Bilateral cervical vagotomy abolished release 
of the humoral blood-borne mediator. Moreover, pharmacological antagonism 
of intrinsic cardiac ganglia abrogated RIC-mediated protection.   
This thesis was the first to reveal a neural component to the mechanism of 
IPC. We suggest a sensory feedback loop in response to IPC, involving 
activation intrinsic cardiac ganglia and post-ganglionic parasympathetic fibres 
projecting to the ventricles.  
Finally, transcutaneous vagus nerve stimulation (tVNS) in healthy human 
volunteers induced release of a blood-borne cardioprotective factor. 
However, tVNS was not significantly cardioprotective in an in vivo rat model 
of IRI.  
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Conclusions 
Release of the humoral blood-borne mediator following RIC is dependent on 
prior vagus nerve activation. Furthermore, intrinsic cardiac ganglia are 
recruited as part of the mechanism of both RIC and IPC. Finally, tVNS is 
suggested to be a novel cardioprotective intervention. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
ACKNOWLEDGEMENTS 
My sincere thanks go firstly to my supervisor, Professor Derek Yellon for his 
patient and invaluable support over the past four years; I could not have 
asked for better supervision. My thanks also go to my secondary supervisor 
Dr Sean Davidson for teaching me a huge amount about both the 
experimental and intellectual approach to basic science. I am greatly 
appreciated to Prof Derek Hausenloy for his intellectual input and guidance 
throughout my PhD. Finally, I am very grateful to Prof Peter Scambler and 
the British Heart Foundation for giving me the opportunity to undertake a PhD 
at UCL. 
I am very lucky to have developed several collaborations over the course of 
my PhD. My thanks firstly to Prof Alex Gourine for his great support and help, 
in particular in developing ideas for the neural cardioprotection story. I am 
very grateful to members of his laboratory, Dr Sveltana Mastitskaya and Dr 
Asif Machada, for their help with several experiments. Secondly, I am grateful 
to Prof Jim Deuchars and Aaron Murray for their invaluable help and 
collaboration with the ‘ear stimulation’ project. These collaborations were 
absolutely fundamental to this PhD, and provided the most interesting 
results. 
I am extremely lucky to have worked with such a fantastic team during my 
time at the Hatter Cardiovascular Institute. My thanks to Dr Jose Vicencio, Dr 
Andy Hall, Dr Sapna Subrayan, Dr Dan Bromage and Dr Niall Burke for their 
great patience in teaching me the various techniques used during my PhD. 
My thanks also to the other members of the Hatter who made my PhD such 
an enjoyable thing to do.  
My heartfelt thanks go to my family and friends for their incalculable support 
and understanding over the past 4 years. Finally thank you to Izzy, who has 
been a constant source of love and support to me for these years and 
hopefully for more to come. 
7 
 
PUBLICATIONS 
Below details publications arising from the work presented in this thesis 
Original research articles: 
Pickard JMJ, Burke N, Davidson SM, Yellon DM (2017) Intrinsic cardiac 
ganglia and acetylcholine are important in the mechanism of ischaemic 
preconditioning. Basic Res Cardiol 112:11. doi: 10.1007/s00395-017-0601-x 
Pickard JMJ, Davidson SM, Hausenloy DJ, Yellon DM (2016) Co-
dependence of the neural and humoral pathways in the mechanism of 
remote ischaemic conditioning. Basic Res Cardiol 111:50. doi: 
10.1007/s00395-016-0568-z 
Bromage DI *, Pickard JMJ *, Rossello X, Ziff OJ, Burke N, Yellon DM, 
Davidson SM (2016) Remote ischaemic conditioning reduces infarct size in 
animal in vivo models of ischaemia-reperfusion injury: a systematic review 
and meta-analysis. Cardiovascular Research. doi: 10.1093/cvr/cvw219 
* = authors contributed equally to this work 
Review articles:  
Pickard JMJ, Bøtker HE, Crimi G, Davidson B, Davidson SM, Dutka D, 
Ferdinandy P, Ganske R, Garcia-Dorado D, Giricz Z, Gourine A V, 
Heusch G, Kharbanda R, Kleinbongard P, MacAllister R, McIntyre C, 
Meybohm P, Prunier F, Redington A, Robertson NJ, Suleiman MS, 
Vanezis A, Walsh S, Yellon DM, Hausenloy DJ (2015) Remote ischaemic 
conditioning: from experimental observation to clinical application: report from 
the 8th Biennial Hatter Cardiovascular Institute Workshop. Basic Res Cardiol 
110:453. doi: 10.1007/s00395-014-0453-6 
8 
 
Sivaraman V, Pickard JMJ, Hausenloy DJ (2015) Remote ischaemic 
conditioning: cardiac protection from afar. Anaesthesia 70:732–48. doi: 
10.1111/anae.12973 
Abstract articles: 
Pickard JMJ, Burke N, Davidson SM, Yellon DM (2016) Acetylcholine 
plays a key role in myocardial ischaemic preconditioning via recruitment of 
intrinsic cardiac ganglia. Cardiovascular Research 111, S33-S34 
Bromage DI *, Pickard JMJ *, Rossello X, Burke N, Ziff O, Yellon DM, 
Davidson SM (2016) Remote ischaemic conditioning reduces infarct size in 
animal in vivo models of ischaemia-reperfusion injury: a systematic review 
and meta-analysis. Cardiovascular Research 111 (suppl 1) S118-S118. 
* = authors contributed equally to this work 
Pickard JMJ, Davidson SM, Yellon DM (2015) Importance of intrinsic 
cardiac nerves in both direct and remote ischaemic conditioning. Heart 101 
(suppl 6), A3-A3. 
Pickard JMJ, Davidson SM, Yellon DM (2014) Investigating coronary 
effluent as a valid model of remote ischaemic conditioning; the role of 
stromal-derived factor one alpha (SDF-1alpha) and nitric oxide. 
Cardiovascular Research 103(suppl 1), S81-S81. 
 
 
 
 
 
9 
 
CONTENTS 
DECLARATION	.......................................................................................................	2	
ABSTRACT	.............................................................................................................	4	
ACKNOWLEDGEMENTS	..........................................................................................	6	
PUBLICATIONS	.......................................................................................................	7	
CONTENTS	.............................................................................................................	9	
FIGURES	..............................................................................................................	12	
TABLES	................................................................................................................	16	
Chapter	1	 GENERAL	INTRODUCTION	...............................................................	17	
1.1	 Coronary	artery	disease	....................................................................................	17	
1.2	 Myocardial	ischaemia-reperfusion	injury	..........................................................	18	
1.3	 Cardioprotective	strategies	...............................................................................	25	
1.4	 Clinical	translation	of	RIC	..................................................................................	41	
1.5	 The	cardiac	nervous	system	..............................................................................	51	
1.6	 GENERAL	RESEARCH	OBJECTIVES	......................................................................	55	
Chapter	2	 GENERAL	RESEARCH	METHODS	.......................................................	57	
2.1	 Animal	usage	....................................................................................................	57	
2.2	 Ex	vivo	Langendorff	perfused	heart	model	of	ischaemia	reperfusion	injury	.......	57	
2.3	 Model	of	cardioprotection	via	transfer	of	plasma	dialysate	..............................	65	
2.4	 Ex	vivo	model	of	isolated	primary	cardiomyocyte	hypoxia-reoxygenation	........	68	
2.5	 Biochemical	assays	...........................................................................................	71	
Chapter	3	 CHARACTERISATION	OF	THREE	MODELS	OF	CARDIOPROTECTION	...	72	
3.1	 Introduction	......................................................................................................	72	
3.2	 Research	aims	and	objectives	...........................................................................	73	
3.3	 Aim	1:	Establish	ex	vivo	model	of	myocardial	ischaemia-reperfusion	injury	......	74	
3.4	 Aim	2:	Establish	model	of	inter-cardiac	cardioprotection	via	transfer	of	coronary	
effluent	......................................................................................................................	82	
3.5	 Aim	3:	Establish	a	model	of	remote	ischaemic	conditioning	via	transfer	of	plasma	
dialysate	....................................................................................................................	96	
3.6	 Summary	.........................................................................................................	109	
10 
 
Chapter	4	 REMOTE	ISCHAEMIC	CONDITIONING	REDUCES	INFARCT	SIZE	IN	
ANIMAL	IN	VIVO	MODELS	OF	ISCHAEMIA-REPERFUSION	INJURY:	A	SYSTEMATIC	
REVIEW	AND	META-ANALYSIS	...........................................................................	110	
4.1	 Introduction	.....................................................................................................	110	
4.2	 Research	aims	and	objectives	..........................................................................	112	
4.3	 Methods	..........................................................................................................	112	
4.4	 Results	.............................................................................................................	122	
4.5	 Discussion	........................................................................................................	132	
Chapter	5	 CO-DEPENDENCE	OF	THE	NEURAL	AND	HUMORAL	PATHWAYS	IN	THE	
MECHANISM	OF	REMOTE	ISCHAEMIC	CONDITIONING	.......................................	141	
5.1	 Introduction	.....................................................................................................	141	
5.2	 Research	aims	and	objectives	..........................................................................	143	
5.3	 Aim	1:	The	vagus	nerve	and	release	of	the	humoral	RIC	mediator	....................	144	
5.4	 Aim	2:	The	role	of	intrinsic	cardiac	ganglia	in	RIC	.............................................	156	
5.5	 Summary	.........................................................................................................	164	
Chapter	6	 INTRINSIC	CARDIAC	GANGLIA	AND	ACETYLCHOLIND	ARE	IMPORTANT	
IN	THE	MECHANISM	OF	CLASSICAL	ISCHAEMIC	PRECONDITIONING	...................	166	
6.1	 Introduction	.....................................................................................................	166	
6.2	 Research	aims	and	objectives	..........................................................................	168	
6.3	 Methods	..........................................................................................................	169	
6.4	 Results	.............................................................................................................	175	
6.5	 Discussion	........................................................................................................	180	
6.6	 Summary	.........................................................................................................	184	
Chapter	7	 STIMULATING	THE	EAR	TO	PROTECT	THE	HEART:	TRANSCUTANEOUS	
VAGUS	NERVE	STIMULATION	IS	A	NOVEL	CARDIOPROTECTIVE	INTERVENTION	.	186	
7.1	 Introduction	.....................................................................................................	186	
7.2	 Research	aims	and	objectives	..........................................................................	188	
7.3	 Aim	1:	transcutaneous	vagus	nerve	stimulation	in	healthy	human	volunteers	.	191	
7.4	 Aim	2:	tVNS	as	a	cardioprotective	intervention	in	a	rat	in	vivo	model	of	
myocardial	infarction	................................................................................................	203	
7.5	 Summary	.........................................................................................................	211	
Chapter	8	 General	conclusions	......................................................................	212	
11 
 
Chapter	9	 References	....................................................................................	215	
Chapter	10	 Appendix	....................................................................................	255	
 
 
  
12 
 
FIGURES 
Figure 1-1. Representative schematic of key cellular events in the 
cardiomyocyte during ischaemia. .................................................................. 20	
Figure 1-2 Representative schematic of the cellular sequelae of reperfusion 
injury. ............................................................................................................. 23	
Figure 1-3: Schematic describing the possible mechanisms of communication 
of RIC. ........................................................................................................... 32	
Figure 2-1. Picture of the Langendorff constant pressure perfusion apparatus 
used throughout the PhD .............................................................................. 59	
Figure 2-2 Picture of pressure transducer with latex balloon attached. The 
fluid-filled latex balloon would be inserted into the left ventricle of isolated 
perfused hearts in order to obtain estimates of left ventricular pressures 
during the cardiac cycle. ................................................................................ 61	
Figure 2-3. Representative images of an isolated perfused rat heart 
undergoing ischaemia-reperfusion injury. A suture is placed around the left 
anterior descending coronary artery and, after a period of stabilisation, 
tightened using a snare contraption to induce ischaemia. Reperfusion is 
initiated by removing the snare contraption. .................................................. 62	
Figure 2-4. Use of Evans blue staining to delineate area-at-risk post-
infarction: ....................................................................................................... 63	
Figure 2-5. Representative images demonstrating stages of calculating 
infarct size using ImageJ software. ............................................................... 64	
Figure 2-6: Schematic describing process of dialysate preparation: ............. 67	
Figure 2-7: IRI protocol for dialysate ex vivo experiments: ........................... 67	
Figure 3-1. Experimental protocols during characterisation of the Langendorff 
isolated heart model. ..................................................................................... 76	
Figure 3-2: Area at risk in isolated rat hearts subjected to either sham, control 
or IPC protocols. ............................................................................................ 77	
Figure 3-3: Comparison of infarct size between sham, control and IPC 
groups. .......................................................................................................... 78	
Figure 3-4. Functional parameters measured in hearts who received either 
sham or IPC. ................................................................................................. 79	
13 
 
Figure 3-5. Schema of the effluent transfer model and experimental 
protocols. ....................................................................................................... 86	
Figure 3-6. Protein concentration in both control and IPC effluent. ............... 88	
Figure 3-7. Infarct size analysis of donor and recipient hearts. ..................... 89	
Figure 3-8. Functional parameters measured in hearts who received either 
control or IPC effluent. ................................................................................... 90	
Figure 3-9. Correlation between infarct size and flow rate indicate link 
between humoral factor and protection in acceptor and donor hearts. ......... 91	
Figure 3-10. Stromal-derived factor 1 alpha does not mediate the protection 
afforded by IPC effluent. ................................................................................ 92	
Figure 3-11: Protocol for in vivo RIC or sham procedures: ........................... 99	
Figure 3-12: In vivo RIC significantly reduces infarct size of the donor heart:
..................................................................................................................... 101	
Figure 3-13: Platelet-rich plasma creates a dialysate that, for both control and 
RIC, induces a cardioprotected phenotype.. ............................................... 102	
Figure 3-14: Removing platelets from the plasma abolishes the artificial 
protection and reveals the significant cardioprotection associated with RIC 
dialysate. ..................................................................................................... 103	
Figure 3-15. Protein concentration in dialysate a plasma following RIC or 
sham. ........................................................................................................... 104	
Figure 3-16. Functional parameters measured in the naïve hearts who 
received dialysate. ....................................................................................... 105	
Figure 4-1. Flow diagram demonstrating study exclusion during systematic 
review. ......................................................................................................... 123	
Figure 4-2. Forest plots detailing the weighted mean difference for each 
included study. ............................................................................................ 127	
Figure 4-3. Impact of experimental factors on the efficacy of A) RIPreC and 
B) RIPerC/RIPostC. ..................................................................................... 128	
Figure 4-4. Reporting of study quality indicators. ........................................ 130	
Figure 4-5. Assessment of publication bias. ................................................ 131	
Figure 5-1. Experimental protocols used to investigate role of the vagus 
nerve in release of the humoral RIC mediator. ............................................ 146	
Figure 5-2. Experimental protocols used for posterior gastric vagus nerve 
stimulation in rats. ....................................................................................... 147	
14 
 
Figure 5-3: Bilateral cervical vagotomy abrogates dialysate-mediated 
protection of naïve-isolated rat hearts ......................................................... 150	
Figure 5-4. Haemodynamic data for bilateral cervical vagotomy experiment:
..................................................................................................................... 151	
Figure 5-5. Dialysate prepared following in vivo stimulation of the posterior 
gastric branch of the vagus nerve does not protect the naïve rat heart. ..... 152	
Figure 5-6. Experimental protocol.. ............................................................. 158	
Figure 5-7. Hexamethonium and atropine abrogate dialysate-mediated 
cardioprotection: .......................................................................................... 160	
Figure 5-8 Haemodynamic data for the intrinsic cardiac ganglia experiment:
..................................................................................................................... 161	
Figure 5-9. Schematic of proposed mechanism of RIC communication (figure 
adapted from that in [267]) .......................................................................... 165	
Figure 6-1 Schema detailing the experimental protocols ............................ 174	
Figure 6-2: Hexamethonium and Atropine abrogate ischaemic 
preconditioning.. .......................................................................................... 176	
Figure 6-3: IPC effluent protects a naïve heart from ischaemia-reperfusion 
injury.. .......................................................................................................... 178	
Figure 6-4: IPC effluent does not protect isolated cardiomyocytes from 
simulated ischaemia-reperfusion injury.. ..................................................... 179	
Figure 7-1. Schematic displaying outer ear anatomy with general sensory 
innervation (figure adapted from that shown in [266]). ................................ 189	
Figure 7-2. Proposed pathway by which transcutaneous vagus nerve 
stimulation elicits its effect on the myocardium. .......................................... 190	
Figure 7-3. Schematic displaying experimental protocols. .......................... 195	
Figure 7-4. Dialysate prepared following tVNS protects a naïve heart to a 
similar level to that observed with RIC dialysate ......................................... 198	
Figure 7-5. Haemodynamic data from the naïve hearts that received 
dialysate.. .................................................................................................... 199	
Figure 7-6. Representative images of the surgical protocol for in vivo 
ischaemia-reperfusion injury model. ............................................................ 205	
Figure 7-7. Method used for transcutaneous vagus nerve stimulation in the 
anaesthetised rat ......................................................................................... 207	
15 
 
Figure 7-8. Experimental protocols used to investigate RIC and tVNS in a rat 
model of ischaemia-reperfusion injury.. ....................................................... 208	
Figure 7-9. Remote ischaemic preconditioning but not tVNS reduces infarct 
size in an animal model of in vivo ischaemia-reperfusion injury.. ................ 209	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
 
TABLES 
Table 1-1: Key trials investigating RIC in the clinic ....................................... 46	
Table1-2: Key upcoming trial investigating RIC in the cli .............................. 47	
Table 2-1. Criteria to indicate a well-perfused, healthy heart ........................ 61	
Table 2-2: Stock perfusion buffer components for cardiomyocyte isolation .. 69	
Table 2-3. Additional components to each solution to be prepared fresh prior 
to the isolation procedure .............................................................................. 70	
Table 4-1. Differences in search strategy between databases ................... 113	
Table 4-2. Data items, developed using the PICOS approach .................... 118	
Table 4-3. Items removed and added from the Cochrane study quality score 
to make the adapted score used in the study. ............................................. 119	
Table 4-4. Main characteristics of included studies.. ................................... 125	
Table 4-5. Meta-analysis comparing the effect of index ischaemia duration on 
WMD in studies investigating remote PREconditioning. ............................. 136	
Table 4-6. Meta-analysis comparing the effect of index ischaemia on WMD in 
studies investigating remote PERconditioning and POSTconditioning. N=16 
comparisons. ............................................................................................... 137	
Table 7-1. General characteristics of healthy participants in the study. ...... 194	
Table 7-2. ECG and respiration rate data collected over the course of each 
intervention. ................................................................................................. 197	
 
 
 
 
 
 
 
17 
 
Chapter 1 GENERAL INTRODUCTION 
1.1 Coronary artery disease 
Coronary Artery Disease describes the group of conditions that precipitate 
from the formation of an atherosclerotic plaque in one or more coronary 
arteries. Progressive accumulation of lipids and fibrous elements in the artery 
wall results in a protrusion of the plaque into the lumen, thereby reducing 
blood flow to the downstream myocardium [409]. This reduction in blood 
supply can manifest initially as stable angina, with patients suffering from 
transient chest pain during exertion. The altogether more serious 
manifestation of CAD, however, is acute myocardial infarction. Here, the 
fibrous cap on the plaque becomes displaced or eroded, exposing the 
prothrombotic region in the plaque core to the blood, thus inducing clot 
formation which can fully occlude the culprit artery. This immediate cessation 
of blood supply renders the myocardium ischaemic, leading eventually to cell 
death or infarction. The myocytes are terminally differentiated cells and do 
not replicate, thus once dead are not replaced. Inflammatory mediators 
infiltrate the infarcted myocardium and replace dead cardiomyocytes with 
collagen, leading to formation of a scar and, crucially, loss of contractility. 
Cardiac muscle efficiency is therefore compromised and this can lead to the 
development of heart failure. 
The formation of an atherosclerotic plaque occurs over several decades, with 
fatty streak lesions detectable in coronary arteries as early as the second 
decade of life. Given the median age of first acute MI in men is estimated to 
be 56 years, the long incubation period for plaque formation is clear, as is the 
opportunity to limit its growth via avoiding its associated risk factors. Lifestyle 
choices such as smoking, poor diet, insufficient exercise, obesity and alcohol 
consumption, in addition to disease states such as diabetes, hypertension 
and hyperlipidaemia can significantly increase the rate of plaque formation 
and rupture. Indeed, it was estimated the above risk factors explain more 
than 95% of the population attributable risk of acute MI among men and 
women [8]. 
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CAD was responsible for over 7 million deaths worldwide in 2008, 12.7% of 
global mortality [94]. Overall age-standardised mortality has decreased since 
the 1980s, particularly in high-income countries. This is attributed to 
decreased exposure to risk factors (e.g. smoking) and improved treatments 
(e.g. primary angioplasty). Lower- and middle-income countries display 
higher mortality to CAD, due to continued exposure to risk factors and poor 
prevention strategies (e.g. control of hypertension). Thus, in combination with 
population growth and aging, deaths from CAD continue to increase, and 
exert a huge economic burden on Western civilisation. 
There exists a need, therefore, to develop cardioprotective interventions that 
can limit the extent of infarction. Indeed, over the past 20 years a huge 
portion of cardiovascular research has been dedicated to finding such an 
intervention, with a multitude of pharmacological and non-pharmacological 
strategies developed in both pre-clinical and clinical research. This PhD 
focuses on one such intervention, namely Remote Ischaemic Conditioning 
[283], which is promising in terms of its translational potential. 
1.2 Myocardial ischaemia-reperfusion injury 
Ischaemia triggers injurious metabolic and ionic changes within the myocyte, 
driven primarily via the lack of glucose and oxygen, which build up over time 
and eventually overwhelm the cell triggering death [133]. The myocardium 
must therefore be reperfused before this point, to restore glucose and oxygen 
within cardiomyocytes and provide a chance for recovery. This reflow of 
blood, however, may actually extend tissue injury via release of reactive 
oxygen species (ROS) from the mitochondria. Termed lethal reperfusion 
injury, it is thought to account for up to a significant proportion of the 
infarction associated with IRI [389]. Indeed, reperfusion injury has been the 
subject of a huge volume of basic and clinical studies over the last 30 years, 
and several strategies have been developed which are able to limit 
reperfusion injury and thus reduce infarction. These interventions, along with 
the cellular events that occur during both ischaemia and reperfusion, are 
discussed below. 
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1.2.1 Ischaemic Injury 
The developing ischaemic injury is governed by a tissue hypoxia, meaning 
the myocyte can no longer generate ATP through oxidative phosphorylation. 
The high energy demand of the myocyte quickly exceeds supply, resulting in 
a rapidly depleting supply of high energy phosphate (HEP), namely 
adenosine triphosphate (ATP) and creatine phosphate (CP) [303]. Notably, 
reduced activity of the mitochondrial electron transport chain will cause the 
membrane potential (Δψm) to subside due to accumulation of protons within 
the mitochondrial matrix. As a result, the F1F0 ATP synthase, which normally 
produces ATP, will reverse to an ATPase in an attempt to maintain the Δψm 
[163, 305]. This process is thought to account for 35-50% of ATP depletion 
during ischaemia, although the literature varies according to species [304]. 
Indeed, following 15 minutes of ischaemia the level of ATP is depleted by up 
to 65%, and by up to 90% after 30 minutes [162]. With ≤15 minutes of 
ischaemia inducing fully reversible injury and ≥30 minutes inducing 
irreversible injury, it seems the ATP depletion is closely related to the extent 
of damage within the myocyte. 
The absence of oxygen will force the myocyte to produce ATP through 
anaerobic glycolysis. In addition to being a less efficient use of substrate, the 
by-product of lactate and protons will cause intracellular acidosis, with the pH 
decreasing to 5.5-6 during ischaemia [214]. The accumulation of protons is 
exacerbated by ATP hydrolysis, which releases inorganic phosphate and 
protons. This progressive acidosis of the cytosol and mitochondrial matrix will 
interact with several intracellular signalling pathways including; (1) inhibition 
of glycolytic enzymes that will further reduce the inefficiency of ATP 
production; (2) inhibition of Ca2+ uptake into the sarcoplasmic reticulum, 
contributing to the calcium overload during ischaemia [89, 183]; (3) 
decreased myofibril contraction, which leads to negative inotropy. 
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Figure 1-1. Representative schematic of key cellular events in the 
cardiomyocyte during ischaemia. 
 
In addition to intracellular acidosis, the increase in protons within the cytosol 
will indirectly cause an increase in cytosolic Ca2+ via a phenomenon called 
the coupled-exchanger theory [6]. The Na+/H+ exchanger (NHE) will extrude 
protons from the cell while pumping Na+ into the cytosol in return. With the 
3Na+/2K+ ATPase rendered useless due to the lack of ATP, the developing 
ischaemia causes a Na+ overload within the myocyte. In response, the 
2Na+/Ca2+ exchanger will reverse, causing intracellular Ca2+ overload as the 
ion gradients favour extrusion of Na+. 
The combined effects of intracellular acidosis, ATP depletion and Ca2+ 
overload will cause a developing ischaemic injury within the myocyte which, if 
prolonged for greater than 20 minutes, will induce irreversible cardiomyocyte 
injury and death [162, 280]. Indeed, a “wave front” of ischaemic injury occurs 
21 
 
which begins in the sub-endocardium and extends transmurally through the 
ventricles over time towards the epicardium [292]. 
1.2.2 Reperfusion Injury 
Timely reperfusion is an absolute prerequisite for the survival of ischaemic 
tissue. Indeed, clinical implementation of early reperfusion in patients 
suffering from acute ST-elevation myocardial infarction (STEMI), induced via 
either thrombolysis or coronary angioplasty, has caused a decrease in 30-
day mortality from 10.5% to 7.8% over the past 10-12 years [387]. In addition 
to these obvious beneficial effects, however, reperfusion can exert 
independent injury to the myocardium, which can lead to myocyte death 
[389]. Termed reperfusion injury, there are four known types as outlined 
below. 
i. Reperfusion arrhythmias. An ischaemic time less than 5 minutes is 
associated with reperfusion arrhythmias but does not lead to cardiac 
cell death [31]. These arrhythmias are self-terminating or easily 
treated in the clinic. 
ii. Myocardial stunning. When the ischaemic period extends from 5 to 20 
minutes, reperfusion will induce a prolonged ventricular contractile 
dysfunction. This state is known as myocardial stunning and again 
does not induce myocyte death; the heart will fully recover its function 
within several days. This transient injury is thought to be mediated via 
a release of reactive oxygen species (ROS), with a seminal study from 
Bolli et al. demonstrating antioxidant therapy abolishes reperfusion 
arrhythmias [39]. Repeated periods of myocardial stunning, however, 
can lead to chronic LV dysfunction as exemplified in patients receiving 
dialysis [50].  
iii. Lethal reperfusion injury. The final and most severe level of injury 
occurs when the ischaemic time is over 20 minutes, where irreversible 
injury occurs to some of the hearts cells, resulting in infarction [84, 
280]. The pathophysiology of such injury is discussed in detail in 
section 1.2.2.2. 
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iv. Microvascular obstruction (MVO). Even after reperfusion of the 
previously ischaemic myocardium, blood flow may still be impeded, a 
phenomenon known as no reflow [28, 192, 204]. This residual 
microvascular obstruction is due to capillary compression by 
endothelial cell swelling, intraluminal protrusions, platelet and fibrin 
microthrombi, and pericyte death [117, 193, 260, 291]. The presence 
of MVO is correlated with ischaemic time, but its effects are not limited 
to ischaemic injury. Indeed, reperfusion induces microvascular injury, 
which can reduce blood flow to areas that initially received adequate 
perfusion [7]. Clinically, it is associated with a larger infarct size, a 
lower left ventricular ejection fraction (LVEF), adverse LV remodelling 
and a worse clinical outcome [118, 356, 376, 377].  
1.2.2.1 Pathophysiology of lethal reperfusion injury 
 
Myocardial lethal reperfusion injury is characterised by contraction band 
necrosis, loss of ionic homeostasis, depletion of HEP and release of 
intracellular enzymes. The cellular events that govern these effects include 
calcium overload, oxidative stress and cell swelling; these are discussed 
below (Figure 1-2). 
Calcium overload and the pH paradox 
During ischaemia, myocytes will become loaded with H+, Na+ and Ca2+ 
through anaerobic glycolysis and the coupled-exchanger theory (see 1.2.1) 
[6]. The reintroduction of oxygen and nutrients on reperfusion will, in addition 
to restoring ATP production via oxidative phosphorylation, cause a rapid shift 
in the extracellular ionic composition, notably inducing a large proton gradient 
across the membrane. Thus, the intracellular acidic pH is rapidly corrected 
via the NHE, with the resultant Na+ overload in the cytosol causing a further 
influx of Ca2+ primarily through the NCX. A large, uncontrolled influx of Ca2+ 
can induce significant and irreversible injury to the cell. The paradoxical 
observation arises, therefore, that if one can delay the restoration of normal 
pH within the cardiomyocyte for an initial period of reperfusion, protection 
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may be observed via decreased Ca2+ overload. Indeed, several publications 
have suggested the existence of such a ‘pH paradox’ [214, 264]. 
Figure 1-2 Representative schematic of the cellular sequelae of reperfusion 
injury. 
 
The large calcium overload that occurs at reperfusion cannot be handled in a 
normal way and results in abnormal cell function. Three major effects of 
calcium overload are discussed below: 
i. Hypercontracture. In addition to increased availability of ATP, the 
raised [Ca2+]i will initiate strong hypercontracture. Apart from its effect 
on heart function, this will cause significant physical stress to the 
myocyte and can contribute towards cell death [98, 297].  
ii. Increased myocyte fragility. Experimental evidence has demonstrated 
the increased [Ca2+]I can induce inappropriate activation of calpains, a 
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family of proteases, that can induce major physical disruption to the 
myocyte via weakening the cytoskeletal framework. 
iii. Mitochondrial dysfunction. A major focal point of reperfusion injury is 
the mitochondrial permeability transition pore (mPTP). An elusive 
channel which, when formed, spans the inner and outer membrane 
and abolishes the highly electronegative (-180mV) mitochondrial 
membrane potential (ΔΨm). This will uncouple the respiratory chain, 
and may cause the outer membrane to burst and release cytochrome 
C, initiating cell death pathways. Calcium overload at reperfusion can 
increase the open probability of the pore, thus increasing the 
opportunity for irreversible injury. 
 
Reactive oxygen species in reperfusion injury 
Reactive oxygen species (ROS) are chemically reactive molecules containing 
oxygen with an unpaired electron in its outermost shell. These will very 
quickly react with a number of intracellular components to achieve a more 
stable configuration [10]. The production of ROS is not limited to purely 
detrimental effects in the myocyte, but plays a role in many essential 
signalling pathways. Indeed, the potentially damaging effects of ROS are 
mitigated under normal conditions by the action of superoxide dismutase 
(SOD) enzymes, which convert superoxide to hydrogen peroxide. A burst of 
ROS occurs within the myocyte during the first few minutes of reperfusion, 
which overwhelms the SODs and thus can induce significant injury within the 
myocyte [328, 408].  
The primary source of ROS during reperfusion is electron leak from the 
respiratory chain complexes, in particular from complex I and III [60, 213, 
274]. Traditionally seen as a non-specific effect of the interaction between a 
dysfunctional respiratory chain and the resupply of oxygen at reperfusion, 
recent evidence has suggested a specific metabolic process governs the 
production of ROS during IR. Namely, accumulation of succinate during 
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ischaemia that, upon reperfusion, indirectly causes extensive ROS 
generation from complex I [61, 271]. Indeed, pharmacological antagonism of 
complex I abrogates ROS production during reperfusion and limits infarct 
size [59]. ROS mediates reperfusion injury through lipid peroxidation leading 
to disruption of the SR and sarcolemma [265], mitochondrial DNA oxidation 
[38], protein oxidation leading to cross-linking and eventual breakdown of 
essential proteins, and increased open probability of the mPTP.  
Cell swelling 
During prolonged ischaemia, the switch to anaerobic respiration for ATP 
production leads to the accumulation of metabolites in the cytosol, in 
particular lactate, which causes an increased osmotic pressure within the 
myocyte. The osmotic gradient created by reperfusion will result in water 
influx into the myocyte with resultant cell swelling. Depending on the degree 
of swelling, this can induce substantial physical stress and, in some cases, 
cell death in the absence of hypercontracture or ROS production. 
1.3 Cardioprotective strategies 
Given the significant and irreversible injury afforded to the myocardium by 
IRI, a great deal of research has focussed on understanding how the heart 
can be protected from such lethality. Indeed, as our understanding of the 
mechanisms of IR-induced injury grew, many cardioprotective interventions 
were developed. Perhaps the most important discovery was that of ischaemic 
preconditioning [255]. Like most breakthrough scientific findings, it had a 
relatively serendipitous origin, but it formed the bedrock of a research field 
now in its 30th year. Not only did it prove cardioprotection was possible, but it 
provided a highly reproducible positive control that enabled research groups 
around the world to investigate the mechanisms of ischaemia-reperfusion 
injury, and develop new cardioprotective interventions. 
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1.3.1 Ischaemic Conditioning (IC) 
In 1986, Murry et al. published a seminal study demonstrating short bursts of 
non-injurious ischaemia and reperfusion rendered the myocardium 
significantly protected from a subsequent sustained ischaemic insult. Termed 
ischaemic preconditioning (IPC), this paradoxical finding was understandably 
met with some consternation. This soon dissolved, however, when the 
remarkable reproducibility of IPC was observed by hundreds of researchers 
across many different models of IRI from isolated cardiomyocytes and 
isolated perfused hearts to in vivo preparations in many species (rat, mouse, 
dog, rabbit and pig). The paradigm was extended by the group of Vinten-
Johansen, with the finding that similar brief periods of ischaemia and 
reperfusion at the immediate onset of reperfusion, following prolonged 
ischaemia, had a similar cardioprotective effect to IPC [404]. Named 
ischaemic postconditioning (IPostC), this phenomenon gave convincing 
evidence that injury occurring at reperfusion was targetable.  
The interesting aspects to IC are threefold; first, the idea that a threshold 
must be reached in order to achieve cardioprotection, second, the window of 
protection offered by IPC and, third, the extent of ischaemic injury protectable 
by IPC. A typical protocol would consist of 2 to 4 cycles of 2-5 minutes 
ischaemia with intermittent 2-5 minute reperfusion. Protection has been 
observed, however, with a single ischaemic episode as short as 60-seconds 
and, unsurprisingly, an ischaemic episode longer than 15 minutes does not 
induce protection. Thus, the optimum protocol lies somewhere between 
these numbers, and increasing the cycles is thought to increase the strength 
of the stimulus. Indeed, this is highlighted with the observation that a diabetic 
rat can be protected by three, but not one, cycles of brief ischaemia and 
reperfusion [372]. A typical IPostC protocol consists of 3 cycles of 30 
seconds reperfusion followed by 30 seconds of coronary reocclusion at the 
immediate onset of reperfusion from the injurious ischaemia [404].  
It is worth noting, indeed, that the field has not been unanimous with its 
acceptance of IPostC, with several studies suggesting neutral effects of the 
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intervention [82, 314]. Moreover, whilst several clinical studies have 
demonstrated positive effects of IPostC on myocardial IRI [229, 344], others 
have shown only a modest or neutral effect [97, 225, 329, 337].  
The standard interval between the end of the IPC protocol and the induction 
of prolonged ischaemia is between 5 and 15 minutes, however the protective 
conditioning lasts for between 1 and 4 hours following the stimulus 
depending on the duration of the injurious ischaemia [113]. The protection 
then wanes but, remarkably, re-emerges 24 hours later in a phenomenon 
known as ‘second window’ of protection (SWOP) [388]. Conversly, IPostC 
was initially thought to be protective if performed within only the first few 
minutes of reperfusion, however it been claimed to remain effective even 
when performed as late as 30 minutes following reperfusion [23, 302]. 
Interestingly, the cardioprotective mechanism of this delayed IPostC seems 
to be distinct from that of early IPostC and IPC [23]. 
Finally, a critical feature of IPC is the strength of protection is dependent on 
the length of index ischaemia. Indeed, in models of permanent coronary 
artery occlusion, or when the sustained ischaemia is prolonged to >2 hours, 
IPC fails to limit infarct size [255]. Thus, the necessity for timely reperfusion is 
clear. IPostC has a more complex relationship with index ischaemia, with a 
bell-shaped curve of protection. An ischaemic time of >60 minutes mutes the 
protection afforded by IPostC [239]. When this is reduced to 45 minutes, 
however, powerful protection is observed. Unexpectedly, when the index 
ischaemia is <30minutes, IPostC seems to give neutral or even detrimental 
results [239, 272, 314]. 
Initially, the cardioprotection afforded by IPC was attributed to metabolic 
adjustments within the cell, in particular a decreased rate of energy 
metabolism [256]. Whilst this is undoubtedly involved in the mechanism, IPC 
seems to be initiated via receptor binding. A landmark study by Liu et al 
demonstrated adenosine receptor activation was fundamental to inducing 
cardioprotection [226]. Indeed, there is no question that IPC is a receptor-
mediated phenomenon, via release of one or more trigger molecules, notably 
28 
 
adenosine, opioids and bradykinin [reviewed in 43]. These will bind to their 
respective G-protein-coupled receptors (GPCR) on the sarcolemma and 
trigger a complex and diverse array of intracellular signalling pathways, which 
leads to attenuation of the injury associated with ischaemia and reperfusion. 
Whilst IPC and IPostC seem to exert cardioprotection via similar 
mechanisms, IPC by definition induces the cardioprotective state prior to IR. 
Here, IPC is distinct as it involves a memory component induced via the 
trigger(s) that must last until the onset of the lethal ischaemia and, crucially, 
until reperfusion to exert its protection via several effector pathways [129]. 
With IPostC, however, the trigger, mediator and effector steps must all occur 
both speedily and almost simultaneously. 
i. Trigger phase (IPC only). The brief cycles of ischaemia induce release 
of several small molecules, including adenosine [226], opioids [74, 
268] and bradykinin [105]. These bind to and activate their respective 
receptors, leading to activation of an intracellular signalling pathway, 
which includes epidermal growth factor receptor (EGFR), 
phosphoinositide-3 (PI3) kinase and Akt, nitric oxide synthase (NOS) 
and protein kinase G (PKG). In addition, a recent publication including 
data presented in this thesis (Chapter 6) has implicated intrinsic 
cardiac ganglia in the trigger pathway [277]. These various signalling 
mechanisms converge on the activation of mitochondrial ATP 
sensitive potassium channels (mitoKATP), resulting in a small increase 
in production of ROS. These ROS are thought to activate, via 
oxidation, several cardioprotective kinases, notably protein kinase C 
(PKC), thus inducing the memory state associated with IPC. Although 
PKC is thought to be the primary source of the memory component, 
there seem to be species-specific differences in the importance of the 
kinase in IPC [reviewed in 21 & 42]. In general, the exact mechanism 
of the memory component is not yet clear. 
ii. Effector phase (IPC and IPostC). In the first few minutes of 
reperfusion, adenosine receptor activation occurs which, perhaps via 
PKC, induces activation of the reperfusion injury salvage kinase 
(RISK) pathway. This pathway, pioneered by the Hatter 
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Cardiovascular Institute, describes a group of kinases whose 
activation is associated with cell survival. For example, activation of of 
PI3-kinase, Akt and extracellular-related kinase (ERK) at reperfusion 
is a fundamental process in IPC-mediated cardioprotection [130, 131, 
251, 396]. Other signal pathways, such as the survival activating factor 
enhancement (SAFE) pathway, involving activation of tissue necrosis 
factor 1 alpha (TNF-1α) and intracellular kinases such as janus kinase 
(JAK) and STAT-3, have also been shown to play a role [210, 212, 
333]. This constellation of receptor-mediated signals is proposed to 
converge on the mitochondria and, perhaps via phosphorylation of 
GSK-3β, prevent the swelling and rupture by inhibiting the formation of 
the permeability transition pore (mPTP) [120, 123]. Preventing 
mitochondrial rupture will significantly shift the balance of the cell 
towards survival during IR.  
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1.3.2 Remote Ischaemic Conditioning 
The major disadvantage of IPC and IPost, from a clinical perspective, is the 
requirement to apply an invasive intervention to the heart directly. In this 
regard, the phenomenon of remote ischaemic conditioning (RIC), which 
allows the protective stimulus to be applied to an organ or tissue away from 
the heart, has the upper hand. 
The experimental study to first describe this cardioprotective phenomenon 
was published by Przyklenk et al in 1993 [283]. In the canine heart, applying 
four 5 min cycles of occlusion and reflow to the circumflex coronary artery 
was found to reduce infarct size induced by 45 minute occlusion and 3 hours 
reperfusion of the left anterior descending (LAD) artery, suggesting that 
cardioprotection could be transferred from one coronary territory to another. 
This transfer of cardioprotection was then extended to a remote organ, the 
kidney, by Gho et al, who demonstrated that 15 minutes of occlusion and 
reflow in the mesenteric artery, could reduce infarct size induced by 60 
minutes ligation and 3 hours reperfusion of the left main coronary artery 
[101], extending the paradigm from intra-cardiac to inter-organ protection. 
Subsequent experimental studies have reported that the preconditioning 
stimulus could be applied to a number of different organs remote from the 
heart including the intestine, liver and brain. However, in terms of facilitating 
the translation of RIC into the clinical setting, the major advance was made 
by Birnbaum et al, who discovered that the RIC stimulus could be applied to 
the gastrocnemius muscle of the hind-limb by partially occluding the femoral 
artery [35]. Furthermore, Oxman et al. demonstrated that the conditioning 
stimulus could be applied non-invasively using a tourniquet applied to the 
hind-limb [263].  The discovery that RIC could be elicited non-invasively, by 
simply inflating and deflating a cuff placed on the upper arm or leg in human 
volunteers, greatly facilitated its translation into the clinical setting. 
One other major advantage of RIC is its ability to confer cardioprotection 
when applied at a number of different time-points in relation to the index 
myocardial ischaemia-reperfusion episode, a feature that has also facilitated 
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its clinical application. The early experimental studies focused on applying 
the conditioning stimulus immediately prior to the index myocardial ischaemic 
episode (remote ischaemic PREconditioning or RIPC [35, 283]), with 
subsequent experimental studies reporting efficacy with the conditioning 
stimulus applied at varying time-points: 12-24 hours prior to the index 
myocardial ischaemic episode (delayed remote ischaemic PREconditioning) 
[231, 405]; after the onset of myocardial ischaemia but prior to reperfusion 
(remote ischaemic PERconditioning) [311]; at the onset of myocardial 
reperfusion (remote ischaemic POSTconditioning) [9]; and most recently, 
even after 15 min of myocardial reperfusion has elapsed (delayed remote 
ischaemic POSTconditioning) [23]. Interestingly, repeated remote post-
conditioning applied once per day for 27 days post-infarction drastically 
improves survival and cardiac remodelling [364]. 
1.3.3 Mechanisms underlying RIC 
The actual mechanistic pathway underlying RIC-induced cardioprotection 
remains unclear, but it can be divided in three inter-related events: (a) 
generation of the cardioprotective signal in the conditioned remote organ or 
tissue; (b) the pathway which conveys the cardioprotective signal from the 
conditioned remote organ or tissue to the heart; and (c) the activation of 
intracellular signalling pathways within the heart which mediate the 
cardioprotective effect (Figure 1). The current paradigm dictates there are 
both neural and humoral aspects to (a) and (b), their involvement and 
potential interdependence are discussed below.  
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Figure 1-3: Schematic describing the possible mechanisms of communication 
of RIC. Brief periods of ischaemia-reperfusion to the limb, via cuff inflation/deflation, 
causes local autocoid release. This in turn activates sensory afferent neurones 
which relay, via the spinal cord, to the DMVN in the CNS. Activation of nuclei within 
the DMVN results in increased vagal nerve firing to the heart which, via release of 
ACh and subsequent activation of mAChRs, induces the cardioprotective 
phenotype. In addition, following activation of afferent sensory neurones in the 
conditioned limb, there is release of a dialysable cardioprotective factor into 
systemic circulation. The source of this factor remains unknown, although 
possibilities include i) from the conditioned limb itself ii) from the central nervous 
system iii) from pre-/post-ganglionic parasympathetic nerve endings within the heart 
iv) from a non-conditioned remote organ/tissue. 
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1.3.3.1 Blood-borne cardioprotective factor (s) 
 
A number of experimental studies have implicated a blood-borne factor(s) 
generated in the RIC-treated animal as potential mediators of 
cardioprotection. The evidence for this includes the following:   
1. Gho et al [101] noted that RIC applied to the intestine would only protect 
the heart if it was reperfused prior to coronary occlusion, suggesting that 
reperfusion was required to wash the cardioprotective factor out of the 
conditioned tissue.  
2. Dickson et al [75, 77] discovered that the ischaemic preconditioning effect 
could be transferred from one rabbit to another non-preconditioned rabbit, 
first via whole blood transfusion, and secondly via transfer of coronary 
effluent from a preconditioned to a naïve isolated heart. Hence, the 
presence and necessity of a blood-borne cardioprotective factor is clear. 
This model has been reproduced across several species [43, 215, 317, 
320] and has played a central role in recent characterisation of the 
humoral factor.  
3. Preliminary evidence suggested an intact opioid receptor system was 
required for protection to occur [74, 320], however opioid levels were not 
raised in IPC effluent [74]. A subsequent study [215] demonstrated raised 
adenosine levels in IPC effluent and, via use of the adenosine receptor 
blocker, 8-(-p-sulfophenyl)theophylline (8-SPT), that adenosine receptor 
activation was required for effluent-mediated protection. Combined 
together, this evidence could suggest adenosine and opioid receptor 
crosstalk [266, 334]. 
4. Current evidence suggests the factor is between 3.5 kDa and 30 kDa, 
thermolabile and hydrophobic. Using dialysis membranes to fractionate 
the proteins within coronary effluent or serum according to their molecular 
weight, several studies demonstrated the factor to be smaller than 30 kDa 
[43, 278, 320, 331] and, crucially, larger than 3.5 kDa [317]. This would 
suggest small molecules, such as adenosine and opioids, are not 
essential for RIC (adenosine 267.24 Da, opioids 500-800 Da, bradykinin 
1060.22 Da). Moreover, using a series of chromatographic and heating 
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steps, it was proposed that the factor was both thermolabile and 
hydrophobic, indicating it may be a protein [43, 317]. 
5. Proteomic analysis of plasma, via a combination of two-dimensional gel 
electrophoresis (2D-DIGE) and mass spectrometry (MS), unmasked an 
altered plasma proteome following RIC. Studies by Lang, Hepponstall and 
Hibert found 4, 51, and 30 differentially expressed proteins in RIC plasma 
relative to control respectively [139, 143, 207]. These proteins, linked to 
the regulation of various cellular functions, including the acute phase 
response, immune response, haemostasis and lipid transport, suggested 
a complex interaction of signalling pathways in response to RIC. Broad 
proteomic analyses, however, are not well suited to the hypothesis of a 
single, small, low abundance protein conveying the cardioprotection, due 
to the large number of high abundance proteins in plasma. Indeed, a 
recent proteomic study in 6 human subjects saw no significant 
upregulation of proteins in plasma following RIC [138]. With this in mind, 
two studies have analysed coronary effluent using liquid chromatography 
(LC) and MS, the advantage being the majority of plasma proteins (high 
abundance) are removed [197, 215]. Initial investigation revealed 185 
unique proteins in coronary effluent following five cycles of 5 minutes 
global ischaemia and 11 minutes reperfusion in an isolated rat heart. Only 
30.3% were plasma proteins, with the remainder originating from the 
cytoplasm and various intracellular organelles. A subsequent publication 
alluded in the discussion to a proteomic (LC-MS) analysis of coronary 
effluent from isolated rat hearts, which found 8-10 peptides were 
increased by >50% relative to control effluent, and ~100 uncharacterised 
ions corresponding to metabolites or proteins [215]. Thus, although high 
abundance proteins are largely excluded in coronary effluent, a significant 
amount of protein is still released, indicating that effluent must be further 
fractionated before MS if a potential biomarker is to be found. 
6. Several experimental studies have suggested that the cardioprotective 
state elicited by an RIC stimulus delivered in vivo remained, even when 
the heart was isolated and subjected to acute MI either on a Langendorff-
apparatus [203] or in a transplanted recipient animal [196]. These findings 
suggest that an intact neural pathway to the heart was not required for 
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RIC-cardioprotection during the acute MI, but it does not of course 
exclude the need for an intact neural pathway at the time of the RIC 
stimulus.  
7. Although the identity of the blood-borne cardioprotective mediator of RIC 
remains unknown, a number of candidate molecules have been 
suggested including opioid [74], adenosine [215], bradykinin [312], 
erythropoietin, calcitonin-gene related peptide, stromal derived factor 1-
alpha (SDF1-α) [72], nitrites [287] and micro ribonucleic acid 144/451 
cluster (miRNA 144/451) [218]. 
 
1.3.3.2 Neural pathway 
 
A number of experimental studies have suggested the involvement of a 
neural pathway in RIC cardioprotection. The evidence for this is summarised 
below:   
1. Gho et al [101], first noted that the ganglion blocker, hexamethonium, 
blocked RIC-induced cardioprotection elicited by intestinal conditioning, 
thereby implicating a role for the autonomic ganglia of the sympathetic 
and parasympathetic nervous systems in inter-organ protection. A 
subsequent study confirmed in human volunteers that trimethaphan, an 
autonomic ganglionic blocker, abrogated limb RIC protection of 
endothelial function [231]. Two studies, however, did not see any abolition 
of RIC with hexamethonium [188, 367], suggesting further investigation is 
perhaps necessary. 
2. Given the involvement of the autonomic nervous system in RIC, it is 
logical to hypothesise that RIC cardioprotection is dependent on an intact 
sensory afferent neuronal pathway at the remote organ or tissue. Indeed, 
transection of the femoral nerve before application of the RIC stimulus 
abolishes cardioprotection [223, 331]. Moreover, Ding et al. noted that 
brief renal artery occlusion (RAO) resulted in increased afferent renal 
nerve activity (ARNA), and its transection also abolished RIC-induced 
cardioprotection [78]. Similarly, direct stimulation of the sensory nerve of 
36 
 
the remote organ or tissue has been reported to recapitulate the 
cardioprotective effect elicited by RIC [81, 83, 248, 288]. Finally, 
stimulation of cutaneous sensory nerves using either topical application of 
capsaicin [290] or surgical skin incision (see later section on remote 
preconditioning of trauma, RPCT) [112, 293] has been reported to also 
mimic RIC cardioprotection. One recent study, however, demonstrated 
femoral nerve section did not abolish hindlimb RIC in the mouse, thus 
there remains contention as to the exact role of the sensory nerve in the 
RIC trigger pathway [287]. 
3. The question arose, therefore, of how the brief ischaemic burden to the 
tissue or organ is translated to sensory afferent activation. Experimental 
studies have demonstrated that the application of brief 
ischaemia/reperfusion to a remote organ or tissue generates factors such 
as adenosine [78, 222, 270], bradykinin [312] and calcitonin gene related 
peptide (CGRP) [48] in the remote organ or tissue which then stimulate 
the local sensory neural afferent pathway. Indeed, the adenosine receptor 
antagonist 8-SPT abrogated the increased ARNA observed by Ding et al. 
following brief RAO [78]. In addition, intrafemoral-arterial injection of 
adenosine, whilst not at a level sufficient to elicit cardioprotection alone, 
was able to induce cardioprotection via a mechanism requiring an intact 
sciatic nerve [331]. Thus, it seems RIC induces local release of a neuro-
active factor, which in turn activates sensory afferent neurones and 
initiates the cardioprotective message.  
4. The final element concerns the efferent limb of the neural pathway to the 
heart.  Initial studies demonstrated that vagal nerve stimulation (VNS) 
mimicked the cardioprotective effect of RIC, whereas with bilateral 
vagotomy this was abrogated [51, 79, 174]. An elegant study by 
Mastitskaya et al demonstrated, using optogenetics, that activation of the 
dorsal motor nucleus of the vagus nerve (DMVN) was sufficient to induce 
cardioprotection [243]. Moreover, this effect was abrogated in the 
presence of atropine. Two papers, however, counteract this paradigm; 
Firstly, spinal cord transection at C7, thereby removing central nervous 
innervation, did not abolish RPCT (see section 1.3.3.5) [167]. Secondly, 
evidence that VNS prior to index ischaemia increases infarct size [49]. 
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1.3.3.3 Neuro-humoral pathway 
 
Initial experimental studies had implicated a blood-borne cardioprotective 
pathway and an intact neural pathway to the conditioned organ or tissue. The 
actual interplay between these components remains unknown, although 
recent studies have investigated the interaction between these two signalling 
components: 
1. It has been reported that RIC by limb ischaemia or intra-arterial 
adenosine releases a dialysable blood-borne cardioprotective factor(s), 
the release of which required an intact sensory innervation of the limb and 
was blocked by pretreatment with the nitric oxide (NO) donor, S-nitroso-
N-acetylpenicillamine (SNAP) [331]. Interestingly, production of NO, via 
activation of nitric oxide synthase, is seemingly not required for production 
of the cardioprotective factor but is required for induction of the protective 
phenotype [318]. 
2. An important experimental study by Redington et al demonstrated that 
direct femoral nerve stimulation or topical application of capsaicin 
generated a dialysate which was able to reduce MI size in a naïve 
isolated rabbit heart, providing the first evidence that the neural pathway 
to the conditioned limb was required to generate the blood-borne 
cardioprotective factor [290]. 
3. In an interesting clinical study, Jensen et al found that plasma dialysate 
obtained from RIC-treated diabetic patients with sensory neuropathy 
failed to limit MI size in an isolated naïve rabbit heart, although plasma 
dialysate harvested from RIC-treated non-diabetic and diabetic patients 
without sensory neuropathy was cardioprotective [164]. 
4. The link between sensory nerve activation and release of the humoral 
factor is likely the vagus nerve. A recent study from Mastitskaya et al. 
demonstrated that surgical section of the vagus nerve below the 
diaphragm abrogated in vivo RIC in rat [242]. This suggested that the 
humoral factor was released following vagal innervation of the gut, 
however this was not explicitly proven. A subsequent study from the same 
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group suggested that glucagon-like peptide 1 (GLP-1) was released from 
the gut following RIC [25]. Finally, a study published using data in this 
thesis added weight to these data, by demonstrating bilateral cervical 
vagotomy prevented release of the humoral RIC mediator [278] (see 
Chapter 5).  
 
Therefore, the current paradigm suggests that the conditioned limb generates 
adenosine in the local circulation, which then activates the sensory neural 
pathway (through a mechanism dependant on nitric oxide), leading to the 
activation of dorsal nuclei within the brainstem. This leads to increased 
systemic vagal tone and subsequent release of a humoral blood-borne factor, 
which moves to the heart and protects [278]. This was a key finding from this 
PhD (See Chapter 5). 
1.3.3.4 Systemic response pathway 
 
There is some evidence, although inconsistent, that a systemic inflammatory 
response is obtained in the setting of reperfusion injury. Reperfusion injury 
per se is associated with a neutrophilic infiltration within the target organ 
[389]. Remote Ischaemic PreConditioning (RIPC) seems to have an anti-
inflammatory effect. For instance, a group conducting experiment on skeletal 
muscle flaps noted that RIPC reduced the number of leucocytes adhering the 
post capillary venules [205]. Similarly, RIPC decreased overall levels of 
interleukin-1β and interleukin-6 in a porcine model of lung ischaemia-
reperfusion injury. In a human forearm endothelial model of ischaemia 
reperfusion injury, neutrophil adhesion was reduced by RIC, as was 
phagocytosis [319]. Even pro inflammatory gene expression in leucocytes 
appears to be suppressed, while the anti-inflammtory gene expression is up 
regulated [195].   
As mentioned above, the vagus nerve appears to play a key mechanistic role 
in RIC. There is evidence that vagus nerve stimulation (VNS) can induce a 
systemic anti-inflammatory effect [261]. One mechanism by which this occurs 
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is release of acetylcholine from the spleen and the gut [40]. Efferent vagal 
firing to the enteric nervous system will release acetylcholine at the synaptic 
junction with macrophages. In the spleen, efferent vagus firing activates the 
splenic sympathetic nerve. This in turn stimulates splenic lymphocytes to 
release acetylcholine. In both cases, the acetylcholine will inhibit release of 
tumour necrosis factor alpha (TNFα), a pro-inflammatory cytokine, from 
macrophages [300]. Given there is a well-defined injurious inflammatory 
response to acute myocardial infarction, reducing systemic inflammation via 
VNS could be additive to the cardioprotective mechanism of RIC. Indeed, 
high serum TNFα is a well-established predictor of mortality following acute 
myocardial infarction [90].  
 
However, when a panel of circulating cytokines were analysed in adults and 
children undergoing cardiac surgery, RIPC did not produce any change in 
anti-inflammatory or pro-inflammatory cytokines [58, 173]. In a similar study 
by Albrecht et al, circulating levels of interleukin-1β, interleukin-8 and tumour 
necrosis factor-α before CPB were increased in patients subjected to RIPC 
compared to control [3]. This pro-inflammatory response directly contradicts 
pre-clinical evidence and hence, the exact role of a systemic response is 
unclear and needs further investigation. 
1.3.3.5 Remote preconditioning of ‘Trauma’ (RPCT) 
 
The concept of RPCT originally arose from the observation that patients who 
had undergone abdominal aortic aneurysm surgery had a greater risk for MI, 
a greater infarct size and increased mortality compared to those who had not 
undergone surgery [298, 349]. Indeed, Ren et al. observed that infarct size in 
mice increased with prior non-ischaemic carotid vascular surgery. However, 
Ren et al. subsequently demonstrated, in the same study, that a small 
cutaneous incision to the abdomen was able to limit MI size in a manner 
similar to RIC [293]. This unusual observation, termed remote 
preconditioning of trauma, has been demonstrated in two further studies, with 
the current paradigm suggesting the protection occurs via activation of Aδ- 
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and C- sensory afferent neurons [112, 167], which confer protection to the 
heart perhaps independent of central innervation [167].  
This compliments the theory that small diameter C-fibre afferents, which 
include nociceptive afferents, are responsible for communicating the 
cardioprotective message away from the conditioned organ/tissue. As 
discussed above, several different methods of activating such afferents 
(TENS [248], capsaicin [290], ischaemia [283], surgical trauma [293]) all lead 
to cardioprotection. Perhaps the commonality between these interventions is 
the C-fibre sensory afferent nerve. 
1.3.4 Which aspects of the RIC mechanism remain elusive? 
In pre-clinical literature, the fundamental questions of the mechanisms of RIC 
have not been adequately answered. Indeed, there is a distinct lack of 
studies that have systematically characterised RIC, particularly in terms of 
the optimal intervention protocol. For example, what are the relative benefits 
of 1 cycle when compared to 3 cycles? Is RIC more effective when applied to 
one or more limbs? Although a recent publication and meta-analysis attempt 
to address these issues, further research is still required [166, 368]. 
Moreover, our recent meta-analysis identified only 31 studies investigating 
RIC in animal in vivo models of myocardial infarction since 1997 ([45] and 
Chapter 4). This is a very small number, particularly when compared to the 
477 studies investigating classical ischaemic conditioning published in the 
same time period [368]. This is perhaps the main reason for our current lack 
of understanding. The paucity of pre-clinical RIC research means there are 
several aspects to the mechanism that remain hidden. The presence and 
necessity of a humoral factor is clear, as is the dependence on intact sensory 
innervation to the conditioned limb for its production. We and others have 
presented a key role for the vagus nerve in RIC, its activation being required 
for subsequent release of the humoral mediator. However, the exact source 
and identity of the blood-borne cardioprotective factor remains unknown. The 
absence of a validated biomarker for RIC significantly hinders one’s ability to 
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interpret neutral data. Thus, identification of this factor remains the Holy Grail 
for pre-clinical RIC research.  
1.4 Clinical translation of RIC 
The non-invasive and low-cost nature of RIC lends itself well to clinical 
translation [323]. The first setting investigated was cardiac surgery, including 
valve replacement and coronary artery bypass surgery. Here, RIC could be 
easily applied to the patient whilst under anaesthesia, thus avoiding potential 
tolerability issues. Cheung et al. first demonstrated a protective effect of RIC 
in children undergoing cardiac surgery for valve replacement [58]. Four 
cycles of 5 min lower limb ischaemia and reperfusion reduced peri-operative 
injury, as measured by serum troponin I. Although several meta-analyses 
indicate an overall protective effect of RIC in this setting [70, 116], there are a 
growing number of neutral trials [149, 391]. In particular, two recent large 
multicentre studies demonstrated no benefit of RIC in patients undergoing 
coronary artery bypass surgery, as measured by 30-day [249] and 1-year 
[122] outcome (Table 1-1). Thus, it appears that RIC is not appropriate for 
use as a therapeutic agent in cardiac surgery, the reasons for which are 
discussed below (section 1.4.1). RIC has also been employed in the setting 
of elective percutaneous coronary intervention (PCI). The first indication of a 
positive effect came from Hoole et al., who demonstrated in 242 patients that 
three 5 min cycles of upper limb ischaemia-reperfusion reduced peri-
procedural injury [150]. Remarkably, this protective effect was still apparent 6 
years following the intervention [73]. Again, there are a mixed population of 
studies in the setting, with both positive and neutral results. A more 
successful therapeutic role for RIC is surely primary PCI in patients suffering 
from ST-elevation myocardial infarction (STEMI). This is the clinical setting 
most similar to the acute ischaemia-reperfusion injury studied in pre-clinical 
models. The majority of trials in this setting have indicated a protective effect 
of RIC, with only one recent neutral study. The ongoing ERIC-PPCI and 
CONDI-2 trial, recruiting 4300 patients, is probably the best chance of 
translating RIC to the clinic [126]. Several key clinical trials investigating RIC 
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are detailed in table 1, and reasons for the failed clinical trials discussed in 
more detail below.  
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Study Patient number Setting RIC protocol Study comments Results 
Cheung (2006) 
[58] 
37 Children 
undergoing 
surgery for 
congenital 
heart defects 
4 x 5 min lower limb 
ischaemia/reperfusion 
- Single centre single blinded study 
- Endpoints of lung mechanics, 
serum cytokines and troponin I 
Decreased serum troponin I in the 
RIC group 
RIC group had lower airway 
resistance at 6hr post-operation 
RIC group had reduced inotropic 
requirement at 3hr and 6hr post-
operation 
ERICCA 
(NCT01247545) 
Hausenloy et al 
[122] 
1610 CABG surgery 
with CPB 
4 x 5 min upper limb 
occlusion/reperfusion 
 
- Multi-centre, single blinded study 
- Primary endpoint MACCE at 1 
year  
- Secondary outcomes include 
serum cTnT AUC, LVEF%, AKI, 6 
min walk test 
No difference in primary outcome 
No difference in any secondary 
outcome 
RIPHeart 
Meybohm et al 
[249] 
2070 All elective 
cardiovascular 
surgery with 
CPB 
4 x 5 min upper limb 
occlusion/reperfusion 
 
- Multicentre, double blinded study 
- Primary endpoint composite all-
cause mortality over 14 days after 
surgery 
No difference in primary outcome 
No difference in any secondary 
outcome 
44 
 
(NCT01067703) 
Hong (2014)  
[148] 
1280 All elective 
cardiac 
surgery on/off 
pump with 
cold blood 
cardioplegia 
4 x 5 min upper limb 
occlusion/reperfusion 
Both PRE- and 
POST-operatively  
- Multi-centre trial 
- Primary endpoint was composite 
outcome 
No difference in composite primary 
outcome. 
No difference in secondary 
outcome (ICU/hospital stay) 
Thielmann 
(2013) 
[340] 
329 Elective CABG 
on pump with 
cold crystalloid 
cardioplegia 
3 x 5 min upper arm 
occlusion/reperfusion 
- Single centre, double blinded 
- AUC serum cTnI primary 
endpoint 
- Mortality as main safety endpoint  
No significant difference in cTnI 
AUC 
Lower all-cause mortality at 1 year 
Lower MACCE at 1 year 
Carrasco-
Chinchilla  
(2013) [54] 
232 Elective PCI 3 x 5 min upper limb 
occlusion/reperfusion 
Remote ischaemic 
postconditioning 
- Single centre blinded study 
- Serum cTnI AUC primary 
outcome 
No difference in cTnI at 24 hours  
Diabetic patients in RIC group had 
higher incidence of PCI-MI 
Davies WR 
(2013)  
[73] 
225 Elective PCI 3 x 5 min upper arm 
occlusion/reperfusion 
- Single centre blinded study 
- 6-year MACCE follow up to 
previous Hoole et al study 
Lower MACCE at 6 years 
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Luo (2013)  
[235] 
205 Elective PCI 3 x 5 min upper arm 
occlusion/reperfusion 
- Single centre unblinded study 
- Both single and combined targets 
stented 
- Serum cTnI AUC primary 
outcome  
Significantly reduced cTnI at 16 
hours 
No change in renal outcome 
Botker (2010)  
[41] 
251 STEMI 
patients 
treated with 
PPCI 
4 x 5 min upper limb 
occlusion/reperfusion 
RIC started in the 
ambulance on 
confirmation of 
STEMI 
-Single centre single blinded study 
-Primary end point was myocardial 
salvage index determined by 
SPECT† 
Increased myocardial salvage in 
the RIC group 
Increased left ventricular ejection 
fraction at 24 hours in the RIC 
group but not at 30 days 
No difference in 30 day MACCE‡ 
Crimi (2013)  
[68] 
96 STEMI 
patients 
treated with 
PPCI 
3 x 5 min lower limb 
occlusion/reperfusion 
Remote ischaemic 
postconditioning 
-Multi centre single blinded study 
- Only TIMI 0 and 1 flow patients 
randomised (total or near total 
occlusion) 
- Primary endpoint CK-MB AUC 
Decreased CK-MB AUC in the RIC 
group 
Decreased myocardial oedema as 
determined on T2-weighted CMR§ 
imaging in the RIC group 
Better ST segment resolution in the 
RIC group 
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Table 1-1: Key trials investigating RIC in the clinic 
 
 
 
 
 
 
 
 
Sloth (2014)  
[326] 
251 STEMI 
patients 
treated with 
PPCI 
4 x 5 min upper limb 
occlusion/reperfusion 
 
-Follow up of MACCE to study by 
Botker at al 
-Median 3.8 years follow up 
Decreased MACCE in RIC group 
compared to the control group 
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Study Patient number Setting RIC protocol Study comments Current progress 
ERIC-
PPCI/CONDI-2 
[127] 
4300 STEMI 
patients 
treated with 
PPCI 
4 x 5 min upper limb 
occlusion/reperfusion 
Given in the 
ambulance (CONDI-
2) or at the hospital 
(ERIC-PPCI) 
Remote ischaemic 
perconditioning 
- Designed originally as two 
separate studies, subsequently 
combined to increase statistical 
power. 
- CONDI-2 in Denmark, ERIC-
PPCI in UK. Multicentre, single 
blinded study. 
- Primary endpoint cardiovascular 
fatality and hospitalisation for 
heart failure at 1 year  
- Secondary outcomes include 
serum cTnT AUC, LVEF%, AKI, 6 
min walk test 
Recruitment of patients to study 
Table1-2: Key upcoming trial investigating RIC in the clinic
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1.4.1 Why the negative clinical trials? 
A number of clinical studies have failed to find any beneficial effects of limb 
RIC in patients undergoing PCI [156], CABG [122, 173, 249] and vascular 
surgery [364] – these include some large clinical trials conducted in 
paediatric [246] and adult cardiac surgery [149, 285]. Several review articles 
have been published analysing the potential reasons underlying the failure to 
translate cardioprotection into the clinical setting [121, 262, 276, 315]. The 
biggest limitations of these clinical trials lie in their study design. The vast 
majority of them have been single-centre trials examining small groups of 
patients, in particular, admitted for elective CABG surgery. This represents 
less than 50% of patients undergoing major cardiac surgery in England and 
Wales. Moreover, most of the trials have been single-blinded, leaving room 
for bias. In fact, one meta-analysis suggests that single-blinded trials were 
mostly positive, while double-blinded ones were mostly negative [391]. 
Secondly, the primary end point used in almost all the trials was the area 
under the curve of a 48-hour or 72-hour collection of troponin or creatinine 
kinase (CK-MB) post-procedure. While there is evidence that higher troponin 
and CK-MB levels after cardiac surgery correlate with increased mortality at 
one year, much of this evidence comes from small single-centre, mixed 
prospective, retrospective and post-hoc analyses, as discussed in a meta-
analysis by Petaja et al [273]. This represents a surrogate endpoint and 
stronger clinical endpoints such as post-operative morbidity and mortality, 
and patient-centred indices such as quality of life are lacking. Thirdly, many 
of the initial studies excluded diabetic patients, as they were proof of concept 
trials. Indeed, several complex high-risk patients with unstable angina, recent 
myocardial infarctions, renal disease and complex surgery, were excluded. 
Co-morbidities have been demonstrated to interfere with the efficacy of 
cardioprotection [92, 372, 380]. Given that the risk profile of patients 
undergoing cardiac surgery or PCI is becoming increasingly complex, this 
represents another major drawback. Finally, a major criticism of the recent 
large scale clinical trials in cardiac surgery is the use of propofol as an 
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anaesthetic agent in a very high proportion of patients. This has been 
documented to inhibit the efficacy of RIC [198]; interestingly, preclinical 
investigation demonstrated it to inhibit vagus nerve firing [361] (discussed 
further in Chapter 5). 
 
1.4.2 Will RIC ever change current clinical practice? 
 
The one setting in which the effect of RIC has been predominantly positive is 
in STEMI patients treated by PPCI with 4 proof-of-concept studies reporting 
cardioprotective effects with limb RIC applied at the time of PPCI [41, 68, 
281, 294]. Indeed, the majority of the published clinical studies have 
established that limb RIC can limit myocardial injury in PCI, CABG and 
STEMI patients. A recent clinical study demonstrated limb RIC could reduce 
the incidence of post-operative atrial fibrillation, acute kidney injury, and it 
could shorten ITU stay in patients undergoing CABG plus or minus valve 
surgery, suggesting some benefit on short-term clinical outcomes post-
surgery [53]. Crucially, no studies have reported a detrimental effect of the 
intervention. As mentioned in section 1.4.1, two of the major issues with the 
previous studies are low numbers and surrogate endpoints. The key to 
translation for RIC lies in a research collaboration between the UK and 
Denmark, which will investigate the effect of limb RIC on improving clinical 
outcomes in STEMI patients treated by PPCI in the RIC-PPCI and CONDI2 
trials [126]. With a combined 4400 patients, these studies will give a very 
good indication as to the potential efficacy of RIC in the setting of PCI. 
Indeed, these large multi-centre trials are very much game-changers in the 
cardiovascular field, in that they will change practise if positive and largely kill 
the field if negative. 
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1.4.3 Summary 
Remote ischaemic conditioning represents a hugely promising 
cardioprotective intervention, which has not yet had the same impact in 
clinical studies relative to other animal models of IRI. The primary reason for 
this, as discussed in section 1.4.1, is a paucity of pre-clinical RIC trials in the 
literature, meaning there is a lack of basic understanding of the RIC 
paradigm. If one does not fully understand a physiological phenomenon, it 
adds great difficulty to potential clinical translation. Clear gaps exist in the 
current paradigm, which would surely aid design of subsequent clinical trials. 
This PhD aims to elucidate several key aspects of the communication phase 
of RIC, focussing on the proposed interaction between the neural and 
humoral pathways. 
 
 
 
 
 
 
 
 
 
 
51 
 
1.5 The cardiac nervous system 
1.5.1 Organisation in the healthy state 
The heart must perform according to the demands of the body at any given 
moment. This beat-to-beat control of cardiac performance is determined by 
two efferent inputs to the heart from the central nervous system, working in a 
reciprocal fashion; the parasympathetic (vagus) nerve is associated with 
depressing cardiac indices, whereas the sympathetic nerve enhances them. 
Parasympathetic pre-ganglionic nerves arise mainly from two nuclei in the 
medulla oblongata, the nucleus ambiguous and dorsal vagal motor nucleus 
[108]. Efferent parasympathetic axons move to the heart through the vagus 
nerve and synapse with intrinsic cardiac ganglia. Sympathetic pre-ganglionic 
nerves arise from the spinal cord, and receive CNS modulation from 
neurones in the hypothalamus and brainstem [107]. These will synapse with 
post-ganglionic sympathetic nerves in intrathoracic ganglia, and innervate the 
sinoatrial and atrioventricular nodes, the atria, ventricles and conducting 
tissue. Innervation of parasympathetic post-ganglionic nerves within the heart 
is perhaps more controversial. The original belief, that parasympathetic fibres 
are sparse or absent from the ventricles, is not supported by the current 
literature [67]. Rather, many studies have confirmed a wide distribution of 
vagal postganglionic neurones throughout the ventricles. Projecting from 
intrinsic cardiac ganglia, they can profoundly influence cardiac rate and 
rhythm [42].  
Sensory innervation to the myocardium is highly complex and originates 
primarily from afferent neurones with cell bodies in the nodose and dorsal 
root ganglia [15]. These neurones will transduce the chemical or mechanical 
milieu within the myocardium and communicate with the central nervous 
system, which then alters the efferent autonomic tone to the heart. There is, 
however, an added layer of complexity, as cardiac sensory afferents have 
also been found in intrathoracic and intrinsic cardiac ganglia, indicating a 
three-level hierarchical organisation of cardiac neuronal control [16]. 
Importantly, intrinsic cardiac ganglia contain both parasympathetic and 
sympathetic post-ganglionic ganglia [14]. Therefore, there exist cardiac 
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neural reflexes, in the absence of any input from the central nervous system, 
which can influence cardiac indices; this is known as the intrinsic cardiac 
nervous system (ICNS).  
Several interesting studies have indicated the level of control the ICNS has 
on cardiac performance. Firstly, an elegant study from McAllen et al 
demonstrated intrinsic cardiac ganglia were able to gate high frequency input 
from the CNS [245]. In addition, the synaptic transmission efficiency was not 
1:1, indicating these intrinsic ganglia do not act solely as synaptic relay 
stations for CNS input [11, 245]. Secondly, populations of neurones in both 
intrinsic and intrathoracic ganglia are able to communicate with each other 
via local circuit neurones [18]; these are the most common type of nerve 
found in the heart [13]. Interestingly, local circuit neurones can process 
afferent and efferent input, influencing both sympathetic and parasympathetic 
post-ganglionic tone from intrinsic ganglia. This enables the ICNS to control 
heart rhythm and rate on a beat-to-beat basis [26]. An example of this control 
is the observation that stabilisation of local circuit neurones, via spinal cord 
stimulation, reduces the potential for atrial fibrillation in dogs [103]. Thirdly, 
perhaps the most remarkable trait of the ICNS is its ability to display 
plasticity. That is, neural networks exist within the heart that can respond to a 
cardiac event and modify efferent neuronal output for the subsequent few 
cardiac cycles [15, 181]. 
The accelerator and brake thesis for cardiac neuronal control is therefore too 
simplistic. The literature currently suggests a more complex hierarchical 
cardiac neural control, with sensory feedback loops to central, intrathoracic 
and intrinsic cardiac ganglia. Local circuit neurones enable efficient 
processing of the sensory information from the myocardium, and this can 
alter the efferent autonomic outflow to finely control cardiac performance.  
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1.5.2 The cardiac nervous system and ischaemia-reperfusion injury 
Some major innervations of the heart receive their blood supply from non-
coronary sources [107]. These presumably would be immune from the 
deleterious effects of acute myocardial ischaemia, however the effect of 
infarction of the ICNS is not thought to be due to direct ischaemic injury to the 
neurones [286]. Sensory afferents within the heart respond to the altered 
chemical milieu during ischaemia, for example release of purines, free 
radicals and lactate from dead myocytes [341, 342], leading to reflex 
changes in sympathetic and parasympathetic tone.  The exact influence on 
efferent output to the heart depends on the region of the myocardium under 
ischaemia [258], although there tends to be a net tachycardia. Indeed, 
patients who have a heart rate of >80 beats-per-min following myocardial 
infarction, indicating high sympathetic tone, have a 39% increased mortality 
after 1-year [33]. In addition, pharmacological denervation of cardiac 
sympathetic afferents attenuated some of the deleterious remodelling 
following heart failure in rats [360].  
Thus, the neuronal response to myocardial ischaemia can have a profound 
effect on the degree of injury post-infarction [190]. Indeed, the complex 
neuronal hierarchy of the ICNS has not evolved to deal with the extreme 
sensory environment of myocardial infarction [182], and it can induce 
structural and functional remodelling of the ICNS [13]. Initial anatomical work 
revealed that the ischaemic scar contained a much higher density of intrinsic 
nerves, with an irregular distribution when compared to healthy tissue [353]. 
This disorganisation, in addition to the increased myocardial noradrenaline 
post-infarction [172], leads to an increased probability of ventricular and atrial 
arrhythmias [14, 362].  
An elegant study from Rajendran at al. used microelectrode techniques to 
measure activity of individual intrinsic neurones in vivo over the course 
myocardial infarction in dogs [286]. It revealed a ‘neural sensory border 
zone’, with afferents within the infarct region displaying different properties 
compared to those within adjacent healthy myocardium. This asymmetry in 
54 
 
afferent sensitivity is thought to underlie the reflex sympatheto-activation 
following infarction [286]. Moreover, these neurones are less sensitive to 
changes in preload and can no longer communicate as effectively through 
local circuit neurones.  
Finally, recent studies have demonstrated that stimulation of the vagus nerve 
can ameliorate the post-infarction remodelling of the ICNS [12, 27]. This 
important finding is discussed further in Chapter 5, where the importance of 
the vagus nerve and intrinsic cardiac ganglia in acute cardioprotection are 
investigated. 
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1.6 GENERAL RESEARCH OBJECTIVES 
The overall aim of this PhD project was to investigate the role of the 
autonomic nervous system in both classical and remote ischaemic 
preconditioning.  This was approached via several experimental projects, the 
objectives of which are set out below. 
Objective 1. To establish and verify in vivo and ex vivo models of 
ischaemia-reperfusion injury, with remote and classical ischaemic 
preconditioning (IPC) (see Chapter 3) 
Aim 1: Establish and verify a rat Langendorff model of IRI and IPC; 
Aim 2: Establish a model of inter-cardiac cardioprotection via coronary 
effluent transfer; 
Aim 3: Establish and verify a model of remote conditioning via transfer of 
plasma dialysate; 
Objective 2. To perform a systematic review and meta-analysis of 
animal in vivo models of myocardial ischaemia-reperfusion injury (see 
Chapter 4) 
Aim 1: Ascertain the overall effect and variability of RIC in reducing infarct 
size in animal models of myocardial ischaemia-reperfusion injury 
Aim 2: Investigate the determinants of RIC efficacy, including variables such 
as RIC protocol and use of supplementary oxygen. 
Objective 3. To investigate the co-dependence of the neural and 
humoral pathways in remote ischaemic conditioning (see Chapter 5) 
Aim 1: Investigate the role of the vagus nerve in release of the humoral RIC 
mediator; 
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Aim 2: Investigate the importance of intrinsic cardiac ganglia in remote 
ischaemic conditioning. 
Objective 4. To investigate the role of acetylcholine and intrinsic 
cardiac ganglia in classical ischaemic preconditioning (see Chapter 6) 
Aim 1: Use a pharmacological approach to investigate the role of intrinsic 
ganglia in myocardial IPC. 
Objective 5. To investigate transcutaneous vagus nerve stimulation as 
a potential novel cardioprotective intervention (see Chapter 7) 
Aim 1: To measure release of a blood-borne cardioprotective factor following 
transcutaneous vagus nerve stimulation in human volunteers; 
Aim 2: To investigate the cardioprotective potential of transcutaneous vagus 
nerve stimulation in a rat model of acute myocardial infarction. 
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Chapter 2  GENERAL RESEARCH METHODS 
Below details the experimental methods employed to investigate the above 
objectives. More detailed experimental protocols are given in each chapter. 
2.1 Animal usage 
Male Sprague-Dawley rats were used at 250-300g throughout all 
experiments. All use of animals was in accordance with the United Kingdom 
(Scientific Procedures) Act of 1986. Rats were housed under 12hr light/dark 
conditions, with standard chow and water provided ad libitum. Animals were 
bred and cared for by the Biological Services Unit at University College 
London.   
2.2 Ex vivo Langendorff perfused heart model of ischaemia 
reperfusion injury 
2.2.1 Preparation of apparatus and perfusion buffer 
The perfusion apparatus, as pictured in figure 2-1, was set up as follows. A 
combination of columns are arranged to facilitate a continuous column of 
fluid, held at 110cm above a cannula to give a static pressure of ~80mmHg, 
using the below calculation. 
p = h . ρ . g 
Where p = pressure (Pa), h = height of the fluid column (m), ρ = density of 
the liquid (water is ~995kg/m3 at 37.5°C) and g = gravitational constant (9.81 
m/s2) 
Thus p = 1.10 * 995 * 9.81 = 10.737 kPa or 80.3 mmHg 
The columns are filled with a modified Krebs-Henseleit buffer (KHB) 
consisting of 118mM NaCl, 25mM NaHCO3, 11mM d-glucose, 4.7mM KCl, 
1.22mM MgSO4.7H2O, 1.21mM KH2PO4 and 1.84mM CaCl2.2H2O. The 
buffer is warmed to 37.5°C and gassed with 95% O2/5% CO2 to obtain a pH 
of 7.35-7.45.  
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2.2.2 Surgical procedures 
Male Sprague-Dawley rats were anaesthetised with an upper-left quadrant 
intraperitoneal injection of 60mg/kg sodium pentobarbital (Animalcare, York, 
UK). Once deep anaesthesia was confirmed by the absence of pedal pain 
withdrawal reflex, the animal was arranged in a supine position ready for the 
surgical procedure. A skin incision is made either side of the rib cage at the 
costal margin to expose the diaphragm and sternum. This incision is 
continued through the ribs at the left and right anterior auxiliary lines to create 
a clamshell thoracotomy. The pericardium is then cut-through, exposing the 
heart and the great vessels, at which point the heart excised via one smooth 
motion with scissors, ensuring a 5-10mm section of the aorta remains intact. 
The heart is immediately arrested by placing in ice cold KHB to limit the 
opportunity for any ischaemic damage before cannulation. The heart is then 
cleaned of any connective/lung tissue, and the aorta is cannulated with the 
perfusate already dripping, minimising the risk of air being introduced into the 
coronary vasculature. The heart is then secured to the cannula with a silk 
suture. It is worth noting that this cannulation step is absolutely fundamental 
to the Langendorff method. The cannula must be positioned close enough to 
the aortic valves so as to create the correct perfusion pressure and enable 
effective flow through the coronary vasculature. If placed too high, insufficient 
pressure will be exerted at the level of the coronary ostia, if too low one risks 
damaging the valves.  
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Figure 2-1. Picture of the Langendorff constant pressure perfusion apparatus 
used throughout the PhD 
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2.2.3 Measuring physiological parameters 
The left atrial appendage is removed and a small deflated balloon, made 
from the tip of an unlubricated latex condom (Durex, UK), is inserted into the 
left ventricle through the mitral valve. The balloon is attached to a catheter, 
which connects to a pressure transducer and bridge amplifier (AD 
Instruments) (figure 2-2). The system is filled with distilled water, which 
enables pressure changes in the LV to be detected in the pressure 
transducer. The balloon is inflated to give a left ventricular end diastolic 
pressure (LVEDP) of 6-10mmHg, providing a physiological preload. The 
bridge amplifier was connected to a PowerLab/8SP data acquisition system 
and linked to Chart 7 (both AD Instruments, Oxford, UK) on a computer. One 
can then visualise the rhythmic pressure of contraction and from it obtain 
several functional measurements, including LV developed pressure. 
A small incision is also made in the right pulmonary opening tract, to facilitate 
coronary drainage and enable insertion of a temperature probe into the right 
ventricle. The probe is connected to PowerLab via a T-type pod (AD 
Instruments, Oxford, UK). Finally, the coronary flow rate can be estimated by 
measuring the volume of effluent that flows from the heart over the course of 
a minute. A period of stabilisation is then necessary to allow the heart to 
become accustomed to its new surroundings and, crucially, to enable the 
experimenter to determine the quality of the preparation. Several exclusion 
criteria were referenced to, including coronary flow rat, arrhythmias, heart 
rate and LV developed pressure, as outlined in table 2-1. 
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Figure 2-2 Picture of pressure transducer with latex balloon attached. The 
fluid-filled latex balloon would be inserted into the left ventricle of isolated perfused 
hearts in order to obtain estimates of left ventricular pressures during the cardiac 
cycle. 
 
Table 2-1. Criteria to indicate a well-perfused, healthy heart 
 
Parameter Criteria for inclusion 
Coronary flow rate (mls/min) >10mls/min, <20 ml/min 
Heart Rate (bpm) >200 
LV developed pressure (mmHg) >70mmHg 
Arrhythmias No continuous arrhythmic episode 
lasting >3-4 minutes during 
stabilisation. 
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2.2.4 Ischaemia-reperfusion injury 
Following successful cannulation of the heart, and prior to insertion of the 
balloon and temperature probe, a 3-0 Mersilk suture (Ethicon, Edinburgh, 
UK) is inserted through the heart to surround the left anterior descending 
coronary artery. After a period of stabilisation, the suture is tightened using a 
snare contraption, which physically closes the left anterior descending 
coronary artery, thereby inducing ischaemia. This is demonstrated in figure 2-
2, where a discolouration of the ischaemic myocardium is clearly visible. To 
induce reperfusion, the snare contraption is removed, therefore loosening the 
suture and allowing the LAD to open and reperfuse the ischaemic tissue with 
buffer. The infarction is clearly visible as a developing pale appearance 
during the reperfusion period. 
Figure 2-3. Representative images of an isolated perfused rat heart 
undergoing ischaemia-reperfusion injury. A suture is placed around the left 
anterior descending coronary artery and, after a period of stabilisation, tightened 
using a snare contraption to induce ischaemia. Reperfusion is initiated by removing 
the snare contraption.  
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2.2.5 Analysis of infarct size  
2.2.5.1 Triphenyl tetrazolium chloride staining 
At the end of reperfusion, the suture surrounding the left anterior descending 
coronary artery was securely re-tied. Around 0.8ml 0.25% Evans blue dye 
was then injected into the heart through the cannula. This enables visual 
differentiation between myocardium at risk and not at risk of infarction from 
the LAD occlusion. That is, myocardium not stained by the dye was at risk of 
infarction. Samples were then weighed, labelled and frozen for a minimum of 
2 hours. The frozen hearts were then sliced into five 2mm sections from the 
LV suture to the apex, then incubated for 15 minutes in 1% triphenyl 
tetrazolium chloride (TTC; Sigma-Aldrich, MO, USA) solution (made up in 
phosphate buffer) at 37.5°C. TTC is reduced by dehydrogenases in live cells 
to form a red pigment. Non-viable tissue is not stained. Following incubation, 
the sections are fixed in 10% formalin (Sigma-Aldrich, MO, USA) for at least 
2 hours. Heart sections were then scanned to a computer for analysis of 
infarct size. 
Figure 2-4. Use of Evans blue staining to delineate area-at-risk post-infarction:  
 
A B C 
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2.2.5.2 Calculation of infarct size using planimetry 
Scanned heart slices were analysed for infarct size using ImageJ software 
(version 1.45, National Institutes of Health, USA). First, heart sections were 
isolated and ventricular spaces removed (Fig. 2-5 A). Thresholding was then 
used to calculate the total ventricular area, the Evans blue area and finally 
the infarcted area. These three figures could then be used to calculate first 
the area-at-risk (ventricular area – Evans blue area), and subsequently the 
infarct size as a proportion of the area-at-risk. 
 
 
Figure 2-5. Representative images demonstrating stages of calculating infarct 
size using ImageJ software. 
(A) Heart sections isolated and ventricular space removed; thresholding then used 
to calculate (B) the total heart area, (C) the Evans blue area and (D) the infarcted 
area. 
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2.3 Model of cardioprotection via transfer of plasma dialysate 
Below describes a model of cardioprotection used in several publications 
[164, 331], which enables study of the release of a blood borne 
cardioprotective factor following an in vivo intervention. Particular focus is on 
remote ischaemic conditioning. This model is employed during chapters 5 
and 7. 
2.3.1 Surgical procedure (rats) 
Male Sprague-Dawley rats (250-350g) were anaesthetised via an upper-left 
quadrant intraperitoneal injection of 20% w/v sodium pentobarditone 
(Animalcare, York. UK) at a dose of 0.05 ml/100g + 0.05ml. Once 
anaesthesia was reached, confirmed via loss of pedal reflex, the animal was 
secured in a supine position on a heat mat. A loop of 5-0 suture (Ethicon, 
Edinburgh, UK) was positioned around the top incisors to enable intubation, 
via optic light trans-illumination of the trachea, using a modified 16G, 1.7 x 51 
mm Abbocath-T intravenous cannula (B. Braun, PA, USA). This cannula was 
connected to either a PhysioSuite (Kent Scientific, CT, USA) or Small Animal 
Ventilator (Harvard Apparatus, Kent, UK), and ventilated with air 
supplemented with 0.5 L/min oxygen. Correct intubation was confirmed via 
observation of the chest moving up and down with the respiratory cycle. Tidal 
volumes were calculated using the formula: tidal volume=7.2 ml/kg. A 2cm 
positive end expiratory pressure was maintained throughout the surgical 
procedure to prevent collapse of the lungs. Finally, core body temperature 
was maintained at 37.0 ± 0.5°C via a rectal probe feeding back to a heat pad. 
The experiment was terminated if core temperature deviated by more than 
1°C either side of this range for more than 5 minutes. 
2.3.2 Interventions (rat) 
Several different interventions were performed on the anaesthetised rats; 
these are described in detail during chapters 4,5 and 6. Blood was sampled 
at the end of each intervention via right ventricular puncture. 
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2.3.3 Interventions (human) 
As part of a collaboration with the University of Leeds, we performed a study 
using healthy human volunteers. This is described in detail during chapter 6. 
Blood samples were taken before and after an intervention via the right 
antecubital vein. 
2.3.4 Preparation of dialysate 
Following blood aspiration, samples were immediately centrifuged at 1600 g 
for 20 min at 21°C, supernatant collected and spun at 10,000 g for 30 min at 
21°C to obtain platelet-free plasma; 9mls of whole blood tended to provide 4 
mls of plasma. A 10cm piece of 12-14kDa dialysis membrane (Spectra/Por, 
Spectrum Laboratories Inc., CA, USA) was soaked for 25 minutes in ddH2O, 
in order to remove the preservative, washing at least twice during this period. 
This was filled with 4 mls of plasma, clamped at either end, placed in a 
beaker containing 200 mls of modified KHB (118mM NaCl, 4.7mM KCl, 
1.22mM MgSO4.7H2O, 1.21mM KH2PO4 and 1.84mM CaCl2.2H2O) and 
dialysed for 24 hours at 4°C (Figure 2-5). Prior to perfusion through the naïve 
heart, the dialysate was supplemented with 25mM NaHCO3 and 11mM d-
glucose. 
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Figure 2-6: Schematic describing process of dialysate preparation: 
Animals are randomised to receive either sham procedure or RIC (4 x 5 min 
hindlimb occlusion and reperfusion). Blood is harvested via puncture of the right 
ventricle and centrifuged first to isolate plasma and, second, to remove platelets. 
The plasma is then dialysed across a 12-14kDa membrane before being perfused 
through a naïve heart prior to IRI. 
 
 
Figure 2-7: IRI protocol for dialysate ex vivo experiments: 
Isolated perfused rat hearts were, after a 20-minute stabilisation period, perfused 
with either control or RIC dialysate for 10 minutes. After a 10 minute washout period, 
the hearts were put into ischaemia via LAD occlusion for 35 minutes, followed by 60 
minutes of reperfusion. 
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2.3.5 Ex vivo ischaemia-reperfusion injury 
Sprague-Dawley rats (250-350g) were anaesthetised with an upper-left 
quadrant intraperitoneal injection of 60mg/kg sodium pentobarbital 
(Animalcare, York, UK). Following conformation of deep anaesthesia, a 
clamshell thoracotomy was performed, the heart excised and immediately 
placed in ice cold KHB. The aorta was then cannulated and coronary 
vasculature perfused with KHB using a Langendorff gravity driven constant 
pressure rig as previously described (section 2.2).  
The hearts then underwent a 20 minute period of stabilisation, followed by 
perfusion of the dialysate for 10 minutes and a subsequent 10-minute 
washout period prior to a 35 minute left anterior descending coronary artery 
(LAD) occlusion and 60 minute reperfusion (see Figure 2-7). At the end of 
reperfusion, infarct size was evaluated using methods described in section 
2.2.5.  
2.3.6 Blinding and data analysis 
The experimenter was not blinded to either application of RIC or sham 
protocols to the anaesthetised rat, nor the subsequent dialysate perfusion 
through the naïve isolated rat hearts. The experimenter was, however, 
blinded to the analysis of infarct size for each heart. Data analysis was 
conducted using Prism; detailed analysis protocols are provided in each 
chapter. 
2.4 Ex vivo model of isolated primary cardiomyocyte hypoxia-
reoxygenation 
Male Sprague-Dawley rats were anaesthetised with 60mg/kg sodium 
pentobarbital, hearts excised and cannulated on a modified constant-flow 
Langendorff apparatus. The hearts were then perfused with a series of five 
solutions, based on an isolation buffer described in table 2-2. Solutions were 
warmed to 37.5°C and gassed with a 100% oxygen. Solution 1, containing a 
small amount of calcium, was perfused through the heart for 4 minutes to 
clear the heart of blood and rejuvenate the heart following cannulation. 
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Solution 2 contained 100μM EGTA and was perfused for 4 minutes in order 
to arrest the heart and prevent myocyte hypercontracture. Solution 3 
contained 100μM CaCl2 and 0.5mg/ml type II collagenase (Worthington, NJ, 
USA) and was perfused through the heart for 8 minutes. The heart should 
appear pale and swollen. At the end of this stage, the ventricular tissue is cut 
from the heart and then cut into small pieces using scissors with the tissue 
bathed in 10mls of solution 3. This solution is then gassed with oxygen and 
continuously agitated. Here, the experience of the operator plays a role, as 
one must observe the right moment to stop the digestion. Too little time, and 
the yield of cells is too small, too long and the collagenase will induce 
myocyte death. The cells are allowed to pellet and calcium slowly re-
introduced via solution 4 (0.5mM CaCl2) and solution 5 (1M CaCl2). Myocytes 
were finally resuspended in M199 medium with added penicillin (100 IU/ml), 
streptomycin (100 IU/ml), L-carnitine (2 mM), creatine (5 mM), taurine (5 mM) 
and BSA (2g/L) (Medium 199, Sigma, UK),  before plating on 35mm dishes 
(VWR international, PA, USA) coated with laminin and left to stabilise 24hr 
prior to commencing the experiment. 
 
 
 
 
 
 
 
 
Table 2-2: Stock perfusion buffer components for cardiomyocyte isolation 
Salts Molarity g/500ml 
   
NaCl 130 
 
3.79 
KCl 
 
5.4 0.2 
MgCl2  
 
1.4 0.066 
Na2HPO4 
 
0.4 0.028 
HEPES  
 
4.2 0.5 
pH to 7.3 at 37°C 
Glucose †  
 
10 0.9 
Taurine †  
 
20 1.25 
Creatine †  
 
10 0.655 
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Solution number Additional components 
Required addition to 
volume stated in first 
column 
(1) 50ml; to clear the 
heart of blood 
750μM CaCl2 37.5μl of 1M CaCl2 
stock solution 
(2) 50ml; to arrest the 
heart 
100μM EGTA 2mg of EGTA 
(3) 40ml; to digest the 
heart 
100μM CaCl2 
0.5mg/ml Collagenase 
40μl of 100mM CaCl2 
15-20mg Collagenase 
(4) 50ml; to 
reintroduce calcium 
0.5mM CaCl2 25μl of 1M CaCl2 
(5) 50ml; to 
reintroduce calcium 
1mM CaCl2 50μl of 1M CaCl2 
Table 2-3. Additional components to each solution to be prepared fresh prior 
to the isolation procedure 
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2.5 Biochemical assays 
2.5.1 Bicinchoninic acid (BCA) assay to measure protein content 
Plasma or dialysate samples were assayed for protein concentration using 
the BCA assay method as described previously [327]. Briefly, 5μl of each 
sample is added to a 96-well plate, followed by 195μl of a 1:50 mix of copper 
II sulphate and bicinconinic acid. This is allowed to incubate for 30mins at 
37°C before being subjected to colorimetric analysis at 470nm using an 
automated 96-well plate reader (Fluostar Omega, BMG Labtech, UK). 
The assay is dependent on two reactions. First, a temperature dependent 
reaction where peptide bonds in the sample reduce Cu2+ to Cu+. The amount 
of Cu2+ reduced is proportional to the protein content of the sample. Second, 
bicinchoninic acid chelates with Cu+ to form the distinctive purple colour 
associated with the assay. This can then be read using the automated plate 
reader described above.  
2.5.2 Acetylcholine assay 
A Choline/Acetylcholine Assay Kit (Abcam, UK) was used to measure the 
concentration of acetylcholine in effluent collected following IPC (3x5min 
global ischaemia-reperfusion) or corresponding control period, as described 
above. The assay was carried out in accordance with the instructions 
provided by the manufacturer. Briefly, via the use of acetylcholinesterase, the 
level of free and total choline was measured in each sample, enabling an 
estimation of the concentration of ACh within the sample.  
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Chapter 3 CHARACTERISATION OF THREE MODELS OF 
CARDIOPROTECTION 
3.1 Introduction 
Soon after the discovery of IPC, research from the Przyklenk group gave the 
first clue to the remote potential of the intervention [284, 371]. In an in vivo rat 
model of IRI, they found that infarct size of preconditioned hearts, as a 
proportion of the area at risk (I/AR), was positively correlated with the area at 
risk, as a proportion of the left ventricle (AR/LV). That is, the larger the 
AR/LV, the larger the IS/AR. No correlation was observed with control hearts. 
This, they suggested, meant the non-ischaemic region contributed to the 
cardioprotection afforded by IPC. Indeed, this observation was corroborated 
in pigs [113], and a mathematical model of this phenomenon suggested a 
factor could diffuse from the non-ischaemic region to the AR and add to the 
protection [371]. Although this hypothesis of diffusion has proved incorrect, 
the experiment that precipitated from this correlation was the first observation 
of RIC, and initiated a huge research field.  
Further to the ‘preconditioning at a distance’ first described by Przyklenk et al 
[283], several other groups extended the paradigm demonstrating application 
of a conditioning stimulus to the kidneys, mesentery or gastrocnemius 
muscle could induce cardioprotection [35, 102]. These data necessitated a 
communication step, and it was suggested a humoral factor was released in 
response to conditioning that moves to the heart via the bloodstream to 
induce protection. Przyklenk’s group followed up this hypothesis with an 
elegant study [75]; coronary effluent collected from an isolated perfused rat 
heart subjected to IPC could induce cardioprotection when perfused through 
a naïve isolated heart prior to IRI. Thus, the presence and necessity of a 
blood-borne cardioprotective factor was clear. It is worth noting, however, 
that the Downey group was not able to replicate the original ‘PC at a 
distance’ experiment in a rabbit model [257].  
Whilst this model of inter-cardiac conditioning has proved a useful 
experimental tool, as the paradigm of RIC expanded it became clear the 
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mechanism of communication was more complex than a humoral mediator 
released from the conditioned limb. Indeed, several experimental studies 
demonstrated the dependence of RIC on intact neural innervation to the 
conditioned limb [102, 222, 223]. However, these models were in vivo in 
nature, meaning one could not ascertain exactly what role the neural 
pathway plays in the RIC paradigm. Thus, a new model of RIC was required, 
containing both in vivo and ex vivo components, which would enable 
differentiation between the trigger, communicator and effector components. 
Developed by the Redington laboratory, it involved preparation of a plasma 
dialysate following in vivo RIC in rabbits, which was then perfused through a 
naïve heart prior to IRI [320]. The model therefore investigates the release of 
a humoral factor into the blood following RIC and, crucially, enabled the 
experimenter to intervene at the in vivo stage to test the regulation of release 
of the humoral mediator. Several publications from groups using this model 
have demonstrated the dependence of the humoral pathway on activation of 
sensory afferent nerves from the conditioned limb [164, 288, 331]. This was a 
huge paradigm shift, highlighting the complexity of the phenomenon. 
Via use of both the models described above, this thesis aims to expand the 
RIC paradigm further, with particular emphasis on the neural pathway in both 
the communication of RIC and the induction of protection within the 
myocardium [278]. 
3.2 Research aims and objectives 
The primary objectives of the chapter were three-fold:  
1. To establish and validate a model of ischaemia-reperfusion injury 
using the Langendorff isolated perfused heart method; 
2. To use the above model to recreate the inter-organ model of classic 
IPC via coronary effluent transfer. 
3. To recreate and validate the model of RIC using transfer of plasma 
dialysate. 
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3.3 Aim 1: Establish ex vivo model of myocardial ischaemia-
reperfusion injury 
3.3.1 Background 
Oskar Langendorff first proposed the concept of retrograde perfusion of an 
isolated mammalian heart in 1895 [208], based on earlier work by Elias Cyon 
on the isolated frog heart. Indeed, the basic principles have largely remained 
the same since and the technique has proved very useful in understanding 
cardiac physiology. In particular, this model has played a central role in our 
understanding of cardioprotection, from initial discovery of ischaemic 
preconditioning [255] to the identification of protective signalling pathways 
[129]. The simplicity and reproducibility of the model, along with the ability to 
study the heart in isolation of other systemic influence, are its primary 
advantages. 
The isolated heart, following excision, is retrogradely perfused with a 
crystalloid buffer via cannulation of the aorta. The pressure created via the 
perfusate will close the aortic valve and force the buffer into the coronary 
arteries via the ostia. The perfusate will then pass through the vascular bed 
of the heart and drain as normal into the right atrium via the coronary sinus. 
In the absence of the pulmonary system, the buffer is then free to drain from 
the heart, thus the heart beats away happily without any fluid filling of the 
ventricles.  
The original method of perfusion, first created by Langendorff, is via 
maintenance of a constant fluid pressure at the aortic root of the isolated 
heart. This was achieved via a sealed pressurised chamber and monitored 
by an attached manometer [208]. Modern, commercially available, apparatus 
is designed in a similar style, however one maintains constant perfusion 
pressure via a negative feedback peristaltic pump. The advantage here is 
that a small volume of fluid is needed to create the necessary pressure for 
perfusion. This enables use of blood supplemented perfusion buffers, or 
investigation of a drug with limited availability or high expense. In addition, 
one is able to measure coronary flow rate continuously and can switch 
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seamlessly to a constant flow set-up. With a known flow rate and perfusion 
pressure, a derivation of Ohm’s law can be used to calculate coronary 
vascular resistance. This mode is therefore preferred for investigating 
coronary vascular tone, smooth muscle or endothelial function. Conversely, 
the constant pressure mode has been well validated in the setting of acute 
ischaemia-reperfusion injury. 
The disadvantage of the commercially available Langendorff apparatus, 
however, is the peristaltic pump. This, in the author’s experience, is very 
prone to dysfunction and unnecessarily complicates the maintenance of 
constant perfusion pressure. Indeed, this can be easily induced via a single 
column of fluid, with the meniscus set at a known distance above the cannula 
tip. Once the aorta of the heart is cannulated, the static fluid column will 
maintain the pressure at the aortic root, and the coronary circulation can 
naturally choose the rate of flow. This is the mode of perfusion used 
throughout this thesis.  
The Langendorff model has been used extensively in the setting of acute 
ischaemia-reperfusion injury. This is easily induced via tightening/loosening 
of a silk suture placed around a coronary artery, and then quantifying the cell 
death that occurs. The model can therefore quickly give an idea as to the 
cardioprotective potential of a particular drug or intervention.  
The aim for this section was to establish and validate a model of IRI using 
isolated perfused rat hearts. To do this, it is necessary to demonstrate a 
reproducible infarct size in response to an injury, with a standard deviation 
small enough to detect a cardioprotective intervention. Here, IPC will be used 
as a positive control. 
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3.3.2 Methods 
The methods used are described in detail in section 2.2. Isolated perfused rat 
hearts were randomised to receive one of three protocols: (1) sham 
procedure, where the heart is perfused without intervention for 140min; (2) 
Control, where hearts received 45min stabilisation followed by 35min left 
anterior descending artery ischaemia and 60min reperfusion; (3) IPC, hearts 
received 3 cycles of 5min global ischaemia-reperfusion immediately prior to 
index ischaemia as described above. 
Following each experiment, hearts were analysed for infarct size using 
triphenyl tetrazolium chloride staining (described in section 2.2.5). An 
indication of functional recovery from ischaemia was observed via 
measurement of left ventricular developed pressure and coronary flow rate. 
In addition, both coronary flow rate and left ventricular developed pressure 
were measured at specific time points throughout the experimental protocol 
(described in section 2.2.3). 
 
 
Figure 3-1. Experimental protocols during characterisation of the Langendorff 
isolated heart model. 
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3.3.3 Results 
An important step in validation of the model is ensuring reproducibility of 
suture placement. Indeed, the area at risk needed to be between 35%-65% 
of the LV area for inclusion in the final data set. If one can maintain a 
constant AAR, then any variability in infarct size is reduced. Too large an 
AAR would induce a large injury from which the heart may not recover, too 
small would induce a smaller injury from which the heart would recovery well. 
Figure 3-2 shows the AAR% in each of the groups, with no significant 
differences between the groups thus indicating procedural consistency.  
 
Figure 3-2: Area at risk in isolated rat hearts subjected to either sham, control 
or IPC protocols.  
No statistical difference was found between the groups, thus confirming surgical 
consistency in placement of LAD suture. 
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Figure 3-3: Comparison of infarct size between sham, control and IPC groups.  
The ischaemia-reperfusion protocol induced a reproducible injury in isolated rat 
hearts. IPC was able to significantly reduce infarct size relative to control 
(40.7±4.4% vs 23.0±4.8%, p<0.05). Normality confirmed via Kolmogorov-Smirnov 
test. Statistical significance was assessed using one-way ANOVA with Tukey’s 
multiple comparison test. 
 
Infarct size analysis revealed that the IR protocol induced considerable and 
reproducible injury to the myocardium (I/AAR = 48.0±1.9%). This injury was 
significantly attenuated by the preceding IPC protocol (I/AAR = 16.2±2.4%, 
p<0.05 vs control). This level of cardioprotection is very much in line with the 
literature [158, 227, 250, 354], thus further validating the model 
characterisation. Sham hearts displayed infarcts of 5.7 ± 1.0%, confirming 
the procedure of hanging and retrogradely perfusing the heart is associated 
with minimal myocardial damage. 
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Figure 3-4. Functional parameters measured in hearts who received either 
sham or IPC.  
Measurement of (A) coronary flow rate and (B) left ventricular developed pressure, 
in naïve hearts that received control or IPC procedures, throughout the ischaemia-
reperfusion protocol. All data presented as mean ± SEM, data analysed by two-way 
ANOVA. 
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Finally, no significant improvement in functional recovery from index 
ischaemia was observed with IPC, both in terms of coronary flow rate and left 
ventricular developed pressure (Fig. 3-4). Interestingly, the coronary flow rate 
increased significantly during the IPC protocol, particularly after the first 
cycle. In addition, during the IPC protocol the developed pressure recovered 
from each ischaemic cycle to only 80% of baseline. 
3.3.4 Discussion 
The Langendorff model of ischaemia-reperfusion injury has been extensively 
described in the literature, and is very well established in the literature. Thus, 
although there are several key caveats to the model, this project did not 
revisit them in the interests of time. It is important, however, to discuss these 
caveats, which include species, gender, age, use of anaesthetic and duration 
of IR.  
• Species. The choice of species is key to the Langendorff IRI model 
[368], due to the inherent variability in the coronary vasculature [244]. 
Small animals such as rabbits, rats or mice are traditionally used due 
to their small size, thus smaller apparatus and less perfusate are 
required, in addition to the reduced cost per animal. Despite the 
obvious limitations to using small mammalian hearts, notably the 
faster heart rate, altered Ca2+ handling and limited collateral flow, they 
are suitable to the buffer perfused Langendorff model as a 
homogenous supply of the myocardium with oxygen and nutrients is 
easier to ensure. The advantage of the Langendorff model, as 
previously mentioned, is its simplicity; the use of small animals 
facilitates this simplicity.  
• Gender. Male rats are almost exclusively used in the study of 
myocardial IRI. This is due to the potential confounding oestrus cycle 
in females. Indeed, oestrogens are associated with significant cardio-
atheroprotection, highlighted perhaps by the reduced CAD incidence 
in females [252], and reviewed nicely by Hodgkin and Maeda [146]. 
There are clear gender differences in the efficacy of cardioprotection 
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[21], which have not been fully defined. Therefore, although IRI is very 
much pertinent to both sexes, only male rats were used in this thesis 
to avoid an unnecessary confounder.  
• Age. The rats used in the model were between 3 and 5 months of age, 
which correlates with a young adult stage of life. Age has been well 
documented to influence the cardiac response to IRI and 
cardioprotective interventions [372]. The effect of age on the 
cardiovascular system is very well described, which precipitates as 
increased incidence of CAD. Thus, investigating IRI in young rats is 
perhaps not the ideal representation of CAD in humans, most 
commonly developing during middle/old age.  
• Duration of IR. The standard IR protocol used in this laboratory for 
isolated hearts is 35 minutes LAD occlusion followed by 60 minutes 
reperfusion. This protocol induces an infarct size that enables effective 
demonstration of cardioprotective interventions such as IPC and RIC. 
The extent of infarction is very much correlated with the duration of 
ischaemia. Whilst reperfusion duration has been recently 
demonstrated to correlate with infarct size in mouse Langendorff [301], 
in the rat model 60min reperfusion gives a similar infarct size to 
120min [93]. Thus, 60min reperfusion was used throughout this thesis. 
This protocol was very tightly controlled for each experiment.  
• Temperature and pH. These are the two most important variables to 
maintain at a consistent level in the Langendorff model [29]. Indeed, 
van Vuuren et al. demonstrated that a very small (0.5°C) reduction in 
temperature impacted the ability to cardioprotect with IPC [355]. In 
addition, pH has a great influence not only on normal cardiac function 
but also the response to ischaemia reperfusion injury. 
The use of functional recovery as a valid endpoint in the Langendorff model 
is controversial. The nature of the model means that no fluid enters the left 
ventricle, instead preload is created artificially via insertion of a balloon 
(section 2.2.3). Although the extent of infarction is associated with myocardial 
function [228], several studies have failed to see a recovery of function 
proportional to the reduction in infarct size induced with IPC [64, 161, 345]. 
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Therefore, infarct size is seen as the more appropriate end point in studies 
investigating cardioprotective interventions. This will be used as the primary 
endpoint throughout this thesis. 
3.4 Aim 2: Establish model of inter-cardiac cardioprotection via 
transfer of coronary effluent 
3.4.1 Background 
The first demonstration of cardioprotection via transfer of coronary effluent 
came from the Przyklenk group in 1999 [75]. Coronary effluent collected from 
an isolated rabbit heart during an ischaemic preconditioning protocol could 
induce powerful cardioprotection when perfused through a naïve isolated 
rabbit heart prior to IRI. Effluent collected during a time-matched control 
period offered no protection to the naïve acceptor heart. This provided the 
conclusive evidence for a humoral factor as the communicative agent for 
IPC. Crucially, it provided the opportunity to intervene at the level of the 
effluent and directly investigate the identity and source of the humoral factor. 
For example, adding an antagonist to the effluent, or analysing for presence 
of a particular molecule/protein.  
Given the similarity of this model to the initial demonstration of remote 
ischaemic conditioning [283], this was interpreted as proof of a humoral 
mediator for this paradigm. However, this is likely not the case as RIC is 
communicated via a complex neuro-humoral mechanism involving, for 
example, the dorsal vagal nucleus in the brainstem. Thus, the model 
demonstrates that IPC is triggered and mediated via release of several 
factors, which locally induce protection. 
Several important additions to the IPC paradigm have been made using the 
effluent model. Given IPC was thought to be receptor-mediated, via small 
molecules such as adenosine and opioids, studies have focussed on these 
as potential mediators of IPC, with contrasting results. Initially, Dickson et al 
could not find any correlation between infarct size and adenosine 
concentration in the IPC effluent [75]. Instead, a further study from the same 
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group suggested opioid involvement, with naloxone abrogating IPC-effluent 
mediated cardioprotection [74]. However, pre-treatment with exogenous Met- 
and Leu-enkephalin failed to elicit a cardioprotective response. In addition, 
contrasting evidence from the Redington group implicated adenosine as a 
mediator of effluent-mediated protection; adenosine was significantly 
increased in IPC-effluent and receptor blockade with 8-(p-
sulfophenyl)theophylline (8-SPT) abrogated IPC-effluent cardioprotection 
[215]. Thus, the combined data suggests the possibility of opioid and 
adenosine receptor crosstalk, a phenomenon implicated in both IPC [266] 
and RIC [335]. 
The second important contribution the effluent model provided was a 
characterisation of the protective factor, with the current paradigm suggesting 
that it is a hydrophobic, thermolabile protein between 3.5kDa and 30kDa in 
weight [138, 215, 317]. This would suggest small molecules (such as opioids 
and adenosine) are not essential for protection. Indeed, there is likely some 
redundancy in this communication step, with more than one cardioprotective 
factor released.  
Thirdly, the model has been used to gain important insights into the 
mechanism of induction of protection in the myocardium. Traditional 
cardioprotective kinases were implicated, including activation of PKC, ERK, 
Akt and PI3K. In addition, two studies have demonstrated that preservation of 
mitochondrial integrity is fundamental to effluent-mediated protection, via 
inhibition of ROS production, preserved outer membrane integrity, improved 
respiration and inhibition of mPTP formation [215, 346]. 
The aim of this section was to recreate the model of inter-cardiac 
conditioning using isolated rat hearts, to enable investigation of the humoral 
communication of IPC. In addition, an exploratory experiment was 
undertaken to investigate the involvement of stromal-derived factor 1 alpha in 
this setting. This is a highly cardioprotective chemokine, acting through the 
CXCR4 receptor, and has recently been implicated in the mechanism of 
remote ischaemic conditioning [390].  
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3.4.2 Methods 
1) Model characterisation 
Isolated perfused rat hearts were used throughout this experiment. Detailed 
methodology for this model is found in section 2.2. Hearts were randomised 
firstly to be either donors or acceptors, and subsequently to either control or 
IPC groups, thus four groups in total : (1) Donor Control hearts underwent 30 
minutes of perfusion during which effluent was collected; (2) Donor IPC 
hearts received three cycles of 5-minute global ischaemia with intermittent 5-
minute reperfusion, during which effluent was collected; (3) Acceptor Control 
hearts received 10 minute perfusion of donor control effluent immediately 
prior to ischaemia; (4) Acceptor IPC hearts received a matched 10 minute 
perfusion of donor IPC effluent immediately before ischaemia. In all groups, 
hearts were subjected to 35 minutes of LAD ischaemia and 60 minute 
reperfusion. 
Three experimental endpoints were used. First, infarct size was measured in 
each heart at the end of reperfusion, using Evan’s blue to delineate the area 
at risk and triphenyl tetrazolium chloride staining to measure cell death 
(section 2.2.5).  
Second, several functional parameters were taken from the perfused heart 
throughout the IRI protocol. Pressure and heart rate measurements were 
taken via a fluid-filled balloon in the left ventricle. In addition, coronary flow 
rate was manually measured at set time points throughout the protocol. 
These are described in more detail in section 2.2.3. 
Finally, protein concentration in both control and IPC effluent was measured 
using the BCA method described in section 2.6.  
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2) Study to investigate importance of stromal-derived factor 1 alpha  
Stromal derived factor 1 alpha (SDF-1a) has powerful cardioprotective 
properties through it’s activation of CXCR4, and recently has been implicated 
in the mechanism of remote ischaemic conditioning [72, 390]. We therefore 
wanted to test whether it was important in this setting. Again, effluent was 
collected from donor hearts following either IPC (3 x 5 min global ischaemia-
reperfusion) or a corresponding control period. This was perfused through a 
naïve isolated heart prior to index ischaemia as described above. The 
CXCR4 antagonist, AMD3100, which prevents SDF-1a binding, was 
perfused for 5min prior to and the duration of effluent perfusion (Figure 3-9).  
Two experimental endpoints were used. First, Infarct size was calculated at 
the end of reperfusion as described in section 2.2.5. Second, coronary flow 
and left ventricular developed pressure were measured at set time points 
during the IRI protocol to give an indication of heart function.  
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Figure 3-5. Schema of the effluent transfer model and experimental protocols.  
Effluent was collected from donor hearts following either IPC or corresponding sham 
protocols. This effluent was subsequently perfused through a naïve isolated rat 
heart immediately prior to a 35min left anterior descending coronary artery 
ischaemia and 60min reperfusion. Donor hearts also received the same ischaemia-
reperfusion injury protocol following effluent collection. Hearts were analysed for 
infarct size at the end of each experiment via TTC staining. 
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3.4.3 Results 
Coronary effluent protects naïve isolated rat hearts from IRI 
There was no difference in observed protein concentration between control 
and IPC effluents (IPC = 72 ± 7 µg/ml vs Control = 81 ± 9 μg/ml, p = 0.43) 
(Figure 3-4). 
Infarct analysis revealed powerful cardioprotection to those hearts treated 
with IPC effluent (IPC effluent I/AAR % = 17 ± 3 vs control effluent = 42 ± 2, 
p<0.05) similar to that observed with direct IPC ((Donor IPC I/AAR % = 22 ± 
6 vs donor control = 41 ± 5, p<0.05) (Figure 3-7). Thus, IPC effluent seems to 
contain within it a cardioprotective protein or molecule that offers significant 
protection to the acceptor heart.  
Functional parameters are expressed as coronary flow rate and left 
ventricular developed pressure, measured throughout the experimental 
protocol (figure 3-7). There was a small, albeit statistically non-significant, 
recovery of function following ischaemia in both endpoints. Interestingly, a 
significant increase in coronary flow was observed following IPC effluent 
perfusion, indicating a vasodilation in the naïve heart and the presence of a 
haemodynamic factor in the effluent.  
There was a clear, but non-significant, correlation between the extent of 
vasodilation and infarct size (r2 = 0.63, p=0.06, n = 6), suggesting that the 
vasodilator may also contribute to cardioprotection (Fig. 3-8). In addition, 
there seemed to be a positive correlation between infarct size of donor and 
acceptor IPC hearts (r2 = 0.48, p=0.09, n = 7), not existent for control (r2 = 
0.21, p=0.36, n = 6), although this correlation was again not significant. 
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Figure 3-6. Protein concentration in both control and IPC effluent. 
Protein concentration in the effluent was analysed using the BCA method (section 
2.6). No significant differences were found between the groups (IPC = 72 ± 7 µg/ml 
vs Control = 81 ± 9 μg/ml, p = 0.43). 
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Figure 3-7. Infarct size analysis of donor and recipient hearts.  
Infarct size as measured by TTC staining revealed IPC effluent can induce 
significant cardioprotection to naïve isolated hearts (IPC effluent I/AAR % = 17 ± 3 
vs control effluent = 42 ± 2, p<0.05). Hearts that effluent was collected from were 
subsequently infarcted; those hearts that received IPC were significantly protected 
relative to control (Donor IPC I/AAR % = 22 ± 6 vs donor control = 41 ± 5 , p<0.05). 
Data presented as mean±SEM, n=6-8 per group.  
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Figure 3-8. Functional parameters measured in hearts who received either 
control or IPC effluent.  
Measurement of (A) coronary flow rate and (B) left ventricular developed pressure, 
in naïve hearts that received control and IPC effluent, throughout the ischaemia-
reperfusion protocol. All data presented as mean ± SEM, data analysed by two-way 
ANOVA. 
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Figure 3-9. Correlation between infarct size and flow rate indicate link between 
humoral factor and protection in acceptor and donor hearts. 
(A) Correlation between I/AAR% of IPC donor and acceptor hearts (r2 = 0.48, 
p=0.09) (B) Correlation between increase in flow (%) in response to IPC effluent and 
the I/AAR% of IPC acceptor hearts (r2 = 0.63, p=0.06), (C) correlation between 
increase in flow (%) in response to control effluent and the I/AAR% of control 
acceptor hearts (r2 = 0.22, p=0.29), (D) correlation between I/AAR% of control donor 
and acceptor hearts (r2 = 0.21, p=0.36) 
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Figure 3-10. Stromal-derived factor 1 alpha does not mediate the protection 
afforded by IPC effluent. 
(A) The antagonist for CXCR4, AMD3100, was perfused through the naïve heart for 
5min prior to and the duration of effluent perfusion. (B) AMD3100 did not abrogate 
IPC effluent mediated cardioprotection. (C) Interestingly, AMD3100 alone seemed to 
induce vasodilation in the naïve heart, observed as an increase in coronary flow 
rate. Data presented as mean ± SEM, data analysed by student’s t-test (B) and 
repeated measures ANOVA (C). 
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SDF-1 does not mediate cardioprotection in this setting  
Figure 3-9A details the experimental protocol; briefly, the CXCR4 antagonist, 
AMD3100, was given to the naïve heart for 5min prior to and the duration of 
effluent perfusion. The drug did not abrogate the cardioprotection afforded by 
IPC effluent (IPC+AMD3100 I/AAR% = 25 ± 3 vs Control +AMD3100 = 41 ± 
2, p>0.05) (Fig. 3-9B). Interestingly, AMD3100 alone appeared to have a 
vasodilatory effect on the heart, as observed by an increase in coronary flow 
rate (Fig. 3-9C). In addition, it augmented the increase in flow observed with 
IPC effluent. 
3.4.4 Discussion 
This model demonstrates, in line with current literature, that the heart 
releases factors into the coronary circulation in response to ischaemic 
conditioning and that these factors, when perfused through a naïve heart 
prior to ischaemia-reperfusion, can limit cell death. This is observed as a 
reduction in infarct size in hearts that received IPC effluent, to a similar level 
as observed with direct IPC. Given IPC is thought to be a receptor-mediated 
effect, via release of small molecules such as adenosine and opioids, it is 
likely that the protection afforded by IPC in the donor heart will mirror the 
protection seen in the recipient heart. Indeed, the infarct sizes of the two 
groups are correlated, although non-significantly, which suggests the 
protective factors released during IPC contributes to protection in the donor 
heart as well as the recipient. The inherent variability in the Langendorff IRI 
model, in terms of infarct size, means that greater numbers are required to 
see a statistically significant correlation.  
Functional recovery of the hearts at the end of reperfusion, as measured by 
LVDP and CFR, was improved in the IPC acceptor hearts, albeit non-
significantly. Studies have reported varied effects of effluent on functional 
recovery [74, 75, 215]; indeed, it may not be a valid marker of 
cardioprotection at one hour of reperfusion, as it is impossible at this stage to 
differentiate between non-viable and stunned myocardium. In addition, the 
Langendorff model is not the ideal model to observe heart function, as the 
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heart is retrogradely perfused and no fluid moves through the left ventricle. 
Nonetheless, it further indicates a beneficial effect of IPC effluent. 
Interestingly, the IPC effluent evoked a ~25% increase in CFR when 
perfused through the naïve heart (Figure 3-3-D), indicating the presence of a 
vasodilatory factor. The strength of the vasodilatory stimulus, as measured 
by increase in CFR, was correlated with the degree of protection afforded to 
the naïve heart. This may indicate that the vasoactive factor is responsible in 
part for effluent-mediated protection. The correlation was not observed with 
control effluent.  
Is inter-cardiac conditioning a valid model of RIC? 
When the model was first proposed, the authors drew similarities to the inter-
organ conditioning observed in vivo. For example, it has been shown that 
brief ischaemia and reperfusion to the kidneys, mesentery and skeletal 
muscle in vivo could protect the myocardium from IRI. Thus, could this inter-
organ protection be taken a step further, namely via transfer of effluent from 
one discretely perfused heart to another, or, indeed, from one animal to 
another? This hypothesis turned out true and the effluent model represents a 
remote form of cardioprotection, responsible for several important 
mechanistic insights into the phenomenon. The model is, however, based on 
too simplistic a view of RIC, that is, the idea that the protective factor is 
released from the conditioned limb. The RIC paradigm is more complex, 
involving both a neural and humoral pathway and, thus, cannot be accurately 
investigated using an isolated heart. An in vivo setting must be used to 
harness full potential of RIC reflex, which is why this project develops the 
dialysate model (section 3.5). Nonetheless, it is an interesting model of 
cardioprotection and, crucially, can be useful to investigate the factors 
released from the heart following IPC and the induction of protection in the 
acceptor heart. Indeed, this model is used in this thesis to investigate the 
involvement of intrinsic cardiac nerves and nitric oxide in the induction of 
protection.  
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Stromal-derived factor 1 alpha  
SDF-1a is know to be cardioprotective, through its action on CXCR4 
receptors and has recently been implicated in the mechanism of remote 
ischaemic conditioning. The CXCR4 antagonist, AMD3100, abrogated the 
efficacy of RIC in an in vivo model of acute myocardial infarction in rat [390]. 
This suggests SDF-1a could be released following RIC and act as a humoral 
cardioprotective mediator [72]. However, AMD3100 did not abrogate IPC 
effluent-mediated protection, suggesting SDF-1a is not released following 
IPC in the ex vivo rat heart.  
The significance of this experiment is that it underlines the fact that this 
model is not an accurate representation of RIC. Rather, the effluent model 
highlights the humoral component to classical IPC, hence it can be used to 
study the identity of these factors and the mechanism of their release. 
Although SDF-1a was not investigated further as part of this thesis, it was an 
important experiment as it revealed something of the nature of the effluent 
model.  
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3.5 Aim 3: Establish a model of remote ischaemic conditioning via 
transfer of plasma dialysate 
Some of the data presented in this section was recently published 
Pickard JMJ, Davidson SM, Hausenloy DJ, Yellon DM (2016) Co-
dependence of the neural and humoral pathways in the mechanism of 
remote ischaemic conditioning. Basic Res Cardiol 111:50. doi: 
10.1007/s00395-016-0568-z 
3.5.1 Background 
The unique mechanistic trait of RIC is the communication of a protective 
message from the conditioned limb to the myocardium and beyond. Initial 
studies suggested this occurred via release of a cardioprotective factor into 
the blood, however it became clear that a neural component was also 
important. How these two fit together within the RIC reflex was not 
immediately apparent; that is, are they mechanistically distinct, or do they 
interact with one another? With this in mind, the Redington group developed 
a model of RIC using a combination of in vivo and ex vivo techniques. Briefly, 
RIC was performed in vivo on rabbits, at which point a large volume of 
venous blood was sampled and centrifuged to isolate the plasma. The 
plasma was then dialysed across a <15 kDa membrane into a 20-fold dilution 
of KHB. This dialysate was then perfused through a naïve isolated rabbit 
heart prior to IRI, the hypothesis being that if a protective factor is released 
into the blood following RIC in vivo, it will be detected as a reduced infarct 
size ex vivo.  
Although this model is based on the assumption that the humoral mediator is 
the endpoint in the communication phase of RIC, it enables investigation into 
the regulation of its release. The first startling discovery this model gave was 
the dependence of the humoral pathway on an intact neural pathway to the 
limb. Indeed, femoral nerve section or stimulation abrogated or induced 
release of the humoral factor following RIC respectively. Similar results could 
be obtained via intra-arterial adenosine, which again were inhibited via 
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femoral nerve section. Moreover, pretreatment with the nitric oxide donor S-
nitroso-N-acetylpenicillamine (SNAP) abrogated release of the factor, 
induced by both RIC and i.a. adenosine. Taken together, these data suggest 
RIC induces local release of adenosine that, via activation of NO-sensitive 
sensory afferent nerves, induces release of the humoral factor.  
The type of sensory nerves activated following RIC have been further 
characterised, based on the observation that both topical capsaicin and 
transcutaneous electrical nerve stimulation (TENS) induce release of a 
protective factor into the blood, with a similar effect to that observed following 
RIC. Thus, it was suggested that activation of small diameter (Aδ- or C-fibre) 
afferents was essential for initiation of the RIC reflex and for subsequent 
release of the humoral factor into the blood [248, 290].  
These three studies were the first to demonstrate an interaction between the 
humoral and neural pathway. Since corroborated in humans [164], it seems a 
reproducible scientific observation that pervades several species. The key 
question that precipitates, however, is how sensory afferent nerve activation 
induces release of the humoral factor. The aim of this section was to 
establish and validate the dialysate model for the first time using Sprague-
Dawley rats. This thesis aims to use the model to elucidate the link discussed 
above, with particular emphasis on the vagus nerve, whose activation has 
been implicated in RIC [51, 79, 174, 243, 278]. 
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3.5.2 Methods 
Detailed methods can be found in section 2.3. 
Male Sprague-dawley rats were anaesthetised and prepared as described in 
section 2.3.1. Subsequently, they had a small cuff placed around their right 
hindlimb and were randomised to receive one of two interventions: (1) 
Remote ischaemic conditioning (RIC) protocol, consisting of 4 x 5 min cuff 
inflation to 200 mmHg with intermittent 5 minute deflations, or, (2) sham 
protocol, consisting of a corresponding time period with no cuff inflation (see 
Figure 3-11). Immediately following each intervention, the animal was 
sacrifices and blood sampled via right ventricular puncture. The plasma was 
subsequently centrifuged to obtain platelet-free plasma, and dialysed across 
a 12-14kDa membrane for 24hr at 4°C. The dialysate was then perfused 
through a naïve isolated rat heart for 10min prior to a 35min left anterior 
descending coronary artery ischaemia and 60min reperfusion.  
In the initial experiments, platelet rich plasma was used for dialysis. However, 
it became clear that platelets were confounding the observed effect, thus 
platelets were subsequently removed from the plasma via an extra 
centrifugation step prior to dialysis.  
Experimental endpoints 
1. The primary endpoint was infarct size, expressed as a percentage of 
the area-at-risk. This was performed at the end of reperfusion using 
Evans blue and triphenyl tetrazolium chloride staining, as described in 
section 2.2.5. 
 
2. Several functional endpoints were also measured in the naïve isolated 
heart throughout the experiment. Pressure and heart rate 
measurements were taken via a fluid-filled balloon in the left ventricle. 
In addition, coronary flow rate was manually measured at set time 
points throughout the protocol. These are described in more detail in 
section 2.2.3. 
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3. Dialysate was analysed for protein concentration using the BCA 
method, described in section 2.6. 
 
Figure 3-11: Protocol for in vivo RIC or sham procedures: 
Anaesthetised rats were subjected to either (1) RIC procedure, consisting of 4 x 5 
min hindlimb ischaemia (n) with intermittent 5-minute reperfusion ( ) or, (2) sham 
procedure, consisting of a time-matched period of anaesthesia. (ii) Following in vivo 
RIC or sham procedures, hearts were excised and perfused on a Langendorff 
system Isolated perfused rat hearts were, after a 20-minute stabilisation period, 
perfused with either control or RIC dialysate for 10 minutes. After a 10 minute 
washout period, the hearts were put into ischaemia via LAD occlusion for 35 
minutes, followed by 60 minutes of reperfusion. 
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3.5.3 Results 
It was important, initially, to confirm that the RIC stimulus given in vivo could 
protect the recipient heart from IRI. Therefore, after the blood was sampled 
for dialysate preparation, the heart was excised, perfused on a Langendorff 
rig and subjected to a 35min LAD occlusion and 60min reperfusion. Those 
hearts that received in vivo RIC demonstrated a significantly reduced infarct 
size (I/AAR=46.9 ± 4.6%, n=5, p<0.01 vs control) relative to control 
(I/AAR=66.9 ± 1.9%, n=5).  
The results of the first set of dialysate experiments are shown in Figure 3-13. 
Hearts that received both control and RIC dialysate displayed a 
cardioprotective phenotype, with infarct sizes of 26.3 ± 1.0% (n=3) and 16.7 
± 1.5% (n=4) respectively. Although RIC dialysate offered statistically 
significant additive protection relative to control (p<0.01), it seemed there 
was a degree of artefactual cardioprotection conferred as a result of the 
experimental design, since the infarct sizes in the control group were smaller 
than expected.  
It is known that platelet activation, or indeed inhibition, can induce 
cardioprotection. The alpha-granule is known to contain several 
cardioprotective proteins, including sphingosine-1-phosphate and stromal-
derived factor 1 alpha (SDF-1α). Crucially, activation and degranulation of 
platelets due to hypothermia has been well described. 
Thus, it was hypothesised that during dialysis the platelets would degranulate 
and release the cardioprotective factors, which in turn move into the dialysate 
and could induce the artificial cardioprotection observed in Figure 3-13. To 
test this, the platelets were removed from the plasma via an additional 
centrifugation step at 10,000 g for 30 minutes at 21°C. The dialysis was 
performed exactly as before, and then perfused through a naïve heart prior to 
IRI. The artificial protection observed in Figure 3-13 was no longer present; 
hearts that received RIC dialysate had a significantly reduced infarct size 
(I/AAR=27.6 ± 2.3%, n=7, vs control I/AAR=42.9 ± 1.2%, n=8, p<0.001). The 
control infarct size was very much in line with the literature for the IR 
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protocol, and much larger than was observed when platelet-rich plasma was 
used. 
 
Figure 3-12: In vivo RIC significantly reduces infarct size of the donor heart: 
Rats were anaesthetised and randomised to receive either in vivo RIC or sham, 
hearts were excised a perfused on a Langendorff rig. The hearts were then 
subjected to 35-minute LAD occlusion and 60-minute reperfusion. Statistical 
analysis was performed via an unpaired, two-way student’s t-test, n=5 per group.  
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Figure 3-13: Platelet-rich plasma creates a dialysate that, for both control and 
RIC, induces a cardioprotected phenotype. Although RIC dialysate offered a 
significantly reduced infarct size relative to control, both dialysates seemed to 
induce a cardioprotected phenotype in the naïve hearts. This is likely artificial 
protection, indicating the presence of a systematic error.  
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Figure 3-14: Removing platelets from the plasma abolishes the artificial 
protection and reveals the significant cardioprotection associated with RIC 
dialysate. Hearts that received RIC dialysate were significantly protected from IRI 
relative to control (I/AAR=27.6 ± 2.3%, n=7, vs control I/AAR=42.9 ± 1.2%, n=8, 
p<0.001). Removing platelets from the plasma seemed to abolish the artificial 
protection seen previously, indicating that platelet activation was occurring and 
releasing a factor into the dialysate which contributed to the protection. 
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Figure 3-15. Protein concentration in dialysate a plasma following RIC or 
sham.  
(A-C) BCA protein assay was employed to measure protein concentration in the 
plasma following either RIC (4x5min hindlimb ischaemia/reperfusion) or sham 
surgery. No difference in plasma concentration was observed between pre- and 
post-dialysis groups, and no difference was observed following RIC relative to sham. 
Interestingly, a 400-fold reduction in protein concentration was observed within the 
dialysate when compared to plasma. 
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Figure 3-16. Functional parameters measured in the naïve hearts who received 
dialysate. 
(A) Coronary flow rate of the naïve recipient hearts. No significant increase in 
functional recovery from ischaemia was observed in hearts that received RIC 
dialysate. (B) Left ventricular pressure in the naïve heart as measure via insertion of 
a fluid filled balloon. Again, no significant improvement in recovery from ischaemia 
was observed in hearts that received RIC dialysate. Data expressed as mean±SEM, 
and analysed using two-way ANOVA. 
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3.5.4 Discussion 
We have demonstrated that a plasma dialysate generated following in vivo 
RIC in rats is able to significantly protect a naïve-isolated rat heart from 
ischaemia-reperfusion injury. Previous studies have prepared dialysate from 
an in vivo rabbit model [248, 289, 331] or indeed humans [144, 164, 320]. 
These used a 20-fold dilution gradient into the dialysate, which is 2.5-fold 
lower than the 50-fold dilution used in this study. This indicates both the 
conserved nature of the RIC mechanism across several mammalian species 
and the remarkable potency of cardioprotection offered by the factor(s).  
The unusual observation here is that platelets seem to release one or more 
factors into the dialysate, which induce cardioprotection. When platelets were 
removed from plasma, the artificial protection observed in Figure 3-13 was 
abolished. This is highlighted when one considers the control infarct sizes for 
platelet-rich (I/AAR= 26.3 ± 1.0%) and –poor (I/AAR= 42.9 ± 1.2%) plasma 
dialysates when perfused through a naïve heart. It is known that platelets 
become activated at low temperatures [91, 175, 402], thus it was 
hypothesised that during the dialysis, which took place at 4°C, platelets 
would activate and degranulate, releasing many proteins into the plasma, 
some of which would diffuse across the membrane into the dialysate. Alpha-
granules of platelets contain many known cardioprotective proteins, including 
insulin-derived growth factor 1 (IGF-1) [171], sphingosine-1-phosphate [194], 
stromal-derived factor-1-alpha (SDF-1α) [241] and adenosine [383]. Indeed, 
unpublished data from this laboratory has demonstrated that platelet 
activation induces a large release of SDF-1α into plasma.  
The evidence surrounding platelets and cardioprotection, however, is 
contentious. Perfusion of isolated rat hearts with rat platelets reduced injury 
from IR, via release of factors including serotonin and adenosine [382–384]. 
However, several studies have demonstrated P2Y12 antagonism, therefore 
presumably inhibiting platelet activation, induces cardioprotection in an in 
vivo model of IRI [63, 385, 386]. Thus, it is not clear where the observation in 
Fig. 3-12 fits in with the literature. The simplest explanation, however, is that 
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activation of platelets in the plasma releases factors into the dialysate that 
induce cardioprotection. Whether platelet activation is a component of RIC 
communication is unknown; this thesis does not focus on the answer to this 
question. 
The great advantage of this model is it allows definition between the different 
components of the RIC reflex:  
• Trigger. At the in vivo level, one can intervene prior to RIC either 
pharmacologically or surgically. This has produced interesting insights 
into the trigger of RIC. For example, the observation that release of 
the humoral factor occurs downstream of sensory nerve activation in 
the conditioned limb was a paradigm shift in the field, demonstrating 
for the first time the interdependence of neural and humoral pathways 
[331]. 
• Communication. The model facilitates characterisation of the humoral 
factor released into the blood following RIC. Several studies have 
attempted to do so via either proteomics or fractionation of the plasma. 
Whilst proteomic studies have proved fruitless thus far [138, 139, 143], 
fractionation of the plasma has suggested the factor is hydrophobic, 
resistant to freezing and thawing, not easily denatured and less than 
15kDa [320].  
• Induction of cardioprotection. One can add various antagonists to the 
dialysate to investigate the mechanisms of initiation of 
cardioprotection. This can be at the level of receptor activation on the 
myocyte, or activation of intracellular signalling pathways. These 
mechanisms have not been well described for RIC; this project aims to 
elucidate some of them.  
Despite it being a useful and valid model of RIC, there are several limiting 
aspects of the study design, which must be considered. First, the choice of a 
12-14kDa membrane for the dialysis was, although based on previous 
literature, arbitrary. Studies using the effluent model have used dialysis to 
suggest a cardioprotective factor exists between 3.5 and 30kDa [43, 317]. 
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Thus, the Redington group used the 12-14kDa cut-off when they were 
developing the dialysate model, with the assumption that inter-cardiac 
conditioning was mediated via similar factor(s) as in vivo limb 
preconditioning. Although this is not an unreasonable assumption, it is made 
without evidence as the two models cannot be absolutely compared. Thus, it 
is not clear whether there is a factor greater than 15kDa, which also 
contributes to protection. Indeed, a recent study implicated apolipoprotein A1 
(Apo-A1) in RIC; this protein is significantly larger that 15kDa [142]. Second, 
the blood sampling technique is different to that of previous dialysate models 
using rabbits. Whereas in rabbits blood was sampled via a vein in the ear, in 
rats the blood was aspirated via right ventricular puncture. This is a very 
invasive procedure, thus perhaps the trauma itself was causing release of 
protective factors into the plasma, contributing to the dialysate-protection. It is 
known that surgical trauma can induce cardioprotection, via activation of 
nociceptive c-fibre afferents [112]. Third, the model is based on the 
assumption that the humoral factor is the end effector of communication. It 
does not rule out the possibility that there is an additional neuronal phase 
upstream of the humoral phase, or indeed the possibility that the humoral 
messenger is the product of neurotransmitter spill-over. This is discussed in 
more detail in chapter 5. 
The potential of this model has not yet been fully realised with respect to RIC, 
with only a handful of studies employing its use thus far. There are several 
fundamental questions surrounding the RIC paradigm which the model can 
help to answer; namely, the link between sensory nerve activation and 
production of the factor and, crucially, the source of the humoral factor. This 
thesis aims to utilise the model and shed light on the above questions. 
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3.6 Summary 
This chapter detailed the characterisation of the Langendorff isolated 
perfused heart model and, subsequently, two models of cardioprotection. The 
work detailed above comprises the majority of the year of work undertaken 
for this thesis. Once characterised, they provided a platform from which to 
investigate the mechanisms of cardioprotection, both in vivo and ex vivo.  
The first, a model of inter-cardiac conditioning via transfer of preconditioned 
coronary effluent, first demonstrated by Dickson et al. [75]. Whilst originally 
presented as proof of a humoral mediator of remote ischaemic conditioning, it 
is more representative of the humoral component to classical ischaemic 
conditioning. This model is used in chapter 7 to investigate the importance of 
the intrinsic cardiac nervous system in classic IPC.  
The second model was adapted from that first presented by Shimizu et al 
[320], designed to investigate the release of a humoral blood-borne 
cardioprotective factor. This model allowed investigation into the mechanism 
of release of the humoral factor, and its mechanism of action on the heart. 
The model is used to this effect in chapters 5 and 6. 
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Chapter 4 REMOTE ISCHAEMIC CONDITIONING REDUCES 
INFARCT SIZE IN ANIMAL IN VIVO MODELS OF 
ISCHAEMIA-REPERFUSION INJURY: A SYSTEMATIC 
REVIEW AND META-ANALYSIS 
This chapter details a collaborative project, with a manuscript co-authored 
with Dr Daniel Bromage [45]. The study was conceived and designed with Dr 
D. Bromage. Mr N. Burke and Dr O. Ziff collected the data for analysis of 
study quality. All other data was collected and the manuscript co-written with 
Dr D. Bromage. The figures were co-prepared with Dr X. Rossello. The 
statistical method was co-designed with Dr X. Rossello and executed in its 
entirety by him. All contributors were from the Hatter Cardiovascular Institute 
(UCL, UK). A version of this study can be found in the thesis of Dr Daniel 
Bromage, although significant changes have been made in line with 
subsequent referee comments. Chapter 10 contains a copy of the published 
manuscript. 
Bromage DI *, Pickard JM *, Rossello X, Ziff OJ, Burke N, Yellon DM, 
Davidson SM (2016) Remote ischaemic conditioning reduces infarct size in 
animal in vivo models of ischaemia-reperfusion injury: a systematic review 
and meta-analysis. Cardiovascular Research (In Press) 
* = Authors contributed equally 
4.1 Introduction 
Myocardial ischaemia-reperfusion injury describes the deleterious 
consequences of several pathological processes and cardiac interventions. 
Most commonly, it is caused by thrombotic occlusion of the coronary artery in 
ST-segment elevation myocardial infarction (STEMI) and subsequent 
reperfusion by primary percutaneous coronary intervention (PPCI), but it may 
result from a range of elective and emergent causes of myocardial 
ischaemia, including cardiopulmonary bypass and spontaneous reperfusion 
of STEMI. Despite constantly improving medical and surgical practice, 
myocardial IRI remains associated with significant morbidity and mortality. 
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For example, in STEMI and despite PPCI, 30-day, 1-year, and 5-year cardiac 
mortality remains 7.3 %, 8.4 %, and 13.8 %, respectively [269].  
As discussed in Chapter 1, the myocardium can be protected from lethal IRI 
by the application of multiple brief cycles of ischaemia and reperfusion to an 
organ or tissue remote from the heart, before, during, or after the index 
ischaemia (preconditioning, perconditioning or postconditioning, 
respectively). Limb remote ischaemic conditioning (RIC) is a cheap, non-
invasive intervention that, since its inception in 1997 [35], has been 
successfully demonstrated in several pre-clinical studies of myocardial IRI. 
Subsequently, several phase II, proof-of-concept clinical studies have 
translated these findings to variety of clinical settings, albeit frequently using 
cardiac enzymes as surrogate markers of cellular injury, including coronary 
artery bypass surgery (CABG) [114, 128, 339, 350], elective abdominal aortic 
aneurysm repair [5, 358], elective cervical decompression surgery [154], 
elective PCI [151], and in PPCI for STEMI [41, 184, 311].  
However, more recent, large clinical-endpoint studies of RIC in cardiac 
surgery have been neutral [122, 249]. Although cardiac surgery may be an 
inappropriate setting for RIC, given the small peri-operative injury and lack of 
injurious warm ischaemia-reperfusion [99], these findings have prompted an 
interrogation of the pre-clinical evidence base for RIC and a perceived lack of 
systematic pre-clinical characterisation of the optimal RIC stimulus. This is in 
contrast to direct ischaemic conditioning that, despite being limited by the 
necessity to intervene before the index ischaemia, has been thoroughly 
characterised [368].  
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4.2 Research aims and objectives 
Well-designed animal studies can provide useful information on relevant 
factors that may influence outcome. We performed a comprehensive 
systematic review and meta-analysis to scrutinize basic studies of RIC in in 
vivo animal models of myocardial IRI. Our aim was to ascertain the overall 
effect and variability of RIC in this context, compared to control (sham 
procedure or no treatment). We further aimed to investigate determinants of 
efficacy, including variables such as RIC protocol and use of supplementary 
oxygen. Our hypothesis was that study quality and publication bias would 
result in over-estimation of the effect size associated with RIC [153, 211].  
 
4.3 Methods 
4.3.1 Systematic review 
The systematic review was performed in accordance with Preferred 
Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
guidelines [221].  
4.3.1.1 Literature search strategy 
A literature search was conducted on 21st August, 2015 by JP. The search 
strategy was defined in an iterative manner, using previously published 
guidelines [95, 237, 238], by DB and JP and peer reviewed by members of 
the Hatter Cardiovascular Institute research group. Our search will be limited 
to reports available in English due to limited time and financial resources for 
translation. We will use the following search strategy, incorporating keywords 
and MeSH terms, for MEDLINE: 
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1. (remote adj2 $condition$).mp. 
2. (remote adj isch$emic).mp. 
3. remote precondition$.mp. 
4. remote postcondition$.mp.  
5. remote percondition$.mp. 
6. limb $condition$.mp. 
7. ripc.mp. 
8. limb isch$emi$.mp. 
9. $condition$.mp. 
10. 8 and 9 
11. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 10 
12. exp Reperfusion Injury/ 
13. exp Myocardial Ischaemia/ 
14. Myocardial Infarction/ 
15. infarct size.mp. 
16. ("infarct size" or "size of infarct*").mp. 
17. cardioprotection.mp. 
18. 12 or 13 or 14 or 15 or 16 or 17 
19. 11 and 18 
20. Limit 19 to animal 
21. Limit 20 to (english language and yr=”1997-Current”) 
22. Limit 21 to review articles 
23. 21 not 22 
Differences in the search strategy between Medline and Embase are 
described in table S1. 
Search term Database 
 Medline Embase 
Cardioprotection cardioprotection.mp. 
(keyword) 
heart protection/ (MeSH 
term) 
Search review 
articles 
limit 21 to review articles limit 21 to “reviews 
(maximizes sensitivity)” 
Table 4-1. Differences in search strategy between databases 
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Lastly, transplanted hearts were added to the exclusion criteria post hoc as it 
was apparent that these experiments fulfilled our inclusion criteria but were 
likely to confer additional injury during the transplantation process. 
4.3.1.2 Study selection 
Study eligibility criteria were defined using the PICOS approach [221]. In vivo 
animal studies were included and were eligible if they investigated the effect 
of limb RIC (pre-, per- or post-) versus a control (sham procedure or no 
treatment) on myocardial infarct size, as measured using tetrazolium chloride 
(TTC) [30], in any mammalian species, regardless of study design. Transient 
infra-renal aortic occlusion was considered as bilateral hind limb ischaemia. 
Studies were excluded if they did not include or report absolute myocardial 
infarct size (IS) as a percentage of area at risk (AAR, defined as the 
myocardial tissue within the vascular territory that is distal to occluded artery 
and, if not reperfused, is at risk of irreversible ischaemic death) [296]. The 
AAR varies depending on the exact position of the LAD suture and variable 
LAD anatomy. Infarct size has a strong positive correlation with AAR and 
therefore, without correction, a small AAR could create false-positive results 
for cardioprotection, and vice versa [392]. Furthermore, studies were 
excluded if they specifically investigated only the ‘second window’ of 
cardioprotection (RIC to infarction interval > 1 h) [206, 240], if RIPostC was 
initiated more than 10 min after reperfusion (after which it is generally 
believed unlikely to be effective) [24, 262], if the animals had co-morbidities, 
if infarct size was only measured using a method other than TTC, or if they 
investigated the impact of RIC in the context of heart transplant. Groups in 
which RIC was administered in combination with another conditioning 
protocol (local conditioning, for example), or with pharmacological treatments 
known to have cardioprotective effects, were excluded. Finally, studies 
investigating neonatal animals were excluded to ensure clinical relevance to 
IRI.  
Reports were excluded if they were not available in English and a publication 
date restriction of 1997-present was imposed in view of the first publication of 
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the efficacy of RIC in the limb [35]. Review articles, abstract articles, 
unpublished material and ongoing studies were excluded. 
Retrieved records were screened for eligibility using the title and abstract, 
followed by the full text. Eligibility assessment was performed independently 
in an un-blinded, standardized manner by 2 reviewers (DB and JP). To 
ensure reliability and improve subjectivity of screening of relevant titles and 
abstracts, DB and JP first independently screened 10% of a random sample 
of the search results. The exercise was repeated until 90% agreement was 
achieved, prior screening all search results. Disagreements between 
reviewers were resolved by examining the full text of the article or by 
consensus. When this failed to resolve the disagreement, attempts were 
made to contact authors of the original study by e-mail, where appropriate. 
Further unresolved conflict was resolved by arbitration from DB. The full text 
of eligible records was retrieved and subjected to full text screening. DB and 
JP performed the same calibration exercise as described prior to un-blinded, 
standardized eligibility assessment. Conflicts were resolved as per the title 
and abstract screening. 
During the title and abstract screening calibration exercise, inter-rater 
agreement was 94%, with no instances of arbitration or reason to contact the 
authors of the study. During full text screening, inter-rater agreement was 
87%, with no instances of arbitration or reason to contact the authors of the 
study. The 13% of references upon which the author disagreed were 
accounted for by screening errors rather than fundamental disagreement 
about the features of the study. 
4.3.1.3 Data extraction 
We have developed a data extraction sheet based on the Cochrane 
Consumers and Communications Review Group’s data extraction template 
[221], which was be pilot-tested on ten randomly-selected included studies, 
and refined accordingly. 
Data were independently extracted by 2 authors (DB and JP) using 
predefined data fields, including study quality indicators. To ensure reliability 
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and improve subjectivity of data extraction, DB and JP independently 
collected data from 10% of a random sample of included studies. The 
exercise was repeated until 90% agreement is achieved, before extracting 
data from all included studies. Disagreements were resolved by consensus. 
When this failed, attempts were made to contact authors of the original study 
by e-mail, where appropriate. Further unresolved conflict was resolved by 
arbitration from DB.  
Following data extraction, searches were conducted based on first and senior 
author name, sample size and size of outcome to identify double counting. 
These parameters were chosen due to expected high completeness and 
based on recommendations in the PRISMA statement [221]. If multiple 
reports for the same study are identified they were compared for logical 
inconsistencies, and subsequently were accounted for by contacting the 
report author by e-mail. We likewise attempted to acquire key missing 
information in the same way.  
4.3.1.4 Data items 
Variables for which data were sought were developed using the PICOS 
approach. Data items were chosen according to experimental variables with 
evidence for an effect on myocardial IRI as these were considered likely to 
impact on the efficacy or RIC, and variables that we considered of potential 
importance. Examples of such variables are species and strain, gender, 
choice of anaesthetic and duration of ischaemia and reperfusion (Table 3-2). 
We also included variables without extensive evidence that we consider of 
potential importance. Although not all the data items have been investigated 
in the literature in the setting of cardioprotection, we aimed to cover a broad 
range of experimental variables in order to obtain a clear picture of how the 
efficacy of RIC may be influenced in vivo. We have not performed a separate 
systematic review but we believe we have accounted for all potentially 
pertinent methodological variables. Any data items added after the review 
started will be highlighted and justified. All extraction forms will be archived 
and made available, if required. 
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We also made the following assumptions: 
• The included studies contained several definitions of pre-, per- and 
post-conditioning. For clarity, despite the terminology used in the 
report, we defined preconditioning as any stimulus where the last 
cycle of ischaemia had been completed by the time of index 
ischaemia, perconditioning as any ischaemic stimulus that overlapped 
in full or in part with the index ischaemia, and postconditioning as any 
stimulus that began at or after the time of myocardial reperfusion. 
• When a report described ‘femoral artery occlusion’ we assumed this to 
be with a vascular clamp. Likewise, where hindlimb occlusion was 
reported we assumed the use of an external cuff or tourniquet. A cuff 
was defined as an external inflatable device, while a tourniquet 
described any other kind of external compression. In all cases we 
assumed the cuff was inflated to an appropriate pressure.  
• We assumed any reperfusion duration ≤4 h to be non-recovery and 
anything over that to be a recovery model. 
• We defined a time of >1hr from the last RIC cycle to the onset of index 
ischaemia as the ‘second window’ of protection. This study was 
concerned with the acute cardioprotective potential of RIC, thus these 
studies were excluded from the analysis.  
• Descriptions of the LAD and left coronary artery (LCA) were assumed 
to be interchangeable in rodents. 
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Category Data item 
Study details First author, senior author, date, report format 
(abstract/full), country of origin 
Populations/subjects 
(P) 
Species, strain, age/weight 
Interventions (I) Pre-/per-/post-conditioning, RIC cycle time, RIC 
number of cycles, number of limbs, RIC technique 
(cuff/clamp), time to index ischaemia, index 
ischaemic duration, coronary territory occluded, 
reperfusion duration, non-recovery vs. recovery, 
anaesthetic type, anaesthetic dose (mg/kg), other 
peri-operative medication, use of anti-coagulant, type 
of anti-coagulant, intubated/ventilated, supplementary 
oxygen 
Outcomes (O) Infarct size as primary endpoint, mean infarct size 
(%AAR), mean AAR, AAR technique, standard 
deviation, SEM, other reported statistical analyses 
(pertinent to infarct) 
Study design (S) Sample size 
Table 4-2. Data items, developed using the PICOS approach 
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4.3.1.5 Risk of bias 
We used a component approach to assess study quality, based on the study 
report, using the ‘Animal Research: Reporting of In Vivo Experiments’ 
(ARRIVE) guidelines [187, 247].  We also used a separate 12-item score, 
adapted from that developed by Macleod et al. in response to a perceived 
failure of translation of promising neuroprotective agents in stroke [236]. We 
removed two and added 4 items, resulting in a 12-item custom score which 
we applied to studies in the meta-analysis. If the monitoring of ST segments 
or rhythms was reported, we assumed that heart rate monitoring as available. 
 
 
Added	to	Cochrane	study	quality	score	 Removed	from	Cochrane	study	quality	score	
Statement	 of	 measurement	 of	 PaO2	 and	
SaO2	
Use	of	animals	with	co-morbidities	
Statement	of	recording	of	ECG	 Blinded	induction	of	ischaemia	
Statement	 of	 measurement	 of	 blood	
pressure	
	
Blinded	application	of	conditioning	protocol	 	
Table 4-3. Items removed and added from the Cochrane study quality score to 
make the adapted score used in the study. 
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Study quality was assessed independently from data extraction and between 
assessors in an un-blinded, standardized manner by 2 reviewers (OZ and 
NB). Disagreements were resolved by consensus in all cases. We assessed 
the relationship between study quality and the overall effect of RIC on 
IS/AAR% using meta-regression, as described above. 
Potential publication bias was assessed by visual inspection of a funnel plot 
for asymmetry, and Egger’s regression analysis for small study effects. No 
protocols were available with which to examine for selective reporting; 
however, the methods and results sections of all included studies were 
carefully compared for inconsistencies. 
4.3.2 Meta-analysis 
We defined the primary outcome as the weighted (unstandardized) mean 
difference (WMD) between infarct sizes in the RIC and control groups. WMD 
was used as all data were presented in the same units and it gives a 
biologically relevant value. In each publication, we identified all independent 
comparisons of IS/AAR% in RIC versus control groups. Where a study made 
multiple comparisons to the same control group, the size of the control group 
was corrected for the number of comparisons made (n/number of 
comparisons) [351]. The secondary outcome was the effect of 5 pre-defined 
experimental variables, which we considered most likely to impact on the 
efficacy of RIC, on WMD. 
Comparisons were grouped according to their use of either remote ischaemic 
preconditioning (RIPreC), or remote ischaemic perconditioning and 
postconditioning (RIPerC/RIPostC). This is due to temporal differences in 
their application that, despite not necessarily occurring via different 
mechanistic pathways [232], have different clinical utility. Specifically, 
RIPerC/RIPostC are clinically applicable to STEMI, whereas RIPreC is not. 
Subsequent analysis was performed for each group separately. 
For each independent comparison, we calculated the effect size as a raw 
difference in IS/AAR% means (the mean of the control groups minus the 
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mean of the experimental group) and the corresponding 95% confidence 
interval (CI). To account for anticipated heterogeneity, we pooled effect sizes 
using random-effects meta-analysis, which considers the within-study and 
between-study variability and weights each study accordingly. Heterogeneity 
was quantified using I2 and T2 statistics. Studies with missing data on any of 
the pre-defined experimental variables were excluded from the meta-
analysis.  
Subgroup analyses were performed using univariate meta-regressions to 
explore which experimental factors and quality indicators contribute to 
heterogeneity. Pre-defined experimental measures included in the analysis 
were as follows: 
1. Species: Studies that used either mice or rats were grouped as ‘small 
animals’, and those using rabbits or pigs were grouped as ‘large 
animals’. 
2. Cycle duration: The reported duration of ischaemia applied to the 
limb in each cycle. In the analysis, studies were grouped as 5, 10 or 
15 minutes of limb ischaemia. 
3. Number of cycles: The number of times this ischaemic episode was 
applied in succession to the limb. Studies were grouped as using 1, 3 
or 4 cycles of ischaemia. 
4. Number of limbs: The RIC protocol reported by each study was 
either applied to one or both (i.e. bilateral) limbs. Conditioning by infra-
renal aortic occlusion was classed as bilateral hindlimb ischaemia, 
whereas studies using supra-renal aortic occlusion were excluded. 
5. Oxygen: Each study was given a binary score according to its 
reported use of supplementary oxygen in their ventilation protocol for 
the in vivo procedure. If the study did not mention whether 
supplementary oxygen was used, it was assumed the animal was 
ventilated with room air. 
The percentage of between-study variance explained by variables of interest 
was assessed using the T2 and adjusted R2 statistics. The significance level 
was adjusted according to the number of comparisons using the Holm-
Bonferroni method and results were considered significant when P<0.01 
[147].  
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Sensitivity analysis was performed to assess the robustness of our findings 
by performing an additional analysis for both the primary and the secondary 
endpoints using the standardized mean difference (SMD; the mean of the 
control group minus the mean of the RIC group, divided by the pooled SD of 
the two groups). We performed a stratified meta-analysis by subgroup to 
validate the results obtained by meta-regression. 
All analyses were pre-specified and performed using STATA/SE, version 
13.1 (StataCorp, College Station, TX, USA); GraphPad Prism version 5.00 
for Windows (CA, USA) and Adobe Illustrator CS6 (CA, USA) were used in 
the production of figures. 
 
4.4 Results 
4.4.1 Study selection 
Our search returned 539 records, including 169 duplicate reports (consisting 
of reports returned by both Medline and Embase). 370 reports underwent title 
and abstract screening, which resulted in 256 exclusions. The remaining 114 
reports were retrieved for detailed full text evaluation. 83 articles were 
excluded, 66 due to failing to meet the inclusion criteria, 12 were abstracts 
and 2 were not retrievable. Of the remaining 34 reports (studies), 3 were 
missing data on one or more important experimental variables that we were 
unable to retrieve by contacting the study authors, and were consequently 
excluded. The remaining 31 studies were included in the quantitative 
synthesis (Fig 4-1).  
123 
 
Figure 4-1. Flow diagram demonstrating study exclusion during systematic 
review. 
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 
[4] Pig M 25-30kg Per 5 5 4 1 20 Clamp N/A 40 LAD 120 NR Y Propofol, fentanyl N SEM 10 59.2 3.17 7 36.5 4.7 
[9] Pig M/F 18-22kg Post 5 5 4 1 20 Cuff N/A 90 LAD 4320 R Y Ketamine Heparin SEM 12 48.4 5.2 12 23 2.4 
[24] Rat M Adult Pre 15 N/A 1 2 30 Clamp 10 30 LAD 120 NR N Pentobarbitone N SEM 8 41 2 12 19 1 
 Rat M Adult Per 15 N/A 1 2 30 Clamp N/A 30 LAD 120 NR N Pentobarbitone N SEM    10 18 1 
 Rat M Adult Per 15 N/A 1 2 30 Clamp N/A 30 LAD 120 NR N Pentobarbitone N SEM    10 18 2 
 Rat M Adult Post 15 N/A 1 2 30 Clamp N/A 30 LAD 120 NR N Pentobarbitone N SEM    10 21 1 
[55] Rat M Adult Pre 5 5 4 1 20 Clamp 5 40 LAD 120 NR N Pentobarbitone N SEM 6 66.5 5.5 6 48.2 5.2 
[111] Rat M 8-10 weeks Per 10 10 1 1 10 Tourniquet N/A 40 LAD 120 NR N Pentobarbitone N SEM 6 54.9 6.01 6 21.9 4.0 
[125] Pig M 27-35kg Pre 5 5 4 1 20 Clamp 5 60 LAD 180 NR Y Propofol, pancuronium, fentanyl Heparin SEM 5 48.8 4.2 5 13.3 2.2 
 Pig M 27-35kg Per 5 5 4 1 20 Clamp N/A 60 LAD 180 NR Y Propofol, pancuronium, fentanyl Heparin SEM       6 18.2 2 
[137] Rat M Adult Pre 5 5 4 2 40 Cuff 10 35 LAD 120 NR Y Pentobarbitone N SD 10 76 14 10 54 15 
[142] Rat M 8-10 weeks Pre 10 10 1 1 10 Clamp 10 40 LAD 120 NR N Pentobarbitone N SEM 9 64.9 2.6 11 52.2 3.7 
[159] Rat M 288+/-9kg Per 10 10 1 1 10 Tourniquet N/A 40 LAD 120 NR N Pentobarbitone N SEM 6 54.6 4.7 6 24.4 5.9 
[168] Rat M Adult Pre 5 5 4 1 20 Clamp 5 40 LAD 120 NR N Pentobarbitone N SEM 7 65.3 2.9 6 47.3 2.2 
[169] Mouse M N/R Pre 5 5 4 1 20 Clamp 5 30 LAD 120 NR N Pentobarbitone N SEM 9 40.6 3.6 6 24.1 2.8 
  Rat M 2-3 months Pre 5 5 4 1 20 Clamp 5 40 LAD 120 NR N Pentobarbitone N SEM 7 65.1 2.7 6 47.3 2.1 
[185] Pig N/R 15kg Pre 5 5 4 1 20 Tourniquet 5 40 LAD 120 NR Y Midazolam, pentobarbitone Heparin SEM 8 53 8 9 26 9 
[189] Rat M N/R Per 15 N/A 1 2 30 Clamp N/A 30 LAD 120 NR N Pentobarbitone N SEM 10 69 2 10 43.4 3.8 
 Rat M N/R Per 15 N/A 1 2 30 Clamp N/A 30 LAD 120 NR N Pentobarbitone N SEM 6 68.6 0.8 6 46.4 4 
[217] Rabbit M/F 2.5-3kg Per 5 1 1 1 5 Clamp N/A 30 LAD 180 NR Y Pentobarbitone Heparin SD 10 31.5 1.3 10 17.1 1.7 
[223] Mouse M 10-12 weeks Pre 5 5 3 1 15 Clamp 5 30 LAD 120 NR Y Ketamine, xylazine, atropine N SEM 10 56.7 3.2 9 21.6 1.6 
[234] Rat M 280-300g Pre 5 5 1 1 5 Clamp 5 30 LAD 120 NR N Pentobarbitone N SD 6 54.7 6 6 28.3 4.9 
 Rat M 280-300g Pre 5 5 3 1 15 Clamp 5 30 LAD 120 NR N Pentobarbitone N SD       6 51.1 7.4 
[243] Rat M Adult Pre 15 10 1 2 30 Clamp 10 30 LAD 120 NR N Pentobarbitone N SEM 7 54.6 3.1 8 36.6 3 
[308] Rat F 200-250g Per 5 5 4 2 40 Clamp N/A 45 LAD 120 NR N Ketamine, xylazine N SEM 22 48.7 3.4 22 42.2 3.9 
[311] Pig N/R 20kg Per 5 5 4 1 20 Tourniquet N/A 40 LAD 120 NR Y Midazolam, pentobarbitone Heparin SEM 10 60 5 10 38 5 
125 
 
 
Table 4-4. Main characteristics of included studies. The main characteristics included: (1) Study reference; (2) Species; (3) Gender; (4) Age 
or weight; (5) Conditioning protocol (pre-, per- or post-conditioning); (6) RIC cycle duration (min); (7) RIC reperfusion duration (min); (8) Number 
of cycles; (9) Number of limbs; (10) Total RIC  ischaemia duration (min); (11) RIC occlusion technique; (12) Time between RIC and index 
ischaemia (min, preconditioning only); (13) Index ischaemia duration (min); (14) Coronary artery occluded; (15) Reperfusion duration (min); (16) 
Recovery or non-recovery; (17) Supplementary oxygen; (18) Induction anaesthetic; (19) Anticoagulants; (20) Measure of variance; (21) Control 
group sample size; (22) Control group mean infarct size (IS/AAR%); (23) Control group variance (IS/AAR%); (24) Conditioning group sample 
size; (25) Conditioning group mean infarct size (IS/AAR%); and (26) Conditioning group variance (IS/AAR%). N/R, not recorded; N/A, not 
applicable; LAD, left anterior descending; R, recovery; NR, non-recovery; SEM, standard error of the mean; SD, standard deviation. 
[318] Rat M Adult Pre 15 10 1 2 30 Clamp 10 30 LAD 120 NR N Urethane N SEM 6 55.5 3.1 6 21.5 3.5 
[336] Rat M 8-10 weeks Per 10 10 1 1 10 Tourniquet N/A 40 LAD 120 NR N Pentobarbitone N SEM 6 54.9 6.5 6 24.7 6.0 
[287] Mouse M 12±3 weeks Pre 5 5 4 1 20 Cuff 5 30 LAD 1440 R Y Ketamine, xylazine N SD 5 37 4 5 17 3 
[364] Rat M 250-280g Per 5 5 4 1 20 Tourniquet N/A 45 LAD 4320 R N Pentobarbitone Heparin SD 8 50.5 4.1 8 35.6 4.2 
[367] Rat M 250-350g Pre 15 0 1 2 30 Clamp 0 30 LAD 120 NR Y Pentobarbitone N SEM 6 62 5 6 52 4 
 Rat M 250-350g Pre 5 10 1 2 10 Clamp 10 30 LAD 120 NR Y Pentobarbitone N SEM    6 42 2 
 Rat M 250-350g Pre 10 10 1 2 20 Clamp 10 30 LAD 120 NR Y Pentobarbitone N SEM    6 37 8 
  Rat M 250-350g Pre 15 10 1 2 30 Clamp 10 30 LAD 120 NR Y Pentobarbitone N SEM       8 18 3 
[373] Rat M 300±25g Pre 5 5 3 1 15 Clamp 5 30 LAD 120 NR N Pentobabitone N SD 6 52.8 5.9 6 29.6 5.8 
[379] Rat M 8 week Per 5 5 4 1 20 Cuff N/A 45 LAD 120 NR N Pentobabitone Heparin SD 8 48.9 6.66 8 33.5 5.8 
[381] Rat M 8-9 weeks Per 10 N/A 1 2 20 Tourniquet N/A 30 LAD 180 NR Y Pentobarbitone N SD 9 60 3 9 48 1 
[395] Rat M 250-300g Per 5 5 3 1 15 Clamp N/A 45 LAD 180 NR N Pentobarbitone Heparin SEM 12 55.8 2.2 12 31.3 1.9 
[401] Rat M 8 weeks Per 10 N/A 1 2 20 Tourniquet N/A 30 LAD 120 NR Y Pentobarbitone N SD 20 71.6 8.7 20 56.9 8.8 
[403] Rat M 230-260g Pre 5 5 3 1 15 Clamp 5 30 LAD 120 NR Y Chloral hydrate N SD 6 51 6 6 20.3 2.4 
[407] Rat M Adult Pre 5 5 3 2 30 Tourniquet 5 30 LAD 180 NR N Chloral hydrate Heparin SEM 12 34.7 5.9 12 14.5 3.5 
 Rat M Adult Per 5 5 3 2 30 Tourniquet N/A 30 LAD 180 NR N Chloral hydrate Heparin SEM    12 15.3 5.2 
 Rat M Adult Post 5 5 3 2 30 Tourniquet N/A 30 LAD 180 NR N Chloral hydrate Heparin SEM       12 19.8 5.9 
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4.4.2 Meta-analysis 
From the 31 included reports, we extracted data on 43 controlled 
comparisons of RIC in models of myocardial IRI. These were split into 22 
comparisons investigating RIPreC, and 21 comparisons investigating 
RIPerC/RIPostC. In total, our analysis includes data from 280 control animals 
and 373 animals undergoing RIC. In the RIPreC group, conditioning reduced 
IS/AAR% by 22.8% (95% CI 18.8-26.9%) when compared to untreated 
controls (P<0.001; n=22 comparisons, Figure 3-2 A). Significant 
heterogeneity was observed (T2=89.2 and I2=99.1%; P<0.001). In the 
RIPreC/RIPostC group, conditioning reduced IS/AAR% by 22.2% (95% CI 
17.1-25.3%) when compared to untreated controls (P<0.001; n=21 
comparisons, Figure 3-2 B). Again, significant heterogeneity was observed 
(T2=90.9 and I2=99.5%; P<0.001). 
We investigated potential experimental sources of the observed 
heterogeneity using meta-regression analysis with IS/AAR% as the 
dependent variable, and did not find any significant associations with efficacy 
of RIC (Figure 3-3).  
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Figure 4-2. Forest plots detailing the weighted mean difference for each 
included study. Forest plots of the effect of A) RIPreC and B) RIPerC/RIPostC on 
IS/AAR%, pooled using random-effects meta-analysis. 22 and 21, respectively, 
controlled comparisons were included, amounting to data from 280 control animals 
and 373 animals undergoing RIC. Red dotted line indicates the average effect size 
(RIPreC = 22.8% and RIPerC/RIPostC = 22.2%). 
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Figure 4-3. Impact of experimental factors on the efficacy of A) RIPreC and B) 
RIPerC/RIPostC.	 
Weighted mean difference (WMD) and the corresponding 95% CI for each variable 
were obtained by subgroup stratification. However, the reported P-value was 
obtained by meta-regression to reduce false-positive findings. Studies that used 
either mice or rats were grouped as ‘small animals’, and those using rabbits or pigs 
were grouped as ‘large animals’. A P value of <0.01 was considered significant. 	
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22.03
23.98
(16.37, 27.69) 0.640 -4.27%
(18.00, 29.96)
27.21
19.45
(21.89, 32.53) 0.042 17.36%
(16.05, 22.86)
20.19
21.67
(15.85, 24.52) 0.653 -4.07%
(16.16, 27.19)
24.09
18.16
(20.97, 27.21) 0.051 15.17%
(11.57, 24.75)
20.65
22.79
(15.55, 25.74) 0.554 -3.81%
(17.97, 27.62)
(12.86, 25.43)19.14
24.11
22.84
(14.81, 33.42)
(20.75, 29.92)
0.254 2.08%
(19.07, 29.20)22.64
19.76
19.63
(13.63, 25.88)
(11.29, 27.96)
0.347 -0.10%
WMD 95% CI P-value Adj R2
Small Animal
Large Animal
5
15
10
1
3
4
1
2
Yes
No
Cycle duration
No. of cycles
No. of limbs
Oxygen
Small Animal
Large Animal
15
10
5
1
3
4
1
2
Yes
No
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4.4.3 Risk of bias 
Reports achieved a median ARRIVE guidelines score of 14 (interquartile 
range 12-14) out of 20 and a median 12-item quality score of 7 (interquartile 
range 6-8; Figure 4-4). A full breakdown of the scores is given in the 
Supplementary material, Tables S7-8. Meta-regression indicated that study 
quality according to either the ARRIVE guidelines score or to a 12-item 
quality score was not associated with the overall effect (P=0.317 and 
P=0.846, respectively). 
Overall, studies performed particularly poorly in several important areas of 
experimental design. For example, with respect to the ARRIVE guidelines 
only 16% reported sample size calculation, 23% reported randomization of 
animals to experimental groups, 23% defined the primary experimental 
outcome and 29% reported detail of adverse events during experiments 
(Figure 4-4 A). Regarding the 12-item quality score, only 32% of studies 
reported measurement of blood oxygen saturation, 13% reported 
measurement of blood pressure during the in vivo protocol and 10% 
performed blinded application of the conditioning protocol (Figure 4-4 B). 
Notably, only 38% of studies performed a blinded assessment of outcome. 
The impact of publication bias on the overall effect was assessed by visual 
analysis of the funnel plot, which suggested that small and negative studies 
might be under-represented (Figure 4-5). However, in Egger’s regression test 
the null-hypothesis of no small-study effect was not rejected at P=0.216 
(estimated bias coefficient 3.75±2.98 SE). 
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Figure 4-4. Reporting of study quality indicators.  
Study quality was assessed using the ARRIVE guidelines on reporting in vivo 
experiments (A) and a 12-item quality score (B). Values are expressed as the 
percentage of studies reporting each quality indicator. 
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Figure 4-5. Assessment of publication bias.  
A funnel plot comparing treatment effect to a measure of study size (precision of the 
effect estimate). The vertical line represents the mean effect size. This plot was 
assessed visually, with further analysis of publication bias performed using Egger’s 
regression test. 
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4.4.4 Sensitivity analysis 
When re-running our analysis using the SMD, all results were similar to those 
found using the WMD. We found a highly significant (P<0.001) overall effect 
of RIPreC (SMD of 11.06; 95% CI 8.52-13.60), as well as a similar level of 
heterogeneity (I2=91.1%). None of the experimental variables were 
significant after correction by multiple comparison. For RIPerC/RIPostC, all 
results using the SMD were likewise similar to those found using the WMD. 
We found a highly significant (P<0.001) overall effect (SMD of 13.14; 95% CI 
10.51-15.77) and similar heterogeneity (I2=93.3%). None of the experimental 
variables were significant after correction by multiple comparison. 
4.5 Discussion 
Our major finding is that both RIPreC and RIPerC/RIPostC have a large 
beneficial effect of both on infarct size. This finding is based on a 
comprehensive systematic review, including over 650 animals. However, 
there were relatively few pre-clinical studies investigating RIC and even fewer 
systematically characterising the protocol, which limited our analysis. 
Furthermore, we found inconsistency in the design of pre-clinical RIC studies 
with very few that were randomized effectively, included both male and 
female animals, and were double blinded with respect to procedure and 
outcome, which highlights the need for further well-designed, pre-clinical 
studies of RIC. 
These are important findings in the context of recent pessimism regarding 
RIC as a genuine cardioprotective phenomenon [309, 400]. Clinical trials 
investigating the efficacy of RIC in myocardial IRI have had mixed results [41, 
122], which has been attributed to clinical variables, including propofol 
administration [198]. However, each of the factors described above may 
influence outcome through lack of generalizability or unconscious bias [211], 
and therefore indirectly impact upon attempts to translate RIC to humans in 
clinical trials [99].  
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4.5.1 Determinants of RIC  
Interestingly, we found high levels of heterogeneity between studies. To 
investigate whether study protocol could account for the observed 
heterogeneity, and to elucidate the determinants of efficacy of RIC, we 
assessed the impact of experimental variables on effect size using a meta-
regression analysis. This approach has been successfully applied to several 
promising pre-clinical interventions to date. For example, Lim et al. were able 
to demonstrate that ciclosporin was not effective at limiting myocardial infarct 
size in pig models of IRI, compared to small animal models [224]. This finding 
might be important in the context of a subsequent neutral clinical study of 
ciclosporin before reperfusion in patients with STEMI [69]. Therefore, finding 
the parameters responsible for heterogeneity can guide pre-clinical and 
clinical study design. 
However, none of the tested experimental variables, which included species, 
cycle duration, number of cycles, number of conditioned limbs and the use of 
supplementary oxygen, were associated with effect size. In a recent analysis 
of pre-clinical studies of local ischaemic preconditioning, which included 
limited analysis of RIC, species (rodent vs. non-rodents) accounted for a 
substantial amount of the observed heterogeneity [368]. Although we found 
no significant association between animal size (rodents vs. non-rodents), 
there was a pattern of increased efficacy of RIPreC in large animals. 
Wever et al. also describe no association between effect size and the 
number, timing and duration of cycles, which is reflected in the present study 
[368]. Specifically, we found 1, 3 and 4 cycles to be equally effective. 
Conversely, in one of the few neutral comparisons in our analysis, Lu et al. 
utilised a protocol consisting of 1 cycle of 5 min RIPreC [234]. Interestingly, 
this amounts to the lowest total ischaemic ‘dose’ (a function of cycle number 
and duration) of any study of RIPreC. Amongst the RIPerC/RIPostC studies, 
only Li et al. applied 1 cycle of 5 min limb ischaemia and reported a relatively 
modest, albeit significant, effect (WMD 14.35%, 95% CI 13.03-15.67%) [217]. 
Others, including Mastitskaya et al., have applied a single cycle of longer 
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duration and achieved greater protection [243]. It is therefore plausible that 
ischaemic ’dose’ or burden, rather than cycle number or duration alone, is the 
dependent variable, but very few studies have examined this systematically 
in vivo. An exploratory analysis of the present data demonstrated no such 
association (data not shown), however this was limited by a narrow 
distribution of total ischaemic times in our dataset. Interestingly, a dose-
dependent effect of RIPreC has been observed, with greater cardioprotection 
after 10 min or 15 min compared to 5 min continuous infra-renal aortic 
occlusion [365]. In a study comparing bilateral and unilateral RIPreC in 
protection against renal ischaemia-reperfusion injury, bilateral was found to 
be more effective [369]. Taken together, this may suggest that total 
ischaemic dose is important, but this needs testing in specifically designed 
experiments. 
Furthermore, there may be an upper limit to what is an effective ischaemic 
dose. A recent characterisation of the RIC protocol ex vivo reported that 4 
and 6, but not 8, cycles of RIC were protective in mice [166]. Similarly, 
although 5 min or 10 min limb ischaemia protected against subsequent liver 
injury, 30 min and 60 min actually increased injury [359]. This issue is worthy 
of further attention, particularly using a more realistic setting of aged animals 
with co-morbidities. This may suggest a therapeutic window for RIC but there 
is very limited pre-clinical evidence, in contrast to direct ischaemic 
conditioning where the number of cycles are demonstrably important [368], 
and it is clear that detailed characterisation of study protocol in vivo is 
urgently necessary in order to answer these questions. 
After a period of limb ischaemia, it has been assumed that reperfusion is 
necessary, either to wash out the putative humoral factor, or because 
reperfusion-induced ROS may be necessary to activate signalling pathways. 
Additionally, some studies have suggested that reactive hyperaemia is an 
important factor in the response [287]. However it is worth bearing in mind 
that the original description in rabbits, where RIPreC was achieved by 55-
65% stenosis of the femoral artery in combination with rapid electrical 
stimulation of the gastrocnemius muscle for 30 min, did not actually involve 
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reperfusion [35]. This appears to support the hypothesis that multiple 
mechanisms are involved [223, 278].  
Similarly, our analysis supports the finding of Wever et al. of no association 
with the number of limbs conditioned [368]. Johnsen et al. further reported 
that 2 and 5 min, in contrast to 10 min, cycles were beneficial in mice [166]. 
This remains consistent with the concept of a therapeutic window of RIC but 
there is a paucity of in vivo experimental data relating to the precise RIC 
protocol. Our analysis demonstrated 10 min cycles to be equally effective as 
5 min cycles, albeit only in larger species as no studies in our meta-
regression used 10 min cycles in mice. We also noticed a pattern of reduced 
efficacy in RIPreC/RIPostC studies using 2 limbs instead of one, which may 
exceed the therapeutic window. However, this finding was not statistically 
significant and should only be considered hypothesis-generating. 
The use of supplementary oxygen in acute myocardial infarction is 
controversial [332], but the role of supplementary oxygen in RIC has not, to 
our knowledge, been investigated. It could be hypothesised that RIC is driven 
by cellular hypoxia in the conditioned limb which, at least in part, might be 
alleviated by ventilation with supplementary oxygen. In addition, excessive 
blood oxygen tension could increase production of reactive oxygen species, 
which has been shown to increase sympathetic drive [52]. This could impair 
the efficacy of RIC given the proposed importance of the vagus nerve [243, 
278]. However, despite finding the conditioning of animals with and without 
oxygen to be equally effective, there was a pattern of increased efficacy in 
animals ventilated with supplementary oxygen in the RIPreC comparisons. 
This has not been specifically investigated but our results would suggest 
further investigation is warranted. 
Furthermore, there is evidence that the degree of cardioprotection conferred 
by RIC is proportional to the duration of index ischaemia. Specifically, 
Kleinbongard et al. demonstrated longer ischaemic times to be associated 
with a greater efficacy of RIC, albeit in a study of patients undergoing CABG, 
which may be related to a greater target for protection [191]. In an 
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exploratory analysis, we found no statistical effect of index ischaemic time 
(Tables 4-5 & 4-6); however, there was a pattern of reduced efficacy of RIC 
at longer ischaemic durations in RIPreC but not RIPerC/RIPostC. This might 
suggest an important role for the timing of intervention, but should be 
interpreted with caution in view of the limited number of comparisons 
available after stratification according to study protocol. 
Experimental	factor		 WMD	 (95%	CI)	 %	Weight	 P-value	 Adj	R-squared		
Duration	of	isch	index	 	 	 	 0.180	 6.41%	
30	 23.42				 (18.26,	28.58)									75.16	 	 	
35	 22.0						 (9.28,	34.72)											3.63	 	 	
40	 16.63			 (13.53,	19.73)										21.20	 	 	
45	 -	 -		 -	 	 	
Table 4-5. Meta-analysis comparing the effect of index ischaemia duration on 
WMD in studies investigating remote PREconditioning. N=20 comparisons; the 
35 min group includes only 1 comparison. 
Experimental	factor		 WMD	 (95%	CI)	 %	Weight	 P-value	 Adj	R-squared		
Duration	of	isch	index	 	 	 	 0.997	 -3.09%	
30	 19.63					(16.54,	22.60)									56.44	 	 	
35	 -	 -											 -	 	 	
40	 31.24				 (29.35,	33.13)										18.84	 	 	
45	 15.32						(2.89,	27.75)							 24.73	 	 	
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Table 4-6. Meta-analysis comparing the effect of index ischaemia on WMD in 
studies investigating remote PERconditioning and POSTconditioning. N=16 
comparisons. 
 
There were several experimental variables that were of considerable interest 
but that lacked sufficient power for statistical analysis. For example, it has 
been suggested that propofol interferes with the development of RIC [198], 
and it has been implicated as a potential reason for the apparent lack of 
translation of RIC [140, 141]. Interestingly, we observed studies where 
propofol (together with either opioid analgesia ± pancuronium) was 
administered to have effect sizes above the mean [4, 125].  
Furthermore, studies reporting the use of mixed gender experimental groups 
reported apparently smaller effect sizes, and one of the few neutral studies 
was performed only in female animals [308]. Gender can potentially impact 
upon ischaemia-reperfusion injury possibly due to the cardioprotection 
conferred by oestrogen [253], and potential temporal variability in 
cardioprotection as a result of the oestrous cycle of female rats [37]. 
However, investigation of the role of gender is conspicuously absent from 
pre-clinical studies of RIC and these qualitative data require further testing in 
formal, well-designed studies. 
An important result of the present study is the need for more pre-clinical 
characterisation of RIC, which as well as the aforementioned variables 
should include the potential role of occlusion technique (arterial clamping vs. 
external compression), which may be important due to the possible 
involvement of limb collaterals [244], the putative effect of shear stress in RIC 
[287], and the role of pre-treatment with heparin, which  has been reported to 
be cardioprotective in the context of IRI [36, 110, 199]. Likewise, it has been 
hypothesised that the interval between the conditioning stimulus and the 
onset of index ischaemia might be an important determinant of the efficacy of 
remote preconditioning [99].  
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A further consideration is the impact of co-morbidities and co-medications on 
the efficacy of RIC. The animal models used in pre-clinical studies frequently 
do not reflect the complex risk factor, co-morbidity and pharmaceutical profile 
of humans with cardiovascular disease [124, 282], which may impede the 
development of RIC. For example, Jensen et al. treated isolated perfused 
rabbit hearts subjected to IRI with plasma dialysate from diabetic patients 
treated with RIC [164]. They were unable to confer cardioprotection using 
dialysate from patients with peripheral neuropathy compared to non-diabetic 
patients and diabetic patients without neuropathy. Baranyai et al. similarly 
found that acute hyperglycaemia abrogated the beneficial effect of RIPerC in 
Wistar rats [22]. However, despite considerable investigation of these 
features in local ischaemic preconditioning (reviewed by Ferdinandy et al. 
[92]), there is little experimental data relating to these factors in the context of 
RIC. Indeed, animals with co-morbidities were specifically excluded from the 
present analysis due to the small number of studies available. Nonetheless, 
co-morbidities should be considered when investigating the optimum protocol 
for the delivery of RIC. 
4.5.2 Risk of bias 
Poor methodological quality and publication bias can result in over-estimation 
of effect size [316, 374, 375]. In turn, this can engender enthusiasm about 
the benefit of a treatment where, in fact, none exists. It is therefore essential 
to examine the impact of study quality on size of effect, to which end we 
found no statistical relationship using meta-regression. 
However, we made some interesting observations. Aspects of the report 
relating to the experimental procedure, including control of temperature and 
recording of the ECG, were generally well reported. However, there was 
generally poor observation of the ARRIVE guidelines, particularly in relation 
to reporting of sample size calculations, randomisation, blinding and adverse 
events, which can result in selective exclusion. For example, in an interesting 
meta-analysis of systematic reviews, Hirst et al. reported that failure to 
randomise significantly increased effect size [145]. Furthermore, appropriate 
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monitoring of experimental animals, including recording of blood oxygen 
saturation and blood pressure, were poorly reported. These facets are clearly 
essential to ensure good quality research and were a central tenet of a recent 
position paper on improving the pre-clinical assessment of novel 
cardioprotective therapies [211]. In some cases these omissions will 
represent inadequate reporting but in others it is likely that these crucial 
elements of study design were not performed. We elected not to analyse 
each quality criterion independently due to insufficient reporting and to avoid 
false positive findings due to multiple comparisons. However, poor 
adherence to certain quality criteria may account for the heterogeneity 
observed in this meta-analysis. 
Finally, our assessment of publication bias by visual analysis of the funnel 
plot suggested that small, neutral studies may be under-represented; 
however, this did not statistically impact on the overall effect size, which is 
reassuring. 
4.5.3 Limitations 
The validity of this meta-analysis is contingent upon the quality of reporting of 
the included studies. Unpublished studies and those with missing data could 
not be included in the meta-analysis, and others did not meet important 
quality criteria including poor information regarding statistical analysis and 
blinding. However, the absence of a statistical impact from study quality or 
publication bias is reassuring in this regard. We were limited by being unable 
to consider manuscripts not available in English and we acknowledge that we 
did not carry out a systematic literature review to determine which 
experimental variables to include in our analyses, which might be subject to 
selection bias. A relatively small number of studies were included in the 
meta-analysis, thereby limiting the power of the study, which was further 
affected by multiple comparisons within individual studies; however, we 
elected to include all comparisons to avoid selection bias. Meta-regression is 
inherently limited; however, to ensure this was as robust as possible we 
performed a stratified meta-analysis by subgroup that yielded similar results, 
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including a highly significant overall effect of RIC, significant heterogeneity, 
and no effect of any of the experimental variables we included in our model. 
4.5.4 Recommendations and Conclusions 
This systematic review and meta-analysis of pre-clinical in vivo studies of 
myocardial IRI demonstrates a significant and highly reproducible beneficial 
effect of RIC. This effect was highly heterogeneous, a finding that may be 
due to un-measurable, multifactorial differences between individual 
experimenters and laboratories. Importantly, however, in vivo studies to date 
suggest the optimal RIC stimulus has not yet been identified. There was a 
paucity of pre-clinical characterisation of the RIC protocol and poor reporting 
of quality indicators. This is important not so the protocol can be translated to 
humans, but in order to understand the key parameters and/or markers that 
will facilitate optimization of the protocol in humans. 
There has been a great deal of debate regarding neutral clinical studies of 
RIC [99, 309]. However, before we try to understand these failings and 
design future studies it is essential to fully describe RIC in pre-clinical 
experiments. At present, studies variably (and apparently randomly) apply 
the intervention to one or two limbs, for varying periods of time, with a 
variable number of cycles and with inconsistent timing with respect to the 
injurious ischaemic episode. To this end, we have identified a need for more, 
well-performed studies with a focus on characterisation rather than detailed 
elucidation of mechanisms. In particular, these should concentrate on 
investigating the potential impact of gender and the number, timing and 
duration of cycles on the efficacy of RIC. These aims would be greatly aided 
by the identification of a biomarker or a critical physiological parameter(s) 
that correlates with protection. More studies investigating the potential benefit 
of RIC in larger species are required before translation to humans and we 
highlight the potential role of supplementary oxygen as particularly interesting 
for exploration. Finally, future research should focus on investigating other 
potential reasons for neutral clinical studies of RIC, including co-morbidities 
and adjunctive therapies. 
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Chapter 5 CO-DEPENDENCE OF THE NEURAL AND 
HUMORAL PATHWAYS IN THE MECHANISM OF REMOTE 
ISCHAEMIC CONDITIONING 
Some of the work presented in this chapter has been recently published. 
Chapter 10 contains a copy of the published manuscript. 
Pickard JMJ, Davidson SM, Hausenloy DJ, Yellon DM (2016) Co-
dependence of the neural and humoral pathways in the mechanism of 
remote ischaemic conditioning. Basic Res Cardiol 111:50. doi: 
10.1007/s00395-016-0568-z 
5.1 Introduction 
Remote ischaemic conditioning was first discovered in 1993, where brief 
ischaemia to the circumflex coronary bed induced protection from a 
subsequent left anterior descending coronary artery infarction [283]. This 
extension of classical ischaemic conditioning was a paradigm shift, and 
revealed for the first time that one vascular bed can communicate with others 
to protect them from ischaemia-reperfusion injury. Soon, other groups 
expanded the paradigm by looking at more remote areas from the heart. Gho 
et al demonstrated that 15min occlusion of the mesenteric artery was 
sufficient to induce cardioprotection [102]. A number of subsequent studies 
added to these data, with brief renal artery and hindlimb/skeletal muscle 
ischaemia both sufficient to protect the myocardium [35, 222, 270]. Indeed, it 
seems there is ability within mammals for the vasculature to communicate 
throughout the body and increase the resistance to ischaemic injury. 
One of the key research interests following these data was in determining the 
pathway by which the cardioprotection is communicated from the conditioned 
limb to the myocardium. Perhaps the most logical pathway is via release of 
one or more humoral factors into the blood stream, which then move from the 
conditioned organ to the heart and protect. This theory was supported by the 
observation that reperfusion of the conditioned organ was necessary to 
induce the remote cardioprotection [102, 366]. Moreover, several studies 
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demonstrated that protection could be transferred from one isolated heart to 
the next. Dickson et al collected coronary effluent from an isolated rabbit 
heart following exposure to classical ischaemic preconditioning, which was 
able to protect a naïve isolated rabbit heart when perfused prior to ischaemia 
reperfusion injury [75] (model described in section 3.4). Moreover, the same 
group demonstrated that protection could also be transferred via transfusion 
of whole blood from in vivo rabbits, who had been preconditioned with brief 
renal artery ischaemia, to a naïve acceptor rabbit [77].  
There was soon an added layer of complexity to the paradigm, with several 
publications proposing a neural pathway for RIC communication. Gho et al 
first demonstrated that the ganglion blocker, hexamethonium, abrogated the 
cardioprotection offered by brief (10min) mesenteric artery occlusion. In 
addition, remote conditioning via skeletal muscle ischaemia was also 
sensitive to ganglion blockade in human subjects. Subsequent studies 
corroborated these data, with Ding et al demonstrating increased firing of 
renal nerve afferents following brief renal artery occlusion. This was 
abrogated by pretreatment with the adenosine receptor antagonist 8-(p-
sulfophenyl)theophylline (8-SPT). This suggested a local release of 
adenosine in the conditioned organ, which triggers RIC via activation of 
sensory afferent nerves. Indeed, an elegant study by Liem et al confirmed 
these data, where intra-mesenteric artery infusion of adenosine (10ug/min) 
was sufficient to induce cardioprotection. This adenosine-mediated remote 
cardioprotection was also sensitive to the ganglion blocker hexamethonium. 
Infusion of the same concentration of adenosine into the portal vein was not 
cardioprotective. Moreover, the same cardioprotection could be achieved by 
intra-mesenteric artery injection of bradykinin and calcitonin gene related 
peptide. These data above suggest that remote conditioning is triggered via 
release of small autocoids in the conditioned organ, which activates sensory 
afferent nerves. These sensory nerves carry the cardioprotective message 
away from the conditioned limb towards the heart. Finally, it is of interest that 
the triggers for RIC and classical IPC are similar. This is investigated in more 
detail in Chapter 7. 
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The neural and humoral pathways of RIC were initially thought of as 
mechanistically distinct. Indeed, when the mesenteric artery occlusion was 
increased to 25 min, hexamethonium no longer appeared to block the 
ensuing cardioprotection. This suggested a humoral component of RIC that 
existed outside of any neuronal dependency. In fact, the current literature 
indicates that both pathways are critically dependent on one another, and the 
communication of RIC occurs via a neuro-humoral process. A key study from 
Steensrud et al demonstrated that a plasma dialysate prepared from rabbits 
that had received limb RIC, could protect a naïve Langendorff rabbit hearts 
from ischaemia-reperfusion injury. When the limb RIC was preceded with 
femoral nerve section, the resulting dialysate no longer protected the naïve 
heart. Moreover, intra-femoral artery adenosine in rabbits produced a plasma 
dialysate that was cardioprotective. This effect was also abrogated by prior 
femoral nerve section, and intra-femoral vein adenosine at the same dose 
had no effect. These data not only support the original work into the neural 
pathway but, crucially, link this mechanism to the release of the humoral 
blood-borne mediator. Indeed, several subsequent publications have proven 
that activation of C-fibre sensory afferents must occur prior to release of the 
humoral factor.  
The downstream effector of RIC following sensory afferent firing, which leads 
to release of the humoral factor, is not clear. Several studies have implicated 
a role for the vagus nerve in remote conditioning, although its relationship to 
release of the humoral factor is not known. The aim of this chapter, therefore, 
was to investigate further the link between the neural and humoral pathways 
of RIC, with particular focus on the vagus nerve and intrinsic cardiac ganglia. 
5.2 Research aims and objectives 
There were two main objectives in this chapter: 
1. To investigate the role of the vagus nerve in the release of the 
humoral RIC mediator; 
2. To investigate the role of intrinsic cardiac nerves in the response to 
the humoral RIC mediator in the myocardium. 
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5.3 Aim 1: The vagus nerve and release of the humoral RIC mediator 
5.3.1 Background 
The vagus nerve is the tenth cranial nerve, and is the most widely distributed 
cranial nerve in the body. The nerve serves as the main conduit for sensory 
and motor parasympathetic fibres, with their somata found in two nuclei in the 
brainstem, the nucleus ambiguous and the dorsal vagal motor nucleus. 
Emerging from the brain via the jugular foramen and descending into the 
body as the right and left cervical vagus, the nerve then branches throughout 
the body and innervates almost every organ, including the heart, lungs, gut, 
liver and kidneys. Indeed, the nerve was named according to its wide 
distribution; vagus translates to ‘wandering’ in Latin. The parasympathetic 
influence on the body is therefore diverse, ranging from regulating the gut 
barrier, to sensation in the outer ear, and of course controlling cardiac 
function.  
The extent of vagal innervation in the heart is controversial. Efferent 
parasympathetic nerves are well documented to widely innervate the atria, 
and exert control on the atrio-ventricular and sino-atrial nodes to modulate 
cardiac function [67]. Although previously thought that the ventricles have 
limited parasympathetic innervation, a growing body of literature has 
demonstrated a clear presence of fibres stained positive for 
acetylcholinesterase and a high density of muscarinic M2 receptors in both 
ventricles [107]. Indeed, stimulation of the vagus nerve decreased left 
ventricular contractility independent of its effect on heart rate [216, 378] and, 
crucially, independent of sympathetic nerve activity [66, 100].  In addition, 
vagus nerve stimulation inhibited both the chronotropic and inotropic effect of 
increased sympathetic tone. Cardiac vagal innervation appeared in evolution 
before sympathetic innervation [107, 338], and the heart in most vertebrates 
operates under fluctuating levels of inhibitory vagal tone.  
The strength of cardiac parasympathetic control is well correlated with risk of 
death following myocardial infarction. Patients who displayed either low heart 
rate variability or baroreflex sensitivity carried significant risk of cardiac 
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mortality following infarction [306]. A subsequent study demonstrated that, 
even in the absence of cardiovascular disease, the ability to recruit the vagus 
nerve is a strong indicator of overall mortality, [65]. These data, in addition to 
the powerful negative inotropy induced by vagus nerve stimulation, led to the 
idea that the nerve could be targeted as a potential therapeutic agent. 
Indeed, a growing body of pre-clinical literature has demonstrated that 
stimulation of the vagus nerve can provide powerful cardioprotection from 
ischaemia-reperfusion injury [174, 219, 321, 347]. 
Interestingly, the vagus nerve has recently emerged as one of the key 
mediators of remote ischaemic conditioning [79, 243]. Section of the vagus 
nerve at the cervical level consistently blocks the cardioprotection of RIC. 
The initial conclusion here was that direct cardiac vagal tone was important in 
the communication of the RIC protective message. However, a recent series 
of studies demonstrated section of the posterior gastric branch of the vagus 
nerve also abrogated RIC [25, 242]. The suggestion here is that non-cardiac 
vagal innervation is important; a cardioprotective factor is released from the 
gut following increased efferent vagal tone to this region. However, these 
data presented do not absolutely prove this link, as release of a humoral 
factor is not measured. This chapter investigates the hypothesis that the 
humoral mediator is released downstream of vagus nerve activation. 
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5.3.2 Methods 
5.3.2.1 Bilateral cervical vagotomy 
The dialysate model was used for these experiments, for which detailed 
methods can be found in section 2.3. 
Male Sprague-Dawley rats (250-300g) were anaesthetised with 60mg/kg 
sodium pentobarbital (Animalcare, York, UK) and prepared as described in 
section 2.3.1. Once stabilised under anaesthesia, the rats were randomised 
to receive one of four interventions: (1) Sham vagotomy + Control, the left 
and right vagus nerves were isolated at the mid-cervical level, but not 
severed, and the rat received a sham-RIC protocol; (2) Sham 
vagotomy + RIC, the same as group 1; however, the rat was subjected to 
RIC; (3) Vagotomy + Control, rats were subjected to bilateral cervical 
vagotomy and received a sham-RIC protocol; and (4) Vagotomy + RIC, rats 
were subjected to bilateral cervical vagotomy and received RIC (Fig. 5-1).  
Figure 5-1. Experimental protocols used to investigate role of the vagus nerve 
in release of the humoral RIC mediator. 
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5.3.2.2 Stimulation of the posterior gastric branch of the vagus nerve 
This experiment was carried out in collaboration with Prof Alex Gourine’s 
laboratory. Svetlana Mastitskaya carried out the in vivo gastric vagus nerve 
stimulation. 
Detailed methods for stimulation of the gastric vagus nerve can be found in a 
recent publication from Mastitskaya et al. [242].  
Briefly, male Sprague-Dawley rats (280-320g) were anaesthetised with 
sodium pentobarbital (60mg/kg; 10-15 mg.kg-1.hr-1 i.v. maintenance). The 
posterior gastric branch of the vagus nerve was identified and cleaned of 
connective tissue. A bipolar silver stimulating electrode was placed on the 
nerve, with the cathode positioned proximally to the target organ 
(stomach/gut). The electrode was attached to a constant current stimulator 
(Model DS3, Digitimer). The stimulator was embedded polyvinylsiloxane 
dental impression material (Super-Dent, Carlisle Laboratories). The animal 
was then randomised to receive either electrical stimulation (10Hz, 0.5mA, 
0.1ms pulse, 1hr) or a corresponding sham period. 
Figure 5-2. Experimental protocols used for posterior gastric vagus nerve 
stimulation in rats. 
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5.3.2.3 Preparation of dialysate 
At the end of each experimental protocol, a clamshell thoracotomy was 
performed and 9ml blood sampled via right ventricular puncture. The blood 
was centrifuged in two stages, described in section 2.3.4, to obtain 4ml 
platelet-free plasma. This was subsequently dialysed across a 12-14kDa 
membrane (Spectra-Por, Spectrum Laboratories Inc., CA, USA) for 24hr in 
200ml of modified Krebs-Henseleit buffer.  
5.3.2.4 Perfusion through naïve isolated heart 
Isolated Langendorff-perfused hearts were prepared from male Sprague-
Dawley rats (250-300g), as previously described in section 2.2. Following a 
20min stabilisation period, the hearts were perfused with the prepared 
dialysate for 10min, with a 10min washout period. The hearts were then 
exposed to a 35min left anterior descending coronary artery ischaemia and 
60min reperfusion. Infarct size was estimated at the end of the protocol using 
the Evans blue and triphenyl-tetrazolium chloride method as described in 
section 2.2.5. 
5.3.2.5 Statistical analysis 
Infarct size was assessed using ImageJ software (version 1.45, National 
Institutes of Health, USA), and expressed as a percentage of the area-at risk 
(IS/AAR %). All data are presented as mean ± standard error. For the 
vagotomy study (section 5.3.2.1), the experimental groups were analysed 
using a one-way analysis of variance (ANOVA). For the second study 
(5.3.2.2), the two groups were analysed using an un-paired students t-test. 
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5.3.3 Results 
5.3.3.1 Bilateral cervical vagotomy abrogates release of the humoral 
RIC mediator 
Sham surgical vagotomy did not influence the efficacy of RIC dialysate to 
protect a naïve, isolated rat heart (control dialysate from sham-surgery rat: 
IS/AAR=40.7±6.3% vs RIC dialysate from sham-surgery rat 
IS/AAR=23.7±3.1, p<0.05) (Fig. 3). When the vagus nerve was sectioned 
bilaterally at the cervical level, RIC dialysate no longer protected the naïve-
isolated heart (control dialysate from vagotomised rat: IS/AAR=31.4±2.4% vs 
RIC dialysate from vagotomised rat: IS/AAR=42.2±3.2%, p<0.05 vs sham-
surgery RIC dialysate) (Fig. 5-3).  
The hemodynamic data for the naïve-isolated hearts that received dialysate 
are shown in figure 5-4. Measurements were taken at the beginning of 
stabilisation, 5min into the index ischaemia and at the end of 60min 
reperfusion. Those hearts treated with RIC dialysate did not demonstrate 
improved functional recovery as measured by coronary flow rate (CFR), left 
ventricular developed pressure (LVEDP) and heart rate (HR). In addition, 
dialysate prepared following bilateral cervical vagotomy did not affect the 
functional recovery when perfused through a naïve-isolated heart.  
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Figure 5-3: Bilateral cervical vagotomy abrogates dialysate-mediated 
protection of naïve-isolated rat hearts: Chart displays left ventricular infarct size 
as a proportion of the area-at-risk. Dialysate was prepared following in vivo 
vagotomy or sham surgery matched with either RIC or sham protocols. This was 
perfused through a naïve-isolated heart prior to IRI. Sham vagotomy did not 
influence the ability of RIC dialysate to induce cardioprotection in the naïve heart. 
Bilateral cervical vagotomy, however, abrogated RIC-dialysate protection in the 
naïve heart, suggesting release of the blood-borne humoral mediator was inhibited. 
Data were analysed via one-way ANOVA with Tukey’s post-hoc test, and presented 
as mean±SEM, with 6-8 animals per group. 
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Figure 5-4. Haemodynamic data for bilateral cervical vagotomy experiment: 
Measurements were taken following 10min of stablilisation, 5min into the index 
ischaemia and at the end of reperfusion. (A) coronary flow rate is expressed as 
ml/min, no significant difference observed between groups. (B) left ventricular 
developed pressure measurement were obtained via insertion of a fluid-filled balloon 
into the left ventricle. RIC dialysate did not affect functional recovery of naïve-
isolated hearts. (C) heart rate is expressed as beats-per-min, again there were no 
significant differences between the groups. Data expressed as mean±SEM, n=6-8 
per group. 
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5.3.3.2 Stimulation of the posterior gastric branch of the vagus nerve 
Dialysate prepared following gastric vagus nerve stimulation did not induce a 
significantly lower infarct size in naïve hearts relative to sham dialysate 
(Stimulation dialysate I/AAR = 41 ± 6 % vs sham dialysate I/AAR = 28 ± 5 %, 
p = 0.13) (Fig. 5-5). In fact, the dialysate prepared following stimulation 
appeared more injurious to the naïve heart, although the sham dialysate 
induced a lower infarct than is normally observed for this ischaemia-
reperfusion protocol (see Fig. 3-14). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-5. Dialysate prepared following in vivo stimulation of the posterior 
gastric branch of the vagus nerve does not protect the naïve rat heart. 
Dialysate prepared following either posterior gastric vagus nerve stimulation or 
sham was perfused through naïve rat hearts prior to induction of ischaemia-
reperfusion injury. No difference was observed between the two groups (Stimulation 
dialysate I/AAR = 41 ± 6 % vs sham dialysate I/AAR = 28 ± 5 %, p = 0.13). Data 
presented as mean ± SEM and analysed using an unpaired student’s t-test. 
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5.3.4 Discussion 
Our study elucidates a novel aspect to the mechanism of RIC 
communication. Namely, release of the blood-borne humoral mediator is 
dependent on prior activation of the vagus nerve. Whilst the importance of 
the vagus nerve in RIC has been previously reported [79, 80, 242, 243], this 
study is the first to prove its involvement in the release of the humoral 
mediator.  
Vagus nerve stimulation has been reported in the literature to offer significant 
cardioprotection from ischaemia-reperfusion injury [79, 243, 322, 347]. 
Indeed, an important study by Mastitskaya et al demonstrated that activation 
of a particular group of pre-ganglionic parasympathetic neurones, in the 
dorsal vagal motor nucleus (DVMN), was sufficient to induce powerful 
cardioprotection in vivo [243]. In a subsequent and very elegant experiment, 
the DVMN was genetically silenced using the allatostatin method [243, 363]. 
This process abrogated RIC-mediated cardioprotection, indicating that this 
group of preganglionic parasympathetic neurones are fundamental for the 
communication of the protective message from the conditioned limb to the 
myocardium. Moreover, a recent study from the same group indicates vagal 
innervation to the stomach and gut is responsible for RIC communication, 
suggesting the release of a blood-borne mediator following vagal recruitment 
[242]. The literature, however, is not fully in agreement with these data [80]. 
Donato and colleagues demonstrated that cervical but not sub-diaphragmatic 
vagotomy abrogated RIC, suggesting direct cardiac vagal innervation to be 
key for RIC communication. The absence of a sham sub-diaphragmatic 
vagotomy group, however, calls the result into question given the huge 
abdominal trauma associated with the abdominal surgery. In addition, 
release of a humoral cardioprotective mediator downstream of vagus nerve 
activation has not been demonstrated in the literature. The key result from 
our study, therefore, is that release of the humoral RIC mediator is 
dependent on prior activation of the vagus nerve.  We further conclude that 
the humoral factor is released from a region of the body innervated by the 
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vagus nerve below the cervical level. Whether this factor is released following 
non-cardiac vagal innervation, however, is not clear.  
Dialysate prepared following stimulation of the posterior gastric branch of the 
vagus nerve did not protect a naïve-isolated heart from ischaemia-
reperfusion injury. This result is in contrast with those data presented by 
Mastitskaya and Basalay [25, 242]. Stimulation of the posterior gastric vagal 
branch induced cardioprotection in vivo, and RIC was blocked with the 
glucagon-like peptide 1 (GLP-1) receptor antagonist exendin(9-39). The main 
conclusions from these two studies were that RIC requires intact 
parasympathetic innervation of visceral organs and GLP-1 receptor-mediated 
signalling. However, there is a lack of clear data indicating a factor is 
released from the gut following RIC. Data presented in Fig. 5-5 suggests that 
this parasympathetic branch might not be important in release of the humoral 
RIC mediator.  
Release of the humoral mediator following RIC is dependent on an intact 
sensory innervation to the conditioned limb [164, 331]. In addition, two 
important studies demonstrated that direct femoral nerve stimulation, topical 
application of capsaicin or indeed transcutaneous electrical nerve stimulation 
generated a plasma dialysate that was able to protect a naïve heart from 
ischaemia-reperfusion injury [248, 290]. These data suggest the sensory 
afferent nerve is the sole means of communication from the conditioned limb, 
and that the factor is released downstream of nerve stimulation. Our study 
perhaps adds to the model by suggesting that the vagus nerve is the link 
between sensory nerve activation in the limb and release of the humoral 
mediator (Fig. 5). 
One interpretation of these data is that vagus nerve stimulation may be 
sufficient to evoke all of the protection conferred by RIC. In the literature, 
chronic vagal nerve stimulation failed to ameliorate cardiac remodelling or 
functional capacity in heart failure patients [399]. However, whether vagus 
nerve stimulation can protect the heart from acute myocardial infarction (AMI) 
in the clinic is unknown. Perhaps the cuff inflation used currently to induce 
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RIC could be replaced with non-invasive stimulation of the vagus nerve [330]. 
A recent clinical study demonstrated that the anesthetic propofol impedes the 
ability of RIC to protect the heart [198]. Propofol is known to be inhibitory to 
vagus nerve activity [361], thus suggesting the anesthetic prevents the 
communication of RIC at the level of the parasympathetic centres in the 
brainstem. Perhaps RIC should be given while the patient remains 
conscious, prior to administration of the anesthetic. Secondly, vagal tone is 
thought to depreciate with age [179]. Therefore, given the high average age 
of patients who suffer AMI, their diminished vagal tone may reduce the 
efficacy of RIC. Further study is required to elucidate the effect of age and 
anesthetics on RIC. In addition, investigation into which branch of the vagus 
nerve is responsible for inducing release of the factor will help reveal the site 
of its release and improve the chance of discovering its identity. 
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5.4 Aim 2: The role of intrinsic cardiac ganglia in RIC  
5.4.1 Background 
The intrinsic cardiac nervous system was overviewed in detail in section 1.5. 
This study aimed to extend the neural paradigm of RIC by investigating 
whether ganglia within the myocardium play a role in the mechanism. There 
exist within the heart intrinsic neural loops that are able to process sensory 
information from the myocardial milieu and modulate efferent autonomic 
output from intrinsic cardiac ganglia, without any necessary input from the 
central nervous system [16–18, 26]. These neural loops are at risk of 
destruction following myocardial infarction, and indeed remodel such that the 
intrinsic cardiac nervous system (ICNS) no longer can function as normal [2, 
119, 157, 286]. This is thought to be responsible for the increased risk of 
arrhythmia following infarction [14]. Whether the ICNS contributes to the 
myocyte death that occurs during ischaemia-reperfusion, however, is not 
known. 
Initial in vivo experiments by Gho et al. demonstrated that ganglionic 
antagonism, using hexamethonium, blocked the cardioprotection of RIC 
[101]. Although this suggested a neural pathway, it did not give resolution as 
to which ganglia were important in the mechanism. In the section above, we 
gave clear evidence that release of the humoral RIC mediator is dependent 
on an intact cervical vagal innervation [278]. These data, in combination with 
two other published studies [25, 242], suggest that non-cardiac vagal 
innervation is important for RIC, with subsequent release of a humoral 
cardioprotective factor. The dialysate model (section 3.5) can be used to 
investigate the transduction of protection in the heart in response to a 
humoral RIC mediator. An interesting question, therefore, is whether intrinsic 
cardiac ganglia play a role in response to the humoral mediator. Indeed, 
given the existence of intrinsic neural reflex loops within the myocardium [15], 
the Langendorff model may not be the denervated preparation as previously 
believed. This study investigates the hypothesis that intrinsic cardiac ganglia 
are recruited by the humoral mediator of RIC as part of the transduction of 
protection within the myocardium. 
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5.4.2 Methods 
5.4.2.1 Materials 
Hexamethonium (Sigma-Aldrich, Missouri, USA) was employed as a 
neuronal nicotinic acetylcholine receptor (nAChR) antagonist. Given it has 
affinity to the muscarinic M2 receptor above 100µM [88], a dose of 50µM was 
used for this study to aid specificity at nAChRs within cardiac ganglia. 
Atropine, a muscarinic acetylcholine receptor (mAChR) antagonist, was used 
at a dose of 100nM. Although often used at micromolar doses in the 
literature, atropine has a high affinity for mAChRs (Kd=0.36nM[343]). Thus 
100nM was chosen, which has recently been demonstrated to effectively 
antagonise muscarinic agonism in isolated hearts [170]. 
5.4.2.2 In vivo procedure and dialysate preparation 
A more detailed description of the dialysate method can be found in section 
2.3. 
Male Sprague-Dawley rats (250-300g) were used throughout the study. 
Following anaesthesia with sodium pentobarbitone (60 mg/kg, i.p.), the rats 
had a small cuff placed around the left hindlimb and were randomised to 
receive either a sham procedure or remote ischaemic conditioning. RIC was 
induced as 4 cycles of 5min hindlimb occlusion (200 mmHg cuff inflation) and 
5min reperfusion. For the sham procedure, the cuff was not inflated.  
At the end of the protocol, a clamshell thoracotomy was performed and 9ml 
blood sampled via right ventricular puncture. The blood was centrifuged in 
two stages, described in section 2.3.4, to obtain 4ml platelet-free plasma. 
This was subsequently dialysed across a 12-14kDa membrane (Spectra-
Por, Spectrum Laboratories Inc., CA, USA) for 24hr in 200ml of modified 
Krebs-Henseleit buffer. 
5.4.2.3  Perfusion of dialysate through a naïve-isolated heart 
Isolated perfused rat hearts were prepared as described in section 2.2. 
Hearts were randomly assigned to one of the following 6 groups: (1) Control 
dialysate, hearts received dialysate prepared from an in vivo rat following 
sham-RIC; (2) RIC dialysate, hearts received dialysate prepared from an in 
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vivo rat following in vivo RIC; (3) Control dialysate + Hexamethonium (50µM); 
(4) RIC dialysate + Hexamethonium; (5) Control dialysate + Atropine 
(100nM); (6) RIC dialysate + Atropine (100nM). In groups 3-6, drug perfusion 
was initiated 5-min prior to and for the duration of dialysate treatment. All 
hearts were perfused with the dialysate for 10-min, with a subsequent 10-min 
washout period, prior to a 35-min LAD index ischaemia and 60-min 
reperfusion. 
Figure 5-6. Experimental protocol. (i) Male Sprague-Dawley rats were randomised 
to receive either RIC (4x5min hindlimb ischaemia-reperfusion) or sham. Dialysate 
was prepared following each intervention. (ii) Isolated hearts were treated with either 
hexamethonium (50μM) or atropine (100nM) for 5min prior to and the duration of 
dialysate perfusion/washout. All hearts received 35 min left anterior descending 
coronary artery ischaemia and 60 min reperfusion. Following each Langendorff 
experiment, infarct size (IS) was determined using TTC staining. 
 
5.4.2.4 Statistical analysis 
Infarct size was assessed using ImageJ software (version 1.45, National 
Institutes of Health, USA), and expressed as a percentage of the area-at risk 
(IS/AAR %). All data are presented as mean ± standard error. The 
experimental groups were analysed using a one-way analysis of variance 
(ANOVA), p<0.05 was considered significant. 
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5.4.3 Results 
Figure 4 displays the infarct size chart from naïve-isolated rat hearts 
subjected to dialysate in the presence or absence of either the ganglionic 
blocker hexamethonium, or the muscarinic antagonist atropine. Those hearts 
treated with RIC dialysate in the absence of either drug induced powerful 
cardioprotection (Sham dialysate IS/AAR=40.1±1.2 vs RIC dialysate 
IS/AAR=27.6±2.3, p<0.05). In the presence of hexamethonium (50µM), RIC 
dialysate was no longer able to protect naïve hearts (Sham dialysate + Hex 
IS/AAR=42.3±4.3 vs RIC dialysate + Hex IS/AAR=45.8±2.7%, p>0.05 vs 
sham dialysate). The muscarinic antagonist atropine (100nM) also abrogated 
RIC dialysate-mediated cardioprotection (Sham dialysate + Atropine 
IS/AAR=40.7±4.8% vs RIC dialysate + Atropine IS/AAR=36.5±3.4%, p>0.05 
vs sham dialysate) (Fig. 5-6). 
The hemodynamic data again indicated that RIC dialysate did not 
significantly influence functional recovery of naïve hearts relative to control. 
In addition, neither hexamethonium nor atropine affected functional recovery 
of the isolated hearts (Fig. 5-7).   
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Figure 5-7. Hexamethonium and atropine abrogate dialysate-mediated 
cardioprotection: Isolated rat hearts were perfused with dialysate prepared 
following in vivo RIC or sham procedures. RIC dialysate significantly protected the 
naïve heart from IRI relative to sham. When the naïve heart was pretreated with 
either the ganglionic antagonist hexamethonium (50µM) or the muscarinic 
antagonist atropine (100nM) abrogated this protection. Data expressed as 
mean±SEM, n=6-8 per group. 
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Figure 5-8 Haemodynamic data for the intrinsic cardiac ganglia experiment: 
Measurements were taken following 10min of stabilisation, 5min into the index 
ischaemia and at the end of reperfusion. (A) coronary flow rate is expressed as 
ml/min, no significant difference observed between groups. (B) left ventricular 
developed pressure measurement were obtained via insertion of a fluid-filled balloon 
into the left ventricle. RIC dialysate did not affect functional recovery of naïve-
isolated hearts. (C) heart rate is expressed as beats-per-min, again there were no 
significant differences between the groups. Data expressed as mean±SEM, n=6-8 
per group. 
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5.4.4 Discussion 
These data provide the first evidence that intrinsic cardiac neural pathways 
are important in the mechanism of remote ischaemic conditioning. Growing 
evidence suggests that cardiac neural control is hierarchical. Indeed, sensory 
information from the heart can be received by: (1) central nervous control 
from medullary autonomic centres in the brain, which provide information to 
the heart via autonomic efferent pre-ganglionic neurons; (2) intrathoracic 
extracardiac ganglia; (3) intrinsic cardiac ganglia [12, 15–18, 152, 180, 230]. 
Intrinsic cardiac ganglia are able to process sensory information from the 
myocardium and directly activate efferent postganglionic nerve firing from 
intrinsic cardiac ganglia, thus neural control of the heart can occur without 
any extracardiac input [26, 180, 181]. The Langendorff perfused isolated 
heart is traditionally thought of as a denervated preparation, however in light 
of recent studies described above, as well as the results from this paper, it 
appears that intrinsic neural loops remain intact in the isolated heart and 
continue to play an important role in its function and ability to withstand 
ischaemia-reperfusion injury.  
Transmission of a sensory message in a pre-ganglionic synapse within 
intrinsic cardiac ganglia is governed via the release of acetylcholine into the 
synaptic cleft, which will bind to and activate nicotinic acetylcholine receptors 
(nAChR), on the post-ganglionic nerve, causing a depolarisation and initiation 
of the nerve impulse [34, 71, 106]. Hexamethonium will antagonise the 
nAChR, thus preventing transmission of information at the ganglia. The 
observation, therefore, that hexamethonium abrogates dialysate-mediated 
protection suggests the humoral factor recruits intrinsic cardiac ganglia as an 
essential process in the induction of cardioprotection. Muscarinic 
acetylcholine receptors (mAChR) are present primarily on the sarcolemma of 
cardiomyocytes [44]. They respond to acetylcholine released from 
parasympathetic post-ganglionic neurons, which innervate the ventricles [67, 
178, 307, 348]. Thus, the observation that atropine, a mAChR antagonist, 
abrogates dialysate-mediated cardioprotection suggests the humoral factor 
induces increased intrinsic post-ganglionic parasympathetic nerve outflow. 
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Previous evidence has demonstrated that hexamethonium and atropine 
abrogate in vivo RIC in rats [79, 101, 243], although the literature is not in full 
agreement [366]. In addition, evidence that the endothelium can be protected 
by RIC discounts the importance of intrinsic nerves in responding to the 
humoral mediator [186]. However, the protection offered to endothelium by 
RIC may be obtained via a different mechanism relative to the myocardium. 
Our data suggest the intrinsic cardiac ganglia play an important role in this 
setting.  
5.4.5 Limitations and future directions 
These data are limited by both the specificity of each drug to the desired 
receptor, and the localisation of each receptor within the heart. 
Hexamethonium is known to have specificity for muscarinic as well as 
nicotinic acetylcholine receptors. Although the dose used was chosen to 
ensure minimal affinity to muscarinic receptors, one cannot be sure of full 
selectivity for nicotinic receptors. Moreover, nicotinic receptors are not only 
expressed in neuronal ganglia within the heart, but also in cardiomyocytes 
[87]. Thus, it is possible that hexamethonium is exerting its inhibition of 
cardioprotection through direct action on cardiomyocytes rather than intrinsic 
ganglia.  
Future work could include use of genetic techniques to further dissect the 
mechanism of RIC. For example, development of murine models of Gi/o 
protein knockout in both cardiomyocytes and intrinsic ganglia.  One could 
then investigate whether cardioprotection by RIC was still effective in each 
model, the hypothesis being that Gi/o knockout within intrinsic ganglia would 
abrogate RIC.  
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5.5 Summary 
Data presented in this chapter, in combination two other recent studies, add 
important information to the RIC mechanism. First, we extended the neuro-
humoral hypothesis by demonstrating release of the humoral RIC mediator is 
dependent on prior vagus nerve activation. Second, the humoral RIC 
mediator exerts protection in the myocardium via activation of intrinsic 
cardiac ganglia. Our data are supported by two recent studies from Prof Alex 
Gourine [25, 242], where non-cardiac vagal innervation and subsequent 
release of glucagon-like peptide 1 (GLP-1)  was necessary for RIC-mediated 
cardioprotection. Moreover, the GLP-1 analogue, exenatide, was able to 
induce powerful cardioprotection by an atropine-sensitive mechanism. This 
suggests activation of intrinsic cardiac ganglia by GLP-1 following RIC, which 
supports our data. 
These findings may appear initially as an inefficient mechanism of 
communication; why, for example, does the vagus nerve not communicate 
directly to the heart? However, it is important to remember that RIC can 
protect several other organs in addition to the heart. In addition, the evidence 
that a denervated/transplanted heart can be protected by RIC argues against 
a role for direct vagal innervation [196]. We therefore suggest the following 
paradigm for RIC communication; brief cycles of ischaemia in the limb induce 
C-fibre sensory afferent firing, leading to increased vagal tone to a non-
cardiac organ, triggering release of a humoral blood-borne factor that 
subsequently induces cardioprotection via activation of intrinsic ganglia (see 
Fig. 5-9 for schematic). 
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Figure 5-9. Schematic of proposed mechanism of RIC communication (figure 
adapted from that in [276]): Serial inflations and deflations of a cuff around the 
upper limb will activate sensory afferent nerves [331]. These in turn will convey their 
message to autonomic regions of the brainstem, leading to increased systemic 
efferent vagal tone. The vagus nerve will innervate an organ remote from the heart, 
which induces release of a dialysable cardioprotective factor less than 12-14kDa in 
size. This factor will move to the heart via the blood and induce a protective 
phenotype within the myocardium, in part via recruitment of intrinsic cardiac ganglia. 
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Chapter 6 INTRINSIC CARDIAC GANGLIA AND 
ACETYLCHOLIND ARE IMPORTANT IN THE MECHANISM 
OF CLASSICAL ISCHAEMIC PRECONDITIONING 
The work presented in this chapter has been recently published. Chapter 10 
contains a copy of the published manuscript. 
Pickard JMJ, Burke N, Davidson SM, Yellon DM (2017) Intrinsic cardiac 
ganglia and acetylcholine are important in the mechanism of ischaemic 
preconditioning. Basic Res Cardiol 112:11. doi: 10.1007/s00395-017-0601-x 
6.1 Introduction 
Ischaemic preconditioning (IPC) is a powerful cardioprotective phenomenon, 
whereby brief cycles of ischaemia to a coronary bed renders it less 
susceptible to subsequent ischaemia-and-reperfusion-mediated infarction 
[255]. Indeed, IPC has emerged as a highly conserved cardioprotective 
intervention, effective in many mammalian species via a similar mechanistic 
pathway (see meta-analysis [368] and recent review [134]). Although studies 
have reported protection by classic IPC in the setting of cardiac surgery 
[160], it is not practical to be used clinically in either this setting or indeed in 
the in the setting of acute myocardial infarction (AMI). However, the potency 
of cardioprotection offered by classic IPC provides a very useful tool to better 
understand the physiological basis of cardioprotection. 
  
There are three interesting mechanistic traits of classic IPC: (i) there are 
several triggers which initiate the protective reflex, (ii) a threshold exists 
that must be surpassed in order for protection to occur and (ii) the presence 
of an effector signalling pathway within the cardiomyocyte is necessary. The 
triggers for IPC are several small molecules, released in the heart following 
the brief cycles of ischaemia. These include adenosine [226], opioids [313] 
and bradykinin [357]. Blocking the receptor for one of these molecules 
abrogates IPC, however this can be overcome by additional cycles of brief 
ischaemia [105]. Thus, IPC involves release of multiple trigger molecules 
that, via receptor activation, converge on a common cardioprotective 
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signalling pathway. This indicates that there exists a threshold that must be 
reached to induce cardioprotection, relating to the strength of the IPC 
stimulus. Protection is observed after a single ischaemic episode of 2.5 min, 
but not after shorter periods [209]. Moreover, the strength of protection 
seems to increase with the number of cycles of IPC, such that three cycles of 
5 min ischaemia affords greater protection than one [368]. Unsurprisingly, 
very long IPC ischaemic cycles no longer provide any cardioprotection [368]. 
Finally, the effector pathway, which involves activation of several well 
characterised pro-survival signalling pathways within the cardiomyocyte [131, 
132] and renders the cell resistant to death. Perhaps the most interesting 
aspect of IPC is that, despite application of the intervention prior to the index 
ischaemia, the majority of protection is provided against reperfusion injury. 
Indeed, we have demonstrated that inhibition of the RISK pathway at the 
point of reperfusion abrogated IPC-mediated cardioprotection [129]. This 
necessitates a memory phase, during which the myocardium “remembers” 
the protective intervention prior to its employment at reperfusion. Indeed, the 
initial window of protection offered by IPC lasts up to 2 hours prior to the 
index ischaemia [206, 220]. The mechanism of this apparent memory phase 
is as yet unclear. 
 
Neural control of the heart is typically thought to be mediated by regions in 
the brainstem and spinal cord. Indeed, the autonomic ganglia that reside 
within the thorax and myocardium have long been thought of as 
monosynaptic relay stations, which serve to confer the complex processing 
and efferent output of the central nervous system. In fact, there exists a 
complex hierarchy of cardiac neural control, with sensory afferent nerves of 
cardiac origin found not just in central nervous system (CNS) ganglia, but 
also intrathoracic and intracardiac ganglia [13]. Intrinsic cardiac ganglia are 
thus able to process sensory information and control efferent post-ganglionic 
autonomic firing within the heart, in the absence of any central modulation 
[11]. Moreover, a recent study revealed a heterogeneous population of 
intrinsic cardiac nerves, in particular local circuit neurons, which respond to a 
variety of stimuli and can influence cardiac function on a beat-to-beat basis 
without CNS influence [26]. Thus, complex neural processing occurs within 
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the heart, not just in response to central efferent input, but also sensory 
afferent information from the myocardium. Whether these reflexes remain 
intact in the Langendorff isolated heart preparation, however, is yet to be 
investigated.  
 
The massive sensory and ischaemic trauma associated with myocardial 
infarction (MI) induces dynamic morphological and phenotypic remodelling of 
the intrinsic cardiac nervous system, not limited to the infarcted region [119]. 
A ‘neural sensory border zone’ of infarction appears, with those afferents 
within the infarcted region becoming less sensitive, and those in the border 
and remote regions preserved or enhanced [286]. The influence of this neural 
remodelling is not yet clear, although it is thought to contribute to ventricular 
arrythmogenesis [57]. In addition, these effects occur over a period of weeks 
following infarction, thus the acute influence of the intrinsic cardiac nervous 
system on IRI is yet to be understood.  
6.2 Research aims and objectives 
The intrinsic cardiac nervous system has recently been implicated in the 
cardioprotection induced by remote ischaemic conditioning and vagus nerve 
stimulation [27, 278]. Here, we present two separate studies designed to 
investigate the importance of intrinsic cardiac ganglia in classical IPC; the 
first using an isolated perfused heart preparation, the second using a model 
of IPC via coronary effluent transfer. 
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6.3 Methods 
Materials 
Dose justification was given in detail for hexamethonium and atropine in a 
recent publication from the same authors [278]. Briefly, Hexamethonium 
(Sigma-Aldrich, Missouri, USA) was employed as a neuronal nicotinic 
acetylcholine receptor (nAChR) antagonist, at 50 µM, to achieve specificity at 
nAChRs within cardiac ganglia. Atropine, a muscarinic acetylcholine receptor 
(mAChR) antagonist, was used at a dose of 100 nM based on its affinity to 
the receptor (Kd=0.36 nM).  
Animals 
All animals received humane care in accordance with the United Kingdom 
(Scientific Procedures) Act of 1986. Male Sprague-Dawley (SD) rats were 
bred at a central animal unit in University College London and were used at a 
weight of 250-300 g throughout the study. 
Langendorff perfused heart preparation 
Rats were anaesthetised with an upper left quadrant intraperitoneal injection 
of sodium pentobarbitone (60 mg/kg) (Animalcare, York, UK). Hearts were 
quickly excised via a clamshell thoracotomy and the aorta cannulated on a 
Langendorff apparatus to allow for retrograde perfusion of modified Krebs-
Henseleit buffer (118 mM NaCl, 25 mM NaHCO3, 11 mM D-glucose, 4.7 mM 
KCl, 1.22 mM MgSO4.7H2O, 1.21 mM KH2PO4 and 1.84 mM CaCl2.2H2O. 
The buffer was warmed to 37.5°C and gassed with 95% O2 / 5% CO2 to 
obtain a pH of 7.35 - 7.45) [for detailed methods see 1]. A fluid-filled latex 
balloon was inserted into the left ventricle to allow for measurement of 
functional parameters, including heart rate (HR) and left ventricular 
developed pressure (LVEDP). Coronary flow rate (CFR) was recorded 
throughout the protocol and the temperature of the heart was maintained at 
37.0 ± 0.5°C. Finally, a 3-0 Mersilk suture (Ethicon, Edinburgh, UK) was 
inserted through the heart to surround the left anterior descending (LAD) 
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coronary artery. All hearts received a 35 min LAD ischaemia and 60 min 
reperfusion.  
Study 1  
Classic ischaemic preconditioning  
Two separate experiments were designed to investigate intrinsic cardiac 
nerves in classic ischaemic conditioning. The first experiment tested 
involvement of intrinsic cardiac ganglia in IPC, via use of the nicotinic 
acetylcholine receptor (nAChR) antagonist, hexamethonium. Isolated 
perfused rat hearts were randomly assigned to one of the following 6 groups: 
(1) Sham IPC, hearts received a 40-min stabilisation period; (2) Control + 
Hexamethonium (50 μM), hearts received a 10-min stabilisation period 
followed by 35 min perfusion with 50 μM hexamethonium. (3) IPC1, hearts 
received one cycle of 5-min global ischaemia followed by a 5-min reperfusion 
prior to index ischaemia (4) IPC3, hearts received 3 cycles of 5-min- global 
ischaemia with intermittent 5-min- reperfusion immediately prior to index 
ischaemia; (5) IPC1 + Hexamethonium (50µM), same as group 3 however 
the hearts were treated with hexamethonium for 5-minutes prior to and the 
duration of the 1-cycle preconditioning; (6) IPC3 + Hexamethonium (50µM), 
same as group 4 however the hearts were treated with hexamethonium for 5-
min prior to and the duration of the 3-cycle preconditioning.  
The second study looked at the importance of muscarinic acetylcholine 
receptors (mAChR) in classic IPC, via use of the drug atropine. Hearts were 
randomly assigned to one of 3 groups: (1) Control + Atropine (100nM), hearts 
received a 10min stabilisation followed by 35-min perfusion with 100nM 
atropine; (2) IPC3, hearts received 3-cycles of 5-min global ischaemia with 
intermittent 5-min reperfusion immediately prior to index ischaemia; (3) IPC3 
+ Atropine (100nM), same as group 2 however hearts were perfused with 
hexamethonium for 5-min- prior to and the duration of the IPC protocol.  
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All hearts subsequently received 35-min LAD ischaemia and 60-min 
reperfusion. At the end of the protocol, hearts were analysed for infarct size 
using methods described below. 
Study 2 
Classic IPC with coronary effluent transfer to naïve isolated hearts 
This study uses a model first pioneered by the Przyklenk laboratory [76], and 
has been used in several subsequent publications by different groups [43, 
215]. Although it is described in the literature as more similar to remote 
ischaemic preconditioning, in fact it likely reflects the humoral aspect to 
classical preconditioning. That is, it enables one to investigate the factors 
released by the heart following IPC. RIC is now generally agreed to occur via 
a more complex neuro-humoral pathway [278].  
In the first part of the experiment, coronary effluent was collected from 
isolated perfused donor rat hearts, randomised into one of the following two 
groups: (1) Donor Control hearts underwent 30-min of perfusion during which 
effluent was collected; (2) Donor IPC hearts received three cycles of 5-min 
global ischaemia with intermittent 5-min reperfusion, during which effluent 
was collected.  
In the second part, recipient hearts were perfused with effluent (from above) 
for 10-min, following 30-min of stabilisation, immediately prior to 35-min LAD 
ischaemia and 60-min reperfusion. These recipient hearts were randomised 
to one of four groups: (1) Ceff, hearts received 10-min perfusion of donor 
control effluent immediately prior to ischaemia; (2) IPCeff, hearts received a 
matched 10-min perfusion of donor IPC effluent; (3) Ceff + Hex, the same as 
group 1, however hearts were perfused with hexamethonium (50 μM) for 5-
min prior to and the duration of effluent perfusion; (4) IPCeff + Hex, same as 
group 2 however hearts were perfused with hexamethonium for 5-min prior to 
and the duration of effluent perfusion. Following reperfusion, all hearts were 
analysed for infarct size using methods described below. 
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Acetylcholine assay 
A Choline/Acetylcholine Assay Kit (Abcam, UK) was used to measure the 
concentration of acetylcholine in effluent collected following IPC (3x5min 
global ischaemia-reperfusion) or corresponding control period, as described 
above. The assay was carried out in accordance with the instructions 
provided by the manufacturer. Briefly, via the use of acetylcholinesterase, the 
level of free and total choline was measured in each sample, enabling an 
estimation of the concentration of ACh within the sample.  
Classic IPC with coronary effluent transfer to naive isolated cardiomyocytes 
In order to ascertain the role of the intrinsic cardiac nerves in classic IPC we 
undertook a series of studies using the isolated cardiomyocyte, where nerves 
are not present. Isolation of adult male Sprague-Dawley rat (250-300 g) 
cardiomyocytes was performed using a previously described protocol [136]. 
Cells were plated on laminin-coated 35 mm dishes (VWR international, PA, 
USA) and left to stabilise for 24-hr prior to use. Dishes were assigned to one 
of the following groups: (1) Normoxia, cells were left in M119 media for the 
duration of the protocol; (2) Vector control, cells were stimulated for 10 min 
with Krebs-Henseleit buffer; (3) Ceff, cells were stimulated for 10-min with 
control effluent; (4) IPCeff, cells were stimulated for 10-min with IPC effluent; 
(5) NECA, cells were stimulated with the adenosine A2B receptor agonist, 5'-
N-ethylcarboxamidoadenosine (NECA). Following stimulation (groups 2-5), 
cells were treated with hypoxic buffer [NaCl 127.8 mM, 14.8 mM KCl, 
KH2PO4 1.2 mM, MgSO4 1.2 mM, NaHCO3 2.2 mM, CaCl2 1 mM, Na. lactate 
10 mM, gassed with 5%CO2-95% N2 to achieve pH6.4], and placed into a 
sealed hypoxic chamber (Billups-rothenberg, CA, USA) filled with 5%CO2-
95% N2 gas mix. Hypoxia was continued for 3 hr at 37°C, at which point the 
cells were removed from the chamber and treated with normoxic buffer 
[Glucose 10 mM, NaCl 118 mM, KCl 2.6 mM, KH2PO4 1.2 mM, MgSO4 1.2 
mM, NaHCO3 22 mM, CaCl2 1 mM, gassed with 5%CO2-95% O2 to achieve 
pH7.4] to simulate reperfusion. The reoxygenation was continued for 1hr, at 
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which point the proportion of cell death was measured via propidium iodide 
staining and confocal microscopy (previously described here [352]).  
Infarct size assessment 
Infarct size of each isolated heart in the above experiments was calculated 
using the following methods, described in detail previously [30]. Briefly, at the 
end of the reperfusion period, the LAD suture was re-tightened and 1ml of 
0.25% Evans blue dye was perfused through the heart in order to delineate 
the area-at-risk of infarction. The hearts were then frozen at -20°C before 
being sectioned into 5-transverse slices and stained for viable tissue by 
immersion in 1% triphenyl-tetrazolium chloride at 37°C for 15-min. Following 
fixation in 10% formalin for 24-hr, the sections were digitally scanned to a 
computer for analysis. Analysis of infarct size (IS) as a proportion of area at 
risk (AAR) was calculated via planimetry using imageJ software (version 
1.45, National Institutes of Health, USA). 
Statistical analysis 
Data groups were first analysed for normality using the Kolmogorov-Smirnov 
test. Statistical differences between two groups were analysed using a 
student’s t-test and more than two groups using a one-way analysis of 
variance (ANOVA) with Tukey’s multiple comparison post-test. All data is 
presented as mean ± standard error of the mean (SEM). Data groups were 
classed as significantly different with a p value less than 0.05. Notation of 
significance is described in figure legends. Analyses were performed using 
GraphPad Prism version 5 for Windows (CA, USA). 
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Figure 6-1 Schema detailing the experimental protocols: Rat hearts were 
subjected to 35 min LAD ischaemia and 60 min reperfusion. Preconditioning was 
induced by three cycles of 5 min global ischaemia-reperfusion. Study one, 
Hexamethonium (1A) and atropine (1B) were perfused through the heart for 5 min 
prior to and for the duration of the conditioning protocol. Study two, coronary effluent 
was collected from isolated hearts either following IPC or control, and subsequently 
perfused through (2A) a naïve isolated heart and prior to index ischaemia. Again, 
hexamethonium was perfused through the recipient heart for 5 min prior to and the 
duration of effluent perfusion. Coronary effluent was used to stimulated isolated 
cardiomyocytes (2B) prior to hypoxia-reoxygenation injury. 
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6.4 Results 
6.4.1 Study 1: Classic ischaemic preconditioning is abrogated by 
hexamethonium and atropine 
In our isolated perfused rat heart model we demonstrated that three cycles of 
IPC (IPC3) was effective at reducing infarct size relative to control (IS/AAR = 
14 ± 2% vs control IS/AAR = 48 ± 3%, p < 0.05) (Fig. 2A). The nAChR 
antagonist, hexamethonium (50 μM), almost fully abrogated this 
cardioprotection (IS/AAR = 37 ± 7%, p > 0.05 vs control).  
In the second part of this study, the muscarinic antagonist, atropine, was 
used to investigate the pathway downstream of intrinsic ganglia. 100 nM 
atropine did not affect infarct size (IS/AAR = 51 ± 3%), however it abrogated 
the cardioprotection induced via 3-cycles of IPC (IS/AAR = 40 ± 3% vs IPC3 
= 15 ± 2%) (Fig. 2B).  
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Figure 6-2: Hexamethonium and Atropine abrogate ischaemic preconditioning. 
(A) Hexamethonium abrogates preconditioning induced by both one and three 
cycles of IPC (n=6-8 per group, * = p<0.05 vs control); (B) Atropine also abrogates 
the protection afforded by IPC3 (n=6 per group except IPC+Atropine where n=5, * = 
P<0.05 vs Control+Atropine). Data presented as mean ± SEM. 
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6.4.2 Study 2: Factors released following classical IPC require intrinsic 
cardiac nerves to induce protection 
Effluent collected from hearts following classic IPC induced significant 
protection when perfused through a second or naïve isolated rat heart prior to 
acute IRI (IS/ARR = 19 ± 2, p < 0.05 vs control IS/AAR = 46 ± 6%). Pre-
treatment of the naïve recipient heart with the nicotinic antagonist, 
hexamethonium, abrogate the protection offered by IPC effluent (IS/AAR = 
46 ± 5 %, p < 0.05 vs IPC effluent) (Fig. 3A). 
A large release of ACh following IPC was observed in these isolated 
perfused rat hearts, with a 10-fold increase in the concentration relative to 
control effluent (IPCeff = 0.36 ± 0.03 μM vs Ceff = 0.04 ± 0.04 μM, n = 4, p < 
0.001) (Fig. 3B). Three of the four control effluent samples did not contain 
any detectable ACh. 
Classic IPC effluent appears not to protect isolated cardiomyocytes from 
simulated IRI 
Cells that were maintained under normoxic conditions throughout the 
experiment exhibited 27 ± 2% cell death (Fig. 4). In cells that underwent 
simulated IR, this was increased to 57 ± 6% and 64 ± 6% after pre-treatment 
with the vehicle control and control effluent, respectively (p < 0.001 vs 
normoxic in both cases). Treating the cells with IPC effluent did not 
significantly reduce cell death (45 ± 6%, p=0.09 vs Ceff). The adenosine A2b 
agonist NECA (used as a +ve control) significantly reduced cell death to 32 ± 
4% (p < 0.01 vs vector control and Ceff) (Fig. 4). 
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Figure 6-3: IPC effluent protects a naïve heart from ischaemia-reperfusion 
injury. (A) effluent collected following IPC significantly protected a naïve isolated rat 
heart via a hexamethonium-sensitive mechanism (n=7-8 per group, * = p<0.05 vs 
control effluent); (C) The concentration of ACh in coronary effluent increases 10-fold 
following IPC (n=4 per group, * = p<0.05 vs Control effluent). Data presented as 
mean ± SEM. 
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Figure 6-4: IPC effluent does not protect isolated cardiomyocytes from 
simulated ischaemia-reperfusion injury. (A) Isolated rat cardiomyocytes were not 
protected from hypoxia reoxygenation injury by prior exposure to IPC effluent. The 
adenosine A2B agonist, NECA, was able to reduce cell death significantly (n=6 in all 
groups except n=4 for NECA, * = p<0.05 vs normoxia); (B) representative images of 
isolated cardiomyocytes subjected to the different protocols, the red staining indicate 
dead cells. Data presented as mean±SEM. 
 
 
 
 
 
 
 
180 
 
6.5 Discussion 
These results are the first indication of a neural pathway in the mechanism of 
classical ischaemic preconditioning. We demonstrated an important role for 
nicotinic and acetylcholine receptors, suggesting that intrinsic cardiac ganglia 
remain active in the isolated heart preparation and are important in conveying 
the protective message. Acetylcholine is released from the heart following 
IPC, perhaps from parasympathetic post-ganglionic nerve endings in the 
ventricles, and induces protection via an atropine-sensitive mechanism. The 
lack of total abolition of protection, in the presence of ganglionic or 
muscarinic antagonism, is likely due to the fact that several factors contribute 
to the IPC mechanism in the isolated heart model [86]. Moreover, coronary 
effluent collected following IPC was able to protect a naïve isolated heart, but 
not isolated cardiomyocytes, from IRI. The protection in naïve hearts was 
abrogated by hexamethonium, highlighting the importance of intrinsic cardiac 
ganglia in the mechanism of IPC. We therefore propose that IPC is governed, 
in part, via a neuro-humoral pathway; a factor released following IPC 
activates intrinsic cardiac ganglia, leading to release of ACh from 
parasympathetic post-ganglionic nerve endings in the ventricles, thus 
inducing cardioprotection via activation of muscarinic receptors. These data 
are, to some extent, additive to our previous study, where we proved an 
important role for intrinsic cardiac ganglia in remote ischaemic conditioning. 
Whilst a neural pathway has been well validated in RIC, this is the first to 
imply a similar intrinsic cardiac neural pathway in IPC. Thus, there appear to 
be more similarities between the mechanisms of classical (direct) and remote 
ischaemic conditioning than were previously apparent [24, 278]. 
Intrinsic cardiac ganglia in the isolated heart 
Intrinsic cardiac ganglia are widely distributed in the myocardium and not 
only relay central efferent pre-ganglionic information, but also are able to 
process sensory afferent information from the myocardium and control 
efferent post-ganglionic firing [26, 230]. Moreover, several anatomical and 
functional studies have indicated a significant presence of vagal neurons in 
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the ventricles, in addition to sympathetic and local circuit neurons [15]. The 
intrinsic cardiac nervous system is therefore able to control cardiac indices 
on a beat-to-beat basis, in the absence of input from the central nervous 
system [16].  
Activation of sensory afferent nerves in the Langendorff heart has previously 
been demonstrated to induce cardioprotection. Perfusion with capsaicin, a 
known activator of C-fibre afferents, induced early and delayed protection 
against ischaemia-reperfusion injury in isolated Langendorff rat hearts [406]. 
In our study, ganglionic antagonism abrogated the protection afforded by 
IPC, suggesting sensory afferent activation occurs following IPC and is 
important in conferring the cardioprotection. We further demonstrated a 10-
fold increase in the ACh concentration in perfusate collected following IPC. 
This suggests activation of post-ganglionic parasympathetic neurones from 
the intrinsic ganglia. Indeed, muscarinic antagonism, using atropine, 
abolished IPC-induced cardioprotection. The parasympathetic nervous 
system has a well defined cardioprotective effect [174, 242, 243, 322], and 
recently emerged as a key mediator of the cardioprotection afforded by 
“remote” ischaemic conditioning (RIC) [25, 243, 278]. Indeed, a recent study 
demonstrated that increased parasympathetic tone ameliorated the functional 
and structural remodelling of the intrinsic cardiac nervous system following 
myocardial infarction [27]. Thus, we propose that there exist similarities 
between the mechanism of remote and classical ischaemic conditioning; an 
intrinsic neural reflex loop in response to the brief ischaemia of IPC, which 
activates cardiac ganglia and increases post-ganglionic vagal tone, leading to 
release of ACh in the ventricles.   
A contentious role for acetylcholine in IPC 
IPC is triggered via release of several small molecules, and their subsequent 
receptor activation in the myocardium. This was first demonstrated by Liu et 
al, who showed that pre-treatment with an adenosine receptor antagonist 
abrogated IPC in rabbit hearts [226]. Exogenous adenosine, perfused 
through the heart prior to infarction, mimicked the cardioprotection of IPC. 
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These data suggested endogenous release of adenosine occurs in response 
to IPC, which protects the myocardium. Two other small molecules, opioids 
[233] and bradykinin [357], were found in subsequent studies to be important 
in the mechanism of IPC, via activation of their receptor. These appear to be 
connected via a common intracellular cytoprotective signalling pathway [267], 
which centres on activation of protein kinase C (PKC) [86]. Coronary effluent 
collected following IPC can protect a naïve isolated heart from infarction [43, 
75], supporting the theory of a humoral trigger for IPC. Indeed, adenosine is 
released into the effluent following IPC, and confers protection to the naïve 
heart via crosstalk with opioid receptors [74, 215]. Bradykinin is not involved 
in this setting due to the requirement for circulating kininogens in the blood, 
not present in the isolated buffer-perfused model [105].  
The role for acetylcholine in IPC, however, is more contentious. While 
several studies from Krieg et al. demonstrated exogenous ACh could induce 
cardioprotection in the Langendorff model, the same group discounts its 
involvement in the mechanism of IPC [200–202]. However, two studies from 
Kawada et al. demonstrated brief, 5 min ischaemia in in vivo rabbit and cat 
models induces interstitial release of ACh in the ventricles [176, 177]. Data 
from our study confirm those of Kawada et al, with a significant release of 
ACh observed in coronary effluent following IPC. Given this observation, we 
hypothesised that isolated cardiomyocytes would be protected from 
simulated IRI following exposure to coronary effluent. Presumably, if ACh 
was mediating protection here, it would act directly on muscarinic receptors 
on the cardiomyocytes in the naïve heart. However, IPC effluent was not able 
to significantly reduce cell death in isolated cardiomyocytes subjected to 
hypoxia-reoxygenation. A small reduction in cell death is observed, likely due 
to the presence of several trigger factors in the effluent [74, 215], however 
this was not statistically significant. This is perhaps due to dilution of factors 
released from the myocardium in the effluent following IPC, such that the 
concentration in the isolated cells would be insufficient for cardioprotection. 
However, we did not investigate whether exogenous ACh of the same 
concentration could induce cardioprotection in isolated cardiomyocytes or 
Langendorff models.  
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Finally, coronary effluent collected following IPC induced powerful 
cardioprotection when perfused through naïve isolated rat hearts, via a 
mechanism also sensitive to hexamethonium. This experiment confirms the 
key point to the study; factors released following IPC require intrinsic cardiac 
ganglia to induce cardioprotection. The neural and humoral components to 
IPC, therefore, are co-dependent.  
Is there a common trigger for classical and remote ischaemic conditioning? 
Our data suggest that both classical and remote ischaemic conditioning (RIC) 
may share a common trigger pathway; i.e. local release of an autocoid, 
activation of sensory afferent nerves and subsequent recruitment of the 
intrinsic cardiac nervous system. RIC is induced via the same principle as 
classical IPC, brief cycles of ischaemia, however applied to a region remote 
from the heart [35]. The trigger for RIC is thought to be local release of an 
autocoid, such as adenosine, which activates sensory afferent nerves 
communicating the protective message away from the conditioned limb. 
Indeed, a small injection of adenosine into the femoral artery is sufficient to 
induce cardioprotection [331], as is activation of C-fibre sensory afferents by 
capsaicin [290] or transcutaneous electrical nerve stimulation [248]. 
Moreover, our study has demonstrated the importance of intrinsic cardiac 
ganglia in IPC, which necessitates prior sensory nerve activation in the heart. 
Classical IPC is known to involve release of adenosine and calcitonin gene 
related peptide [215, 226], both of which are know to activate sensory 
afferent nerves. Perhaps, therefore, these are the trigger for this aspect to 
IPC. The trigger for both RIC and classical IPC appear to share important 
similarities, with both neural and humoral components [278].   
A recent meta-analysis revealed that ischaemic preconditioning had variable 
efficacy in mammalian species; namely, IPC was more effective in rodents 
relative to non-rodents [368]. Myocardial autonomic innervation is known 
differ according to the species’ size [310], however it is not clear whether 
these differences relate to the species-specific effect of IPC. Finally, with 
respect to remote ischaemic conditioning, although there appear to be 
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differences in the signalling cascades important for cardioprotection between 
species [324], a recent meta-analysis revealed no difference in the efficacy of 
cardioprotection relative to species [45].  
Study limitations 
The key limitation of the study lies in the specificity of hexamethonium to 
neuronal nicotinic acetylcholine receptors. Hexamethonium is widely used 
within the literature as a ganglionic blocker, being a neuronal nicotinic 
acetylcholine receptor antagonist. Although it has some affinity to muscarinic 
M2 receptors, this becomes negligible at concentrations below 100 µM [88], 
and it has an IC50 of 11 µM at nAChRs [109]. Thus, for the purposes of this 
study 50 µM was used in order to achieve high specificity to nicotinic 
receptors, but the potential may remain for non-specific effects. The second 
issue relates to the spatial expression of nicotinic receptors within the 
myocardium. Although nicotinic receptors are largely limited to the intrinsic 
cardiac ganglia, there is evidence for expression of the receptors on the 
myocytes [87]. Thus, there is a small possibility that hexamethonium is 
exerting its effect through non-ganglionic action.  
Secondly, these data do not fully ascertain the role of ACh within the effluent. 
An important additive experiment would be to treat a naïve-isolated heart with 
acetylcholine at the same level observed within the effluent. In addition, it is 
possible that stimulation of isolated cardiomyocytes with effluent for longer 
than 10-min could reveal cardioprotection.  
6.6 Summary 
This is the first study to implicate intrinsic cardiac ganglia in the mechanism 
of classical ischaemic conditioning. We propose that IPC activates an 
intrinsic cardiac neural reflex and is an important part of the cardioprotective 
mechanism. This is a significant finding for several reasons. The langendorff 
perfused heart was traditionally thought of as a denervated preparation, 
however clearly this is not true given the current data, in addition to our 
recent publication [278]. Moreover, these data add to the paradigm that IPC 
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is a receptor-mediated phenomenon. However, there seems to be an added 
layer of complexity, with the intrinsic ganglia responsible for conferring a 
portion of the cardioprotection. This is of importance given the issue of co-
morbidities in the clinical setting. For example, diabetes has been well 
documented to decrease the efficacy of IPC [372]; perhaps this could be 
explained by the peripheral sensory neuropathy that occurs as the disease 
progresses [164]. Whether the peripheral sensory nerve activation induced 
via remote ischaemic conditioning is comparable to that of classical 
ischaemic conditioning is not clear. Further work is necessary to ascertain 
the exact nature of the involvement of intrinsic ganglia in this setting. 
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Chapter 7 STIMULATING THE EAR TO PROTECT THE 
HEART: TRANSCUTANEOUS VAGUS NERVE 
STIMULATION IS A NOVEL CARDIOPROTECTIVE 
INTERVENTION 
7.1 Introduction 
There remains a clinical need for interventions that limit the extent of 
myocardial ischaemia-reperfusion injury. One such intervention, remote 
ischaemic conditioning (RIC), has proven popular in translational research 
due to its non-invasive nature and promising pre-clinical data [35, 276, 283]. 
Subjecting the upper or lower limb to brief periods of ischaemia and 
reperfusion can communicate significant protection to the myocardium from 
an injurious ischaemic insult. Clinical trials have investigated the efficacy of 
RIC in limiting the injury associated with coronary artery disease in several 
settings, including ST-elevation myocardial infarction (STEMI), and coronary 
artery bypass surgery (CABG). Whilst a majority have demonstrated 
cardioprotection, particularly in patients suffering from STEMI [41, 68, 294, 
325, 370], two recent large-scale trials failed to demonstrate improved 
outcome in patients undergoing coronary artery bypass surgery [122, 249]. 
Thus, investigation into the basic mechanisms underlying RIC has gained 
new importance; not only to explain the current lack of translation, but also to 
offer new opportunities by which the cardioprotective reflex can be accessed. 
The key process that requires further laboratory investigation is the 
communication of the protective message from the conditioned limb to the 
myocardium. The focal point of this communication in the literature is release 
of a blood-borne humoral factor. Shimizu et al demonstrated that a plasma 
dialysate generated following RIC in human volunteers was able to protect a 
naïve isolated rabbit heart [320]. This highlighted the remarkably conserved 
and stable nature of the humoral factor. Several subsequent studies 
demonstrated that release of the humoral mediator is dependent on intact 
sensory innervation to the conditioned limb [248, 289, 290, 331]. Moreover, 
increased vagal tone has been proven essential in the communication of RIC 
from the conditioned limb to the myocardium [79, 243, 278]. Genetic silencing 
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of vagal preganglionic neurones, in the dorsal vagal motor nucleus (DMVN), 
abrogated in vivo RIC in a rat model of acute myocardial infarction. 
Conversely, stimulation of the DVMN via optogenetics was sufficient to 
induce cardioprotection in vivo [243]. In addition, a recent paper from the 
same group suggested non-cardiac vagal innervation is fundamental to the 
RIC mechanism [242]; section of the posterior gastric branch of the vagus 
nerve abrogated RIC-mediated cardioprotection. Finally, we have recently 
demonstrated that bilateral cervical vagotomy prior to RIC abrogates release 
of the humoral mediator [278]. This suggests a complex neuro-humoral 
mechanism of RIC communication, initiated with sensory afferent activation 
in the conditioned limb leading to increased vagal tone and subsequent 
release of a humoral mediator, perhaps from the gut [25].  
There may, therefore, be an opportunity to bypass the RIC cuff and stimulate 
the vagus nerve directly to achieve the same cardioprotective endpoint. 
Several pre-clinical studies have demonstrated as much, with vagus nerve 
stimulation inducing powerful cardioprotection in animal models of acute 
ischaemia-reperfusion injury [174, 347]. Within the clinic, VNS is difficult to 
achieve in the setting of acute myocardial infarction (AMI) given the invasive 
procedure required to fit the stimulating device. Emerging data, however, 
have demonstrated that the tragus of the ear can be stimulated electrically to 
increase systemic vagal tone [62]. Indeed, the vagus nerve provides a large 
portion of the sensory innervation to the ear, in particular to the tragus and 
inner concha (Fig. 7-1) [32, 275]. Electrical stimulation of these regions, 
known as transcutaneous vagus nerve stimulation (tVNS), has been 
demonstrated to produce cognitive, behavioural and cardiovascular effects 
similar to that of direct vagus nerve stimulation [20, 299, 393]. Indeed, a 
recent clinical study demonstrated that sensory nerves in the tragus project 
to the nucleus tractus soltarius (NTS), a central autonomic centre, and thus 
are consistent with classical vagal projections [96]. Therefore, tVNS is 
emerging as a viable non-invasive mechanism to influence systemic vagal 
tone. This chapter investigates whether tVNS is a viable novel 
cardioprotective intervention.   
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7.2 Research aims and objectives 
There were two main objectives in this chapter: 
1. Investigate efficacy of transcutaneous vagus nerve stimulation in 
releasing cardioprotective blood-borne factors in healthy human 
volunteers; 
2. Investigate transcutaneous vagus nerve stimulation in an in vivo rat 
model of myocardial ischaemia-reperfusion injury. 
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Figure 7-1. Schematic displaying outer ear anatomy with general sensory 
innervation (figure adapted from that shown in [275]). 
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Figure 7-2. Proposed pathway by which transcutaneous vagus nerve 
stimulation elicits its effect on the myocardium. Figure taken from [254]. Afferent 
projections from the auricular branch of the vagus nerve synapse with cell bodies in 
the nucleus of the solitary tract (NTS). Projections from the NTS can control both 
sympathetic and parasympathetic outflow to the heart. DVN=Dorsal vagal nucleus, 
NA=Nucleus ambiguous, CVLM/RVLM=Caudal/Rostral ventrolateral medulla, 
IML=intermediolateral nucleus. 
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7.3 Aim 1: transcutaneous vagus nerve stimulation in healthy human 
volunteers 
Below describes a collaborative project with Prof Jim Deuchars’ laboratory in 
the University of Leeds. The study was conceived and designed by Prof 
Derek Hausenloy, Dr Nephtali Marina and myself. The first part of the study, 
involving human volunteers, was carried out by Aaron Murray at the 
University of Leeds. The second part of the study, involving the dialysate 
model described in section 3.5, was performed at the Hatter Cardiovascular 
Institute by myself. The manuscript is currently under review with JACC: 
Basic to Translational Science 
Pickard JM, Murray A, Marina-Gonzalez N, Yellon DM, Deuchars SA, 
Deuchars J, Hausenloy DJ Transcutaneous vague nerve stimulation 
induces release of a dialysable cardioprotective factor in healthy volunteers. 
(under review) 
7.3.1 Background 
Sensory innervation of the ear is supplied by branches of three cranial 
nerves; the vagus, trigeminal and facial (see Fig. 7-1). A branch of the vagus 
nerve, called the auricular branch of the vagus nerve (ABVN), innervates the 
cymba concha, tragus, antihelix and cavity of concha [275]. The ABVN is a 
remnant of the embryonic nerve supplying the first branchial arch, and arises 
from the superior jugular ganglion of the vagus nerve [115]. In rats and 
humans, afferent projections from the ABVN have been demonstrated to 
terminate at the nucleus of the solitary tract (NTS), dorsal raphe, locus 
coeruleus and amygdala [96, 135]. Of particular interest with respect to a 
cardiovascular effect is the NTS, which is known to control efferent 
parasympathetic tone from the dorsal vagal motor nucleus and the nucleus 
ambiguous. The NTS is also able to communicate with sympathetic centres 
in the ventrolateral medulla. Clancy et al. demonstrated that transcutaneous 
vagus nerve stimulation (tVNS) in healthy human volunteers improved heart 
rate variability, indicating parasympathetic predominance [62]. In the same 
study, a decrease in sympathetic nerve activity was measured via 
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microneurography following tVNS [62]. These effects are consistent with a 
neural pathway for tVNS, proposed by Murray et al. in a recent review (see 
Fig. 7-2 and [254]. 
Transcutaneous vagus nerve stimulation has therefore emerged as a novel 
mechanism to non-invasively increase systemic vagal tone. Indeed, given the 
wide-ranging innervation of the vagus nerve, this intervention is being 
investigated in the treatment of several pathologies, including epilepsy, 
depression and cardiovascular disease. 
Given the importance of the vagus nerve in the release of the blood-borne 
humoral mediator of RIC [278], we hypothesised that non-invasive vagus 
nerve stimulation might mimic RIC and induce release of a similar 
cardioprotective factor. We performed a study using healthy human 
volunteers, in collaboration with Prof Jim Deuchars University of Leeds. The 
Deuchars research group has carried out significant work on transcutaneous 
vagus nerve stimulation [62], and have the requisite facilities and ethical 
approval to perform a randomised human trial using tVNS.  
7.3.2 Methods 
Human tVNS trial design – University of Leeds 
Ten healthy volunteers were recruited to the study (see Table 1 for 
participant details). Each volunteer was required to attend the Deuchars’ 
laboratory at the University of Leeds on two separate occasions spaced at 
least 7 days apart. On the first visit, each volunteer was randomised to 
receive either remote ischaemic conditioning (RIC) (4 cycles of 5 min inflation 
to 200mmHg and 5 min deflation of cuff around upper limb), or 40 minutes of 
non-invasive low-level electrical stimulation applied to the tragus of the ear 
via an auricular electrode clip connected to a transcutaneous electrical nerve 
stimulation (TENS) machine. The tVNS stimulation protocol consisted of 
200μs pulse width at 30Hz, with the amplitude varied (10-50mA) depending 
of sensory threshold of the subject. The volunteer would return at least 1 
week later and receive the alternate intervention to the first visit.  For both of 
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the above protocols, a baseline blood sample was taken from an antecubital 
vein into a heparinised vial before the intervention is applied and a second 
blood sample will be taken after RIPC or tVNS (Fig. 1).  In addition, three 
sets of data (ECG, blood pressure and respiration) were recorded from 
research participants during their first visit to the lab: (1) a 10 minute baseline 
(control) period before the intervention/stimulation was applied, (2) the 40 
minute intervention period during which either tVNS or RIPC is applied and 
(3) a 10 minute recovery period after the intervention.  When participants 
were receiving RIC, data were derived from the 5min episodes of 
reperfusion. The participants reported mild to moderate discomfort during the 
ischaemic episodes, this may have confounded the HR measurements. The 
ECG recordings were analysed using Spike2 software to calculate the time 
interval between each individual heart. Changes in heart rate are separated 
into high and low frequencies.  This technique can then be used to determine 
heart rate variability (HRV) - a measure of how much variation there is in the 
time intervals between heartbeats.  An improved HRV is associated with 
increased activity in the parasympathetic nervous system. 
Blood samples were immediately centrifuged at 1600 g for 20 min at 21°C to 
obtain plasma, followed by 10,000g for 30min at 21°C to obtain 4mls of 
platelet-free plasma. This was then frozen at -80°C. After collection of all the 
plasma samples, these were sent in batch to the Hatter Cardiovascular 
Institute.  
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Table 7-1. General characteristics of healthy participants in the study. The 
table displays the gender, height (cm), age and weight of each participant. 
 
 
 
 
 
Participant) Gender)
(M/F))
Age) Height)
(cm))
Weight)
(kg))
BMI)
UCL1) M" 48" 172" 68" 22.9"
UCL2) F" 35" 158" 45" 18"
UCL3) M" 26" 174" 73" 24.1"
UCL4) M" 24" 183" 69" 20.6"
UCL5) F" 49" 164" 60" 22.3"
UCL6) F" 29" 167" 59" 21.1"
UCL7) M" 23" 180" 79" 24.3"
UCL8) F" 23" 174" 71" 23.4"
UCL9) F" 30" 163" 57" 21.4"
UCL10) M" 22" 181" 87" 26.5""
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Figure 7-3. Schematic displaying experimental protocols. 
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Dialysate preparation and perfusion through naïve isolated rat hearts – Hatter 
Cardiovascular Institute 
The dialysate model has been previously described in this thesis (section 
3.5). Briefly, plasma samples were thawed and dialysed across a 12-14kDa 
membrane into 200mls of modified KHB for 24hrs at 4°C. Dialysate was then 
perfused through a naïve isolated rat heart for 10min prior to a 35min 
ischaemia and 60min reperfusion. Infarct size was analysed using 
triphenyltetrazolium chloride staining (section 2.2.5). 
Statistical analysis 
For the ECG and respiration measurements, data were first analysed for 
normality using the Shapiro-Wilk test. One-way repeated measures ANOVA 
was used to assess changes in each dataset alone over time. Friedman’s 
test and Wilkoxon signed ranks test used for data that was not normally 
distributed. For the infarct analysis, data groups were first analysed for 
normality using the Kolmogorov-Smirnov test. Both tVNS and RIC groups 
were analysed relative to their respective baseline dialysate groups using a 
paired student’s t-test. Haemodynamic data from the Langendorff 
experiments were analysed using a 2-way repeated measures ANOVA with 
Bonferroni’s post-test. All data are presented as mean ± standard error of the 
mean (SEM). Data groups were classed as significantly different with a p 
value less than 0.05. Notation of significance was as follows: *=p<0.05, 
**=p<0.01 and ***=p<0.001. Analysis was exclusively performed using 
GraphPad Prism version 5 for Windows (CA, USA). 
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7.3.3 Results 
Effect of tVNS/RIC on ECG and respiration rate data 
Figure 2 displays the heart rate (HR) and heart rate variability (HRV) 
recorded for each patient whilst receiving either RIC or tVNS. No significant 
differences were observed in HRV between both interventions over time. No 
differences were observed in HRV during either tVNS or RIC alone over time. 
A significant change in HR over time was observed during tVNS, but not 
during RIC. However, no significant differences were observed between both 
intervention groups over time. Respiration rate was not significantly altered 
during either intervention over time.  
 
Table 7-2. ECG and respiration rate data collected over the course of each 
intervention. A baseline measurement was taken prior to each intervention. 
Measurements were taken at 10min intervals during both RIC and tVNS. A final 
measurement was taken following a 20min recovery period. Data presented as 
mean(SEM). Heart rate in patients ungergoing tVNS was found to significantly 
change over time (p>0.05). All other groups displayed no statistical significance. 
 
 
 
 
! Baseline! 10min! 20min! 30min! 40min! Recovery!
LF/HF!ratio! ! ! ! ! ! !
!!!tVNS! 1.13(0.23)! 0.84(0.14)! 0.93(0.14)! 1.12(0.24)! 1.10(0.25)! 1.15(0.23)!
!!!RIC! 0.84(0.17)! 0.83(0.19)! 0.87(0.17)! 1.28(0.23)! 1.01(0.16)! 0.99(0.23)!
Heart!Rate! ! ! ! ! ! !
(((tVNS! 61.6(1.2)! 60.3(1.6)! 59.8(1.5)! 59.9(1.5)! 61.8(1.3)! 62.9(1.2)!
(((RIC! 60.9(2.5)! 60(2.0)! 59(2.3)! 58.5(2.2)! 59.6(2.0)! 60.9(2.2)!
Respiration!
Rate!! ! ! ! ! ! !
(((tVNS! 16.7(0.6)! 16.6(0.6)! 16.5(0.5)! 16.6(0.7)! 16.4(0.8)! 17(0.6)!
(((RIC! 16(0.6)! 16.6(0.7)! 16.4(0.7)! 15.7(0.9)! 16(0.9)! 15.8(0.7)!!
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tVNS dialysate is equally as protective as RIC dialysate 
Although 10 participants were recruited from the study, blood was only 
sampled from 8 due to 2 of the subjects experiencing a collapsed vein. Two 
of the plasma samples in the RIC group were not usable, leaving 6 usable 
samples. Dialysate prepared following RIC in human volunteers significantly 
protected the naïve isolated rat heart from IRI, relative to baseline dialysate. 
Interestingly, tVNS dialysate also induced significant cardioprotection to the 
naïve rat heart with respect to baseline dialysate. The protection offered by 
tVNS dialysate was equal to that of RIC dialysate. 
 
 
 
 
 
 
 
 
 
Figure 7-4. Dialysate prepared following tVNS protects a naïve heart to a 
similar level to that observed with RIC dialysate. Chart displaying infarct size of 
naïve perfused rat hearts that received human dialysate prepared following either 
RIC or tVNS. All hearts received 35min left anterior descending coronary artery 
ischaemia and 60min reperfusion. Data presented as mean ± SEM. 
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Figure 3 displays the haemodynamic measurements taken during the 
Langendorff experiments. No significant differences were observed between 
the groups in coronary flow rate, left ventricular developed pressure or heart 
rate over the ischaemia-reperfusion protocol.  
Figure 7-5. Haemodynamic data from the naïve hearts that received dialysate. 
Measurements of coronary flow rate, left ventricular developed pressure and heart 
rate in the naïve perfused rat hearts that received dialysate across the ischaemia-
reperfusion injury protocol. Data presented as mean ± SEM. No statistical 
significance was observed following a repeated measures ANOVA.   
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7.3.4 Discussion 
This study is, to our knowledge, the first to demonstrate the cardioprotective 
potential of tVNS. Although we do not measure a direct protective benefit in 
the human volunteer, the indirect endpoint indicates that a humoral 
cardioprotective factor is released into the blood following tVNS. Similarly, we 
demonstrate that RIC in human volunteers produces a dialysate that can 
protect a naïve rat heart. Although this has been observed in several other 
studies, it reinforces the interesting observation that the humoral factor is 
highly conserved and thus affords this cross-species protection. Given RIC is 
known to require vagus nerve activation as part of the mechanism, tVNS 
could be a novel intervention to activate similar cardioprotective pathways.  
Growing evidence suggests that vagal afferents in the outer ear are linked to 
central vagal centres. Stimulation of the concha, which contains only vagal 
afferents, resulted in activation of the nucleus of the solitary tract (NTS) and 
other projections consistent with vagus nerve activation [96, 135]. Sensory 
innervation to the tragus, however, is supplied by the trigeminal and vagus 
nerves in roughly equal proportions [275]. Therefore, it is plausible that the 
beneficial effects of tragus stimulation come from trigeminal, as well as vagal, 
afferent activation. Recent evidence, however, strongly indicate a systemic 
vagal effect following tVNS. Clancy et al demonstrated an increase in heart 
rate variability (HRV) and decrease in sympathetic nerve activity following 
tVNS to the tragus [62]. Thus, given the pre-clinical data regarding the vagus 
nerve and RIC, in combination with the study above, it is likely that the 
cardioprotective effect of tVNS is due to vagus nerve activation in the tragus.  
There was a small, but non-significant, decrease in LF/HF ratio during tVNS. 
This indicates an increase in heart rate variability, and vagal predominance. 
Although this was not statistically significant, the absolute decrease observed 
was similar to that measured by Clancy et al. (n=48), where a significant 
decrease in LF/HF was observed. The lack of statistical significance with our 
data is perhaps an effect of the natural variability in vagal tone between 
participants, thus increasing the numbers may reveal a significant effect.  
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Several recent studies, including one from this group, demonstrated that 
release of the humoral blood-borne factor following RIC is dependent on an 
intact vagus nerve [25, 242, 278]. Sectioning of the vagus nerve at the 
cervical level abrogated release of the humoral cardioprotective factor 
following RIC. Moreover, section of the vagus nerve below the diaphragm 
abrogated the cardioprotection induced by RIC in an in vivo rat model of 
myocardial infarction. This suggested that non-cardiac vagal innervation was 
important in the mechanism of RIC, which acted to release a humoral blood-
borne cardioprotective factor. This factor has since been suggested to be 
glucagon-like peptide 1 (GLP-1). The current paradigm therefore suggests 
that RIC increases vagal tone to an organ below the diaphragm, likely the 
gut, triggering release of GLP-1 into the blood, which then moves to the heart 
and induces protection. Our data provides the first evidence that the increase 
vagal tone achieved following RIC can also be recruited by tVNS; both 
interventions produce a dialysate that is equally protective to a naïve rat 
heart. Finally, we did not observe a correlation between HRV following tVNS 
and infarct size (R2 = 0.014). This suggests that the cardiovascular effect of 
tVNS is not responsible for the cardioprotection, in line with the recent 
literature described above. Although not proven in the current study, our 
suggestion is that RIC and tVNS share key mechanistic similarities.  
There is great deal of heterogeneity in the application of tVNS in the 
literature, both in terms of site and parameters of stimulation on the ear [254]. 
However, there are a growing number of promising trials demonstrating a 
benefit in several cardiac pathologies. Two pioneering studies in the field 
were performed on patients undergoing coronary artery bypass surgery [397, 
398]. Electrical stimulation to the cymba concha, via acupuncture needles 
attached to both ears, was applied for 15min per day for 10 days following 
the operation. Patients who received stimulation had a better outcome 
following surgery, as measured by improved left ventricular ejection fraction 
and reduced incidence of angina at rest. A more recent study stimulated the 
internal surface of the auricle for 10 days in patients suffering from CAD 
[279]. The incidence of angina attacks significantly decreased and this was 
associated with a decreased LF/HF ratio, indicating increased vagal tone to 
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the heart. Moreover, in patients with severe heart failure, a 15-day course of 
daily tVNS almost doubled the 6-minute walk test distance [1]. This effect 
was coupled with a reduction in heart rate and improved NYHA functional 
class. 
In addition to heart failure and CAD, tVNS has been investigated as a 
treatment of myocardial arrhythmias. Studies in anaesthetised dogs have 
demonstrated a protective effect of tVNS on atrial fibrillation (AF), following a 
sustained period of rapid atrial pacing [56, 394]. Furthermore, tVNS treatment 
in dogs that had recovered from a myocardial infarction significantly 
attenuated cardiac remodelling and improved left ventricular function. This 
effect has also been observed in the clinical setting; tVNS reduced the 
duration of AF in patients suffering from paroxysmal AF who presented for 
AF ablation [330].  
The primary advantage for tVNS is its ease of application. Current clinical 
practise for vagus nerve stimulation involves a surgical procedure, under 
general anaesthetic, to insert a device around the left or right cervical vagus 
nerve. Studies investigating the merits of VNS in the cardiac setting have 
thus far proven ineffective [104, 399]. The surgery to insert the device carries 
significant risks, not least from the anaesthesia and proximity of the vagus 
nerve to the carotid artery. This poses an issue in particular for very sick or 
older patients. Moreover, the vagus nerve is known to carry a high number of 
sympathetic fibres. Indeed, when the cervical vagus nerve was stimulated in 
dogs, activity of neurones in the stellate ganglion increased [295]. This 
increased sympathetic nerve activity would clearly be detrimental to patients 
suffering from cardiovascular disease. Thus, current practise for VNS is likely 
too crude to produce an effective outcome. Perhaps tVNS could provide a 
viable alternative, given its specific recruitment of the parasympathetic 
nervous system and non-invasive application.  
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7.4 Aim 2: tVNS as a cardioprotective intervention in a rat in vivo 
model of myocardial infarction 
7.4.1 Background 
Given the data presented in section 7.3, we decided next to try and create a 
model of tVNS in the laboratory. This would allow more detailed investigation 
into the mechanism of action. The auricular branch of the vagus nerve 
appears to be well conserved in mammals; studies have demonstrated 
benefits of tVNS in cats, dogs, rats and mice [19, 155, 259, 330]. With 
respect to the rat, a tracing study revealed the ABVN is connected to 
parasympathetic regions of the brain [135], consistent with that seen in 
humans [96]. Moreover, in rat models of acute myocardial infarction, 
stimulation of the vagus nerve has been demonstrated to be highly 
cardioprotective [79, 174, 243]. These studies, however, all used invasive 
methods to access and stimulate the nerve. Two recent studies have 
investigated tVNS in a rat model of cerebral ischaemia-reperfusion injury [19, 
165]. Electrical stimulation of the tragus or cymba concha decreased brain 
infarct size and improved post-infarction recovery, following 2hr middle 
cerebral artery occlusion. We therefore hypothesised that tVNS could 
ameliorate infarct size in a rat model of myocardial ischaemia-reperfusion 
injury. 
7.4.2 Methods 
In vivo model of myocardial ischaemia-reperfusion injury 
Male Sprague-Dawley rats were used throughout the study. Animals were 
anaesthetised with 60mg/kg sodium pentobarbital (i.p.) (Animalcare, York, 
UK). Surgery began once both pedal and tail reflexes were abolished. Depth 
of anaesthesia was monitored throughout the surgery, and additional 
pentobarbital was administered as required (25mg/kg, i.p.). 
The animal was first arranged in a supine position on a temperature-
controlled mat (Harvard Apparatus, Kent, UK), with tape securing all four 
limbs. A rectal temperature probe was inserted and body temperature 
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maintained at 37±0.5°C. A tracheostomy was performed and the trachea 
cannulated using a modified 16G, 1.7 x 51 mm Abbocath-T intravenous 
cannula (Smiths Medical International Ltd, Kent, UK). Positive pressure 
ventilation was provided by connection to a Small Animal Ventilator (Harvard 
Apparatus, York, UK). Tidal volumes were calculated using the following 
allometric formula: tidal volume = 7.2 ml/kg. Finally, 2 cmH2O of positive end 
expiratory pressure were added by submersion of the expiratory tubing in 
water. This is important to prevent lung collapse during open chest surgery. 
Hair removal cream was applied to the left side of the thorax to facilitate 
surgery. A skin incision was made in the left lateral position, 1 cm below the 
forelimbs. Superficial muscles were sharp dissected. Blunt thoracotomy of 
the left fourth intercostal space was performed in order to gain access to the 
thoracic cavity. The pericardium was torn with splinter forceps (B. Braun, PA, 
USA). The LAD coronary artery was under-run with a 6-0 braided silk non-
absorbable suture with 9.3 mm, 3/8 curved needle (Ethicon, C of Edin, UK) 
positioned approximately 2 mm below the tip of the left atrium. After passing 
loops of 3-0 braided silk (Ethicon, C of Edin, UK) over each arm of the suture 
to facilitate reperfusion, ischaemia was initiated by occlusion of the ligating 
suture.  
Successful ischaemia was confirmed by the occurrence of ST-segment 
elevation in the EGC trace, myocardial blanching and hypokinesia of the 
anterior wall of the heart. Ischaemia, as indicated by ST-segment elevation, 
was maintained using surgical clamps as ballast on each end of the ligating 
suture. The open wound was covered by a moistened swap to prevent 
desiccation and heat loss. Following 35 min of ischaemia, reperfusion of the 
LAD territory was initiated by release of the occluding suture, which was left 
in place to facilitate subsequent analysis, and successful reperfusion 
confirmed by reversal of the ST-segment elevation and myocardial colour 
change. Following induction of reperfusion, the open wound was closed 
using metal surgical staples. 
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Figure 7-6. Representative images of the surgical protocol for in vivo 
ischaemia-reperfusion injury model. (A) The animal is anaesthetised, ventilated 
and arranged in a supine position on a temperature controlled mat; (B) The heart 
was access via thoracotomy of the intercostal space; (C) A suture was inserted 
around the left anterior descending coronary artery and tightened using a snare to 
occlude the artery and induce ischaemia; (D) Following 35min ischaemia, the suture 
was released to reperfuse the myocardium and the skin closed using surgical 
staples. 
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Experimental protocols 
A schematic of the experimental design is displayed in figure 7-8. All animals 
received 35min left anterior descending coronary artery ischaemia and 
120min reperfusion. Prior to induction of ischaemia, animals were 
randomised to receive one of four separate interventions.  
1. Remote ischaemic conditioning (RIC): induced via a modified 
pressure cuff placed around the left-hindlimb. This consisted of 4 x 5 
min cuff inflation to 200 mmHg with intermittent 5 min deflations.  
2. Sham RIC: where the cuff was applied to the animal for the same time 
period but not inflated.  
3. Transcutaneous vagus nerve stimulation (tVNS): two modified 
stainless steel clips were attached to the left and right tragus of the 
animal (see Figure 7-7). These were connected to a constant current 
stimulator (DS3, Digitimer, Hertfordshire, UK). Stimulation was 
initiated 5min prior to reperfusion; a 30sec train consisting of 0.5ms 
pulse duration at 0.5mA and 20Hz. Stimulation was applied every 
5min for 1 hour. This protocol was taken from that used in a recent 
study that demonstrated the neuroprotection induced by tVNS [19]. 
4. Sham tVNS: where the clips were attached to the left and right tragus 
without any electrical stimulation. 
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Figure 7-7. Method used for transcutaneous vagus nerve stimulation in the 
anaesthetised rat. (A) The rat ear has a clear tragus (indicated with an arrow); (B) 
A modified metal clip could be attached to the tragus; (C) Current was driven 
through the clip by a Digitimer DS3 constant current stimulator. 
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Figure 7-8. Experimental protocols used to investigate RIC and tVNS in a rat 
model of ischaemia-reperfusion injury. All rats received 35min left anterior 
descending coronary artery ischaemia and 60min reperfusion. Remote ischaemic 
conditioning (RIC) consisted of 4 cycles of 5min hindlimb ischaemia, induced via a 
small cuff, with intermittent 5min reperfusion. Transcutaneous vagus nerve 
stimulation (tVNS) consisted of two small clips attached to the left and right tragus of 
the rat; stimulation was started 5min prior to reperfusion and continued for 1 hour. 
 
Infarct analysis 
Following reperfusion, a clamshell thoracotomy was performed and the heart 
excised as described in section 2.2.2. The aorta was cannulated and 
perfused with 5mls cold phosphate-buffered saline solution to clear the heart 
of blood. Infarct size was then assessed using the method described in 
section 2.2.5. 
Statistics 
Data are presented as mean ± standard error, and were analysed using a 
one-way analysis of variance. A p value of less than 0.05 was considered 
significant. 
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7.4.3 Results 
In vivo tVNS does not appear to significantly reduce infarct size 
Figure 7-17 displays the infarct sizes across all four experimental groups. 
Those animals that received RIC were significantly protected from ischaemia-
reperfusion injury relative to sham RIC (I/AAR% = 26 ± 5 vs Sham RIC = 54 
± 5, p>0.05).  Those animals who received tVNS had a mean infarct size of 
30 ± 8 %. Although this was lower than those who received sham tVNS (45 ± 
6 %), it was not found to be statistically different (p = 0.17). 
 
 
 
 
 
 
 
 
 
Figure 7-9. Remote ischaemic preconditioning but not tVNS reduces infarct 
size in an animal model of in vivo ischaemia-reperfusion injury. The chart 
displays infarct size, expressed as a proportion of area at risk (I/AAR%), for each 
experimental group. All data presented as mean±SEM. Those animals that received 
remote ischaemic conditioning (RIC) were significantly protected from ischaemia-
reperfusion injury. Animals that received transcutaneous vagus nerve stimulation 
(tVNS) displayed a reduced infarct size relative to sham tVNS, however this was not 
statistically significant.  
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7.4.4 Discussion 
This study failed to demonstrate a cardioprotective effect of tVNS in a rat 
model of myocardial ischaemia-reperfusion injury. Although a reduction in 
infarct size was observed in animals that received tVNS, it was not 
statistically significant. RIC induced significant cardioprotection, consistent 
with the literature, thus acting as a positive control for the model.  
The tVNS protocol used in this study was chosen to match that used in a 
recent neuro-protection study by Ay and colleagues [19]. Electrical 
stimulation of the tragus reduced infarct size in a rat model of cerebral 
ischaemia-reperfusion injury. This is the only study in the literature that has 
demonstrated a measurable effect of tVNS in a rat model. Moreover, the 
stimulation was given as a per-/post-conditioning intervention, as this more 
closely aligns with its potential clinical application.   
This result is at odds with the human data presented in the previous section, 
where tVNS induced release of a cardioprotective blood-borne factor. 
Despite the obvious difference in species, there are two other key issues that 
could explain the different outcomes. First, the stimulation parameters used 
in the animal study are different to those used in the human study. As 
described above, this decision was made to align the rat study more closely 
to the published study that also used a rat model. The amplitude and 
frequency of stimulation was significantly different, and this could explain the 
lack of protection observed in the rat. Secondly, it is possible that the 
dialysate model does not provide adequate information to suggest a 
cardioprotective effect. That is, release of a cardioprotective blood-borne 
factor might not be sufficient to reach threshold for cardioprotection in vivo.   
These data should therefore be considered only preliminary for several 
reasons. First, there was a large amount of variability in infarct size with rats 
following tVNS. Indeed, one could argue that protection did not occur in two 
of the five animals (Fig. 7-9). The key question, therefore, is whether 
adequate stimulation was achieved in all five animals. The tragus is relatively 
small in the rat (Fig. 7-7), therefore it is difficult to ensure good conduction 
211 
 
between the stimulating clip and tragus. There are currently no biomarkers 
that indicate appropriate tVNS stimulation. Thus, it is highly possible that the 
strength of tVNS varied between each animal. Moreover, only one stimulation 
protocol was used in the study. With IPC and RIC, a threshold must be 
reached in order for cardioprotection to occur; there exists an optimal 
protocol for both interventions in order to achieve the maximum effect [46, 
368]. Given the reduction in infarct size observed with tVNS, albeit non-
significant, it is important to test different stimulation parameters before 
drawing firm conclusions as to its cardioprotective potential. Perhaps, there 
exists a protocol that sufficiently activates the vagus nerve so as to reach the 
threshold for cardioprotection.  
One solution could be to measure cervical vagus nerve activity during tVNS 
in the anaesthetised rat. If the tVNS is working via increased vagal tone, this 
would be detected as increased cervical vagus activity. The rat could then be 
infarcted, and the infarct size correlated against vagus nerve activity following 
tVNS; the hypothesis being that higher vagus nerve activity following tVNS 
would be associated with lower infarct size.  
7.5 Summary 
This chapter has introduced transcutaneous vagus nerve stimulation as a 
potential novel cardioprotective intervention. Dialysate prepared following 
tVNS in human volunteers significantly protected a naïve-isolated rat heart 
from ischaemia-reperfusion injury. In addition, remote ischaemic conditioning 
produced a dialysate that protected a naïve heart to a similar level. This 
suggests that tVNS activates a similar mechanistic pathway to RIC, both 
inducing release of a blood-borne cardioprotective factor. In the subsequent 
study, tVNS did not reduce infarct size in an in vivo model of rat ischaemia-
reperfusion injury. A small reduction in injury was observed, however, which 
warrants further investigation into the optimal stimulation parameters.  
It is very important to develop an animal model for tVNS for two reasons: 
first, it allows detailed investigation into the mechanism of action; second, 
one can easily investigate and determine the optimal tVNS protocol for 
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cardioprotection. Our data do not allow a firm conclusion as to the potential 
for tVNS as a cardioprotective intervention, but provide an interesting starting 
point requiring further investigation.  
 
Chapter 8 General conclusions 
The overall aim of this thesis was to investigate the mechanisms by which 
remote and classical ischaemic conditioning communicate their protective 
message. Particular focus was given to a neuro-humoral pathway, with key 
similarities observed between the mechanisms of both IPC and RIC. Indeed, 
preliminary data presented in this thesis suggest an important role for the 
intrinsic cardiac nervous system in response to blood-borne factors released 
following both interventions. Moreover, the vagus nerve was found to be a 
fundamental communicative step between the induction of RIC in the limb 
and release of a humoral mediator. We suggest that there exists a complex 
interaction between the sensory perception of brief ischaemia-reperfusion 
injury and release of cytoprotective humoral factors into the blood.  
A large portion of time during this PhD was spent developing and 
characterising the two models of cardioprotection; the IPC effluent transfer 
model and RIC plasma dialysate model. In doing so, this not only created the 
platform to investigate our hypotheses, but also enabled a thorough 
understanding of the nature of the two cardioprotective interventions. The 
effluent model demonstrated that humoral factors were released following 
IPC that induced vasodilation and cardioprotection to a naïve heart. The 
dialysate model revealed a humoral component to RIC and enabled 
investigation into the mechanism of its release and induction of protection in 
the myocardium.  
Using the dialysate model, we revealed that bilateral cervical vagotomy 
abrogated release of the humoral blood-borne mediator (Chapter 5), which 
added to the current neuro-humoral paradigm for the communication of RIC 
form the conditioned limb to the myocardium. This result is complimented 
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nicely with two other recent studies; the suggestion is that RIC triggers 
increased vagal tone to the gut, releasing glucagon-like peptide 1 into the 
blood, which then moves to the heart and induces protection. However, 
dialysate prepared following stimulation of the gastric vagal nerve did not 
protect a naïve heart (section 5.3.2.2), indicating release of a factor did not 
occur. Thus, this hypothesis remains equivocal and requires further 
experimentation. We further demonstrated that the humoral RIC mediator 
appears to recruit intrinsic cardiac ganglia, in as much as protection was 
abrogated when hexamethonium was co-infused with the plasma dialysate. 
These data prompted the question of whether intrinsic cardiac ganglia were 
important in the mechanism of classical ischaemic preconditioning (IPC). 
Indeed, pretreatment with the ganglionic antagonist hexamethonium 
abrogated the cardioprotection of IPC in the isolated perfused heart. 
Moreover, we measured a release of acetylcholine in coronary effluent 
following IPC, and the muscarinic antagonist atropine also abrogated IPC. 
This indicated that intrinsic neural pathways remain active in the isolated 
heart preparation and can influence cardioprotection in the absence of any 
input from the central nervous system.  
Perhaps the most surprising result was presented in Chapter 7, where 
stimulation of the tragus in the ear induced release of a blood-borne 
cardioprotective factor. However, we were not able to reproduce these data 
in an in vivo rat model of myocardial infarction. Thus, this chapter should be 
considered preliminary data, however tVNS represents a highly interesting 
intervention that merits further pre-clinical investigation. 
As a final point, the meta-analysis (Chapter 4) highlighted one of the key 
pitfalls of translational medicine; the rush to perform a clinical trial in the 
absence of sufficient pre-clinical data. We were only able to find 31 studies 
investigating RIC in animal in vivo models of myocardial infarction. Given the 
intervention was discovered in 1993, this rate of just over one study per year 
is insufficient when considering the number of clinical trials using RIC in the 
same period. Indeed, there remains a lack of clarity as to the most effective 
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protocol for RIC. In addition, the recent discovery of a key role for the vagus 
nerve in RIC could explain the apparent lack of efficacy in the clinic; vagal 
tone is known to depreciate in patients suffering from coronary artery disease 
(CAD). However, despite recent setback in large clinical outcome studies, 
RIC remains a clinically feasible, non-invasive, inexpensive intervention with 
the potential to improve outcome in CAD patients.  
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Chapter 10 Appendix 
Below are attached the three original research publications arising from data 
presented in this thesis. Note that the page numbers and references 
correspond to the individual manuscripts, not to the overall document. 
